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Abstract 
Curcumin is a polyphenolic compound isolated from the rhizomes of Curcuma 
longa. Curcumin has been demonstrated to have antioxidant, anti-inflammatory, and 
anticancer properties. Moreover, it has been shown to exhibit beneficial effects in the 
treatment of several neurodegenerative diseases including Alzheimer’s and 
Parkinson’s diseases. However, the molecular and cellular targets mediating the 
pharmacological actions of curcumin remain largely unknown. In this study, the 
effects of curcumin application on the functional properties of the nicotinic 
acetylcholine receptor, a prototype for ligand gated ion channels were investigated. 
Using the two-electrode voltage clamp technique, the results showed that curcumin 
co-application caused a significant potentiation of the action of human α7-nicotinic 
acetylcholine receptors (α7-nAChR) expressed in Xenopus oocytes. Importantly, 
curcumin was found less effective on other nicotinic receptor subunit combinations 
and other members of ligand-gated ion channels. Curcumin significantly decreased 
desensitization of α7-nAChR suggesting that it acts as a type II PAM. High affinity 
binding site for curcumin on α7-nAChR was also verified by molecular docking study. 
In the second part of this study, the neuroprotective effects of curcumin in an 
animal model of Parkinson’s disease was investigated. Stereotaxic micro-neurosurgery 
was successfully established (for the first time in our university) and used to induce 
the toxin based (6-hydroxydopamine; 6-OHDA) animal model of Parkinson’s disease. 
This was followed by testing the behavior of the animals, tissue collection, 
immunohistochemistry, striatal fiber density measurement, and stereological data 
analysis. Systemic administration of curcumin alleviated 6-OHDA-induced motor 
abnormalities and protected against substantia nigra pars compacta dopaminergic 
neuronal loss, through an α7-nAChRs-mediated mechanism. The protective effects of 
curcumin were completely reversed by the administration of the α7-nAChR-selective 
antagonist methyllycaconitine (MLA).  
In summary, the results of this study suggest that α7-nAChR-mediated activation 
is an important mechanism for the neuroprotective effects of curcumin in toxin-based 
(6-hydroxydopmine; 6-OHDA) animal model of Parkinson’s disease. 
Keywords: Curcumin, α7-nAChR, Xenopus oocytes, Parkinson’s disease, 6-OHDA – 
neuroprotection  
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خصائص تفعيل في   في مستقبلات الأسيتايل كولين النيكوتينية 7دور وحدات ألفا 
 الكركم الوقائية للجهاز العصبي
 الملخص
تتميز نبتة م. يعتبر الكركم أحد مركبات البولبفينول والمستخلص من جذمور نبات الكرك
لسرطان. وزيادة على ذلك، لمضاد  كذلك، و صائص: مضادة للالتهابات، الأكسدةخبعدة  الكركم
أمراض  ج عدد من الأمراض مثلعرفت هذه النبتة بخصائص دوائية واستخدمت بفاعلية لعلا
ولقد وضعت عدة فرضيات لآلية عمل الكركم  التنكس العصبي كداء الزهايمر وداء باركنسون.
وفي هذا السياق  ية للنبات.إما عن طريق القنوات الأيونية أو النواقل لكل هذه الخصائص الدوائ
 المرتبطة بربيطة أيونية محددة.قمنا بدراسة تأثير مادة الكركم على القنوات الأيونية 
وظيفة مستقبلات الأسيتايل كولين النيكوتينية المكونة من لقد بدأنا بدراسة تأثير الكركم على 
ثبيت الجهد خدام تقنية ت) و ذلك باستsuponeXو المستنسخة في بويضات ضفادع ( 7وحدات ألفا 
كهروفسيولوجية استتنتجنا أن مادة التجارب الالكهربائي باستخدام قطبين كهربائيين. من خلال 
. 7المكونة من وحدات ألفا  مستقبلات الأسيتايل كولين النيكوتينية الكركم لها تأثير محفز على  
ية المرتبطة القنوات الأيونموعة وهذا التأثير خاص فقط بهذه المستقبلات دون غيرها من بقية مج
مستقبلات مستقلبات مادة الكركم على  ات وثم قمنا بدراسة تأثير مشتق .بربيطة أيونية محددة
لهذه يضا أوقد أعطت تأثير محفز  7المكونة من وحدات ألفا  الأسيتايل كولين النيكوتينية 
 المستقبلات ولكن بدرجة أقل من مادة الكركم.
مادة ل الوقائي تأثيرالفي الجزء الثاني من البحث بدراسة قمنا  المعطيات، فإنناوبناءا على هذه 
 المرض وتطور الكركم على نموذج داء باركنسون. وذلك باستخدام الجرذان وتحريض حدوث
وحقن مادة  -للمرة الأولى بجامعة دولة الإمارات العربية المتحدة-من خلال جراحة  المخ الدقيقة 
قد تبع ذلك اختبار سلوك الحيوانات، جمع الأنسجة، و .هيدروكسيدوبامين-6 الأعصاب السامة
أثبتت النتائج أن الكركم يتمتع . والكيمياء المناعية، وتحليل البيانات المجسمة لجمع النتائج
الأسيتايل كولين النيكوتينية المكونة من عن طريق مستقبلات  بخصائص وقائية للجهاز العصبي
) ALMالتأثيرات الوقائية للكركم بإعطاء دواء ميثايلكاكونيتين (تم عكس  كما 7وحدات ألفا 
  .7المضاد الانتقائي لوحدات الألفا 
 xi
 
 
 
 
وذات هو آلية مهمة باستخدام الكركم  7 وحدات ألفاتشير نتائج هذه الدراسة إلى أن تنشيط 
 .لمرض باركنسونفي النموذج الحيواني  تأثير وقائي على الجهاز العصبي
المكونة من وحدات ألفا  نةمستقبلات الأسيتايل كولين النيكوتي ،كمرالك الرئيسية: البحثم مفاهي
 وقاية الجهاز العصبي ،هيدروكسيدوبامين-6 ،داء باركنسون ،7
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Chapter 1: Introduction 
1.1 Curcumin 
Curcumin is a polyphenolic compound, the main ingredient of turmeric (Curcuma 
longa), and a member of the ginger family (Zingiberaceae) (Aggarwal and Sung, 
2009). The plant grows largely in India, China and other tropical countries (Aggarwal 
et al., 2007). Vogel and Pelletier were the first to report the isolation of a “yellow 
coloring-matter” from the rhizomes of Curcuma longa (turmeric) and named it 
curcumin in 1815. Vogel found that turmeric is a mixture of many components and 
successfully isolated a pure curcumin oil in 1842. In 1910, Milobedeska and Lampe 
characterized  its structure as diferuloylmethane, or 1,6-heptadiene-3,5-dione-1,7-bis 
(4-hydroxy-3-methoxyphenyl)-(1E, 6E) (Figure 1), and three years later they 
synthesized curcumin (Gupta et al., 2012). Curcumin exhibits keto–enol tautomerism, 
where enol forms predominant in an alkaline medium while keto forms in acidic and 
neutral media (Priyadarsini, 2014). 
 
Figure 1: The source and chemical structure of curcumin. 
(A) The root of turmeric. (B) Crystallized powder of curcumin. (C) The enol and keto 
forms of curcumin [Modified from (Zhang et al., 2013)]. 
Curcuma Longa 
Rhizome 
Turmeric 
Curcumin (Enol form) 
Curcumin (Keto form) 
(A) (C) (B) 
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Curcuminoid (the yellow pigmented fraction of turmeric) forms 3-5% of turmeric 
and is composed mainly of three derivatives; curcumin (diferuloylmethane, curcumin 
I), demethoxycurcumin (DMC, curcumin II), and bisdemethoxycurcumin (BDMC, 
curcumin III) (Anand et al., 2008; Goel et al., 2008). Recently, cyclocurcumin has 
been isolated as a curcuminoid component of turmeric by Kiuchi et al. (Kiuchi et al., 
1993). Among all, curcumin is the most abundant (~77%) followed by DMC (~17%) 
and BDMC (~3%) (Anand et al., 2008; Goel et al., 2008). Curcumin is hydrophobic 
in nature and not soluble in neutral solvent e.g: water, but soluble in organic solvents 
e.g: dimethylsulfoxide (DMSO), ethanol, and acetone (Priyadarsini, 2009). 
1.1.1 Natural Curcumin Analogues and Metabolites 
As mentioned earlier, curcumin I, curcumin II, curcumin III, and cyclocurcumin 
collectively known as curcuminoid, are considered the natural turmeric analogues 
(Table 1.A - D).  
There are numerous curcumin metabolites that have been reported and are 
available commercially, including tetrahydrocurcumin (THC), dimethyl curcumin, 
didemethyl curcumin, Vanillylidenacetone, Di-(tert-Butyl-dimethylsilyl) Curcumin, 
O-tert-Butyl-dimethylsilyl Curcumin, and curcumin-d6 (Table 1.E - K). 
  
3 
 
 
 
 
Table 1: Curcumin analogues and metabolites 
 
 
b. Bisdemethoxycurcumin c. Demethoxycurcumin  d. Cyclocurcumin 
e. Tetrahydrocurcumin f. Demethyl curcumin g. Didemethyl curcumin  
h. Di-(tert-Butyl-
dimethylsilyl) Curcumin 
 
i.Vanillylidenacetone j. O-tert-Butyl 
dimethylsilyl Curcumin 
k. Curcumin-d6 
a. Curcumin 
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1.1.2 Pharmacokinetics and Pharmacodynamics of Curcumin  
Curcumin has a low bioavailability in plasma and tissue due to its poor absorption, 
rapid metabolism, as well as rapid systemic elimination. Various studies have been 
conducted on the pharmacokinetics and pharmacodynamics of curcumin, the first of 
which was reported by Wahlstrom and Blennow 1978 in Sprague-Dawley rats. 
Curcumin had poor absorption from the gut, and nearly 75% of curcumin was excreted 
in the feces with negligible amounts being detected in blood plasma (Wahlström and 
Blennow, 1978). Holder et al. experimented with deuterium- and tritium-labeled 
curcumin given intravenously (I.V) and intra-peritoneally (I.P), and observed that 
majority of curcumin was excreted in bile and then in feces (Holder et al., 1978). 
Ravindranath in 1980, used three different doses (10, 80, and 400 mg/kg) of tritium-
labeled curcumin, and detected curcumin in tissue of interest after 12 days of 
administration. The percent of absorbed curcumin (60-66%) remained constant with 
no difference between doses indicating that increasing the dose did not increase 
absorption, thus there is a dose-dependent limitation of curcumin’s bioavailability 
(Ravindranath and Chandrasekhara, 1981). Pan et al. in 1999, administered 100 mg/kg 
of curcumin I.P to mice to investigate the pharmacokinetics of curcumin.  After one 
hour of administration, curcumin level in spleen, liver, and kidney were 26.1, 26.9, 
and 7.5 μg/g, respectively, and a minute trace levels (0.41 mg/g) were detected in the 
brain (Pan et al., 1999). 
Studies of curcumin’s pharmacokinetics in humans yielded more or less similar 
data, a peak plasma level of 0.41–1.75 µM have been obtained after administration of 
4 – 8 g of curcumin orally in humans (Cheng et al., 2001). After several experiments, 
Perkins, 2002 concluded that humans need a daily dose of 1.6 g curcumin to produce 
5 
 
 
 
 
an effect (Perkins et al., 2002). Many groups have shown that the liver is the primary 
site of curcumin metabolism, where it undergoes extensive reduction via alcohol 
dehydrogenase, followed by conjugation (Garcea et al., 2004; Hoehle et al., 2006; 
Wahlström and Blennow, 1978).  
Almost all studies verified that unformulated curcumin has poor bioavailability in 
animal models and humans. To improve curcumin bioavailability, different 
formulations have been developed. For example, a nanocurcumin was developed to 
enhance curcumin solubility in aqueous solution. Cheng et al. 2013, prepared a 
nanoparticle form of curcumin that yielded a higher plasma concentration and higher 
AUC by six times. Moreover, mean residence time in the brain was longer in a mice 
model (Cheng et al., 2013). 
In another study, Polylactic-co-glycolic acid (PLGA) is one of the forms of 
formulated curcumin, was employed and was reported to enhance curcumin 
bioavailability by 5.6 folds and also extended curcumin half-life. This was due to 
improvement of water solubility of the compound -which is known to be highly 
lipophilic as mentioned previously-, more induction of intestinal juices facilitating 
ingestion, higher permeability enhancing absorption, and elongating residence time in 
the intestine which allowed for more absorption (Xie et al., 2011) 
Liposomal curcumin is another formulated curcumin a form of drug carrier which 
helps to increase the solubility of the compound. Liposome-encapsulated curcumin 
(LEC) increased curcumin bioavailability by facilitating cellular uptake and increasing 
its absorption. Different forms have been generated,  silica-coated flexible liposomes 
loaded with curcumin (CUR-SLs) and curcumin-loaded flexible liposomes (CUR-
FLs), were found to enhance curcumin bioavailability by 7.76- and 2.35 folds higher, 
respectively, compared to unformulated curcumin (Li et al., 2012). 
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Cyclodextrin (CD), is a form of cyclic oligosaccharides, which encapsulates and  
facilitate its cellular uptake, bioavailability, and elongates its half-life (Prasad et al., 
2014).  
CD encapsulated curcumin improves curcumin permeability 1.8 fold across skin 
in animal model compared to unformulated curcumin (Rachmawati et al., 2013). 
Curcumin bioavailability can be enhanced up to 2000% in humans and to 154% in 
rats, by administrating piperine (a component derived from pepper and a known 
inhibitor of hepatic and intestinal glucuronidation) along with curcumin. Concomitant 
piperine administration with curcumin significantly decreased elimination and half-
life clearance of curcumin (Anand et al., 2007; Shoba et al., 1998). 
1.1.3 Molecular Targets of Curcumin 
Based on the extensive pieces of evidence from both in-vitro and in-vivo studies, 
several molecular targets of curcumin have been identified. Curcumin interacts with 
transcription factors, e.g., nuclear factor-kB (NFκB), and signal transducer and 
activator of transcription (STAT) proteins (Shishodia et al., 2007), growth factors and 
their receptors, e.g. epidermal growth factor receptors and HER2 (Chen et al., 2006; 
Soung and Chung, 2011), cytokines, e.g., interleukin 1b (IL-1b), interleukin 6 (IL-6) 
(Cho et al., 2007), enzymes, e.g., hemoxygenase-1 (HO-1) (McNally et al., 2007), and 
genes regulating cell proliferation and apoptosis (Aoki et al., 2007). This ability of 
curcumin to modulate or interact with multiple cell signaling pathways and proteins, 
strongly indicates that this polyphenol is an effective multi-targeted compound (Figure 
2) (Goel and Aggarwal, 2010; Hasima and Aggarwal, 2012; Rainey et al., 2015; 
Ravindran et al., 2009). This conclusion is in line with several recently published 
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reports identifying curcumin as a potent epigenetic regulator (Kunnumakkara et al., 
2016). 
 
Figure 2: Molecular targets of curcumin. 
Multiple cellular and molecular targets of curcumin has been identified, including: 
transcription factors (STAT1, PPRPδ, FOXO,…), growth factors (IGF, TGF, 
CDK2,…), inflammatory biomarkers (IL6, COX2, iNOS, NFκB,…), tumor suppressor 
genes (P53, PTEN, Rb) protein kinases (MAPK, AKT, PKA, PKC,…), oncoproteins 
(Fos, c-Myc, c-Met), and apoptotic genes (Bax, Bcl-2, caspase 8,…) (Hasima and 
Aggarwal, 2012). 
 
1.1.4 Biological Properties of Curcumin 
Curcumin has been traditionally used in Asian countries as a dietary spice and as 
a medical herb for several pathologies due to its anti-inflammatory (Ammon and Wahl, 
1991; Brouet and Ohshima, 1995; Dikshit et al., 1995), antioxidant antimicrobial and 
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anticancer properties (Limtrakul et al., 1997; Rao et al., 1995), anti-arthritic (Deodhar 
et al., 1980), hepatoprotective (Kiso et al., 1983), anti-thrombotic (Srivastava et al., 
1985), cardio-protective (Dikshit et al., 1995; Nirmala and Puvanakrishnan, 1996a; 
Srivastava et al., 1985), and hypoglycemic properties (Arun and Nalini, 2002; Babu 
and Srinivasan, 1995; Srinivasan, 1972). Moreover, it has been shown to exhibit a wide 
range of pharmacological activities including the treatment of several 
neurodegenerative diseases such as Alzheimer and Parkinson’s diseases (Figure 3). In 
the next section, we will be discussing some of the biological properties of curcumin 
(Zhou et al., 2011). 
 
Figure 3: Therapeutic potential of curcumin. 
Curcumin has been shown to exhibit a wide range of pharmacological activities in 
central and peripheral body systems, through its anti-oxidant, anti-inflammatory and 
neuroprotective properties (Zhou et al., 2011). 
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1.1.4.1 Anti-inflammatory Effects 
Inflammation is a physiological process by which our body fight against infections 
triggering host immune response. It is a complex interaction that aims at removing the 
invading agent or damaged tissue. Over-activation of the immune system and 
inflammatory responses may cause further tissue damage (Joe et al., 2004). 
Inflammation plays a major role in a number of pathological conditions including: 
neurodegenerative, autoimmune, cardiovascular, endocrine, and neoplastic diseases 
(Brouet and Ohshima, 1995; Liu and Hong, 2003; Nosalski and Guzik, 2017). 
Interaction with and modulation of the effects of various inflammatory mediators by 
curcumin demonstrated its anti-inflammatory properties (Aggarwal and Harikumar, 
2009; Jurenka, 2009). Curcumin can inhibit inflammatory cytokines, interleukins 
(ILs), chemokines, as well as inflammatory enzymes, cycloxygenase-2 (COX-2), 
inducible nitric oxide synthase (iNOS) and cyclinD1 (Creţu et al., 2012). Curcumin 
has been shown to diminish GFAP level (Yu et al., 2010), suppress NF-kβ activity, 
and reduce the levels of tumor necrosis factor- α (TNF-α) (Chen et al., 2014). 
1.1.4.2 Anti-oxidant Effects 
It is well known that oxidative stress plays a major role in acute, chronic, and 
degenerative diseases. Oxidative stress results from imbalance between formation and 
neutralization of reactive oxygen species (ROS) in our body, leading to generation of 
free radicals and energy failure (Pham-Huy et al., 2008). Curcumin has a strong anti-
oxidant activity compared to vitamin C and E (Toda et al., 1985). The potent activity 
of curcumin against pro-oxidants such as superoxide radicals, hydrogen peroxide and 
nitric oxide radical, as well as enhancing anti-oxidant enzymes such as catalase, 
superoxide dismutase (SOD), glutathione peroxidase (GPx) and heme oxygenase-1 
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(OH-1) results in a decrease in lipid peroxidation and subsequently organ damage 
(Jeong et al., 2006; Reddy and Lokesh, 1994, 1992). Curcumin induced heme 
oxygenase-1 and protected endothelial cells against oxidative stress (Motterlini et al., 
2000). Curcumin inhibition of free radical formation protected rat myocardial tissue 
from isoprenaline (ISO)-induced ischemic injury (Manikandan et al., 2004; Nirmala 
and Puvanakrishnan 1996a, 1996b). Curcumin provided anti-oxidant protection 
comparable to vitamin E on renal cell lines by its inhibitory effect on lipid 
peroxidation, cytolysis, and lipid degradation (Cohly et al., 1998).  
The methoxy and phenolic groups on benzene rings and the β-diketone moiety in 
the curcumin structure (Figure 4) are thought to be the cause of its anti-oxidant 
properties (Sandur et al., 2007; Sreejayan and Rao, 1996). 
 
 
 
Figure 4: Curcumin structural features. 
Curcumin has three chemical entities in its structure: two aromatic ring systems 
containing O-methoxy phenolic groups, connected by a seven carbon linker, consisting 
of α, β-unsaturated diketone moiety [Modified from (Bagchi et al., 2015)]. 
 
  
Aromatic 
ring 
Aromatic 
ring 
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1.1.4.3 Neuroprotective Effects 
Our previous discussion has shown that both the anti-oxidant and anti-
inflammatory effects of curcumin together form the basis of beneficiary effects of 
curcumin in several neurological diseases affecting the central as well as the peripheral 
nervous system. Curcumin as a multi-targeted compound can serve as a 
neuroprotective agent. Oral administration of (50, 100 and 200 mg/kg) curcumin 
protected Swiss albino mice against rotenone-induced dysfunction in the 
mitochondrial respiratory chain and conserved the mitochondrial enzyme complex 
(Khatri and Juvekar, 2016). Anti-oxidant properties of curcumin improved the levels 
of acetylcholine esterase enzyme in mice compared with negative control animals 
which was reflected on motor behavioral assessments (Khatri and Juvekar, 2016). 
Alzheimer’s disease is a neurodegenerative disorder and the most common cause of 
dementia worldwide. The main pathological hallmark is the aggregation of Aβ 
amyloid protein plaque formation, which has not been phagocytosed due to microglial 
dysfunction. Curcumin has anti-protein aggregation properties (Darvesh et al., 2012), 
and could inhibit plaque formation and accumulation, and activated microglial 
phagocytic activity (Cole et al., 2007; Ono et al., 2004). 
1.1.4.4 Anti-cancer Effects 
In 1987, Kuttan and colleagues carried out the first clinical trial to investigate the 
anti-cancer properties of curcumin. He included 62 patients having external cancerous 
lesions and used an ointment containing ethanol turmeric extract. Patients who 
received this treatment reported a significant improvement in their symptoms of pain, 
itching, smell, and lesion size (Kuttan et al., 1987). Since this study, several other trials 
have been conducted on different types of cancer insuring the dose dependent chemo-
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preventive effect of curcumin in head and neck, breast, gastrointestinal (colon, 
pancreatic, stomach, esophageal and oral carcinogenesis), and cervical cancers (Bayet-
Robert et al., 2010; Cao et al., 2016; Carroll et al., 2011; Cheng et al., 2001; Epelbaum 
et al., 2010; Ghalaut et al., 2012; Kim et al., 2011). Curcumin was not tested as a single 
anti-cancer agent only, but also as an adjuvant anti-tumor agent and to reduce adverse 
effects of other chemotherapeutics (Belcaro et al., 2014; Garcea et al., 2005). 
Curcumin can suppress carcinogenesis at different stages of promotion, angiogenesis, 
and growth (Conney et al., 1991; Huang et al., 1992; Robinson et al., 2003). 
1.1.5 Effects of Curcumin on Different Ion Channels and Receptors 
Depending on the above discussion, several types of ligand-gated ion channels and 
receptors have been suggested to be involved in mediating pharmacological actions of 
curcumin. In this study, we are investigating the effect of curcumin application on the 
functional properties of α7-nicotnic acetylcholine receptors mainly and other ligand 
gated ion channels. 
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1.2 Acetylcholine Receptors 
Acetylcholine (ACh) is one of the key neurotransmitters in the central and 
peripheral nervous systems. It can bind and transmit signals through two types of 
receptors, classified by their sensitivity to either muscarine or nicotine; muscarinic 
acetylcholine receptors (mAChRs) and nicotinic acetylcholine receptors (nAChRs). 
Muscarinic acetylcholine receptors are a family of G-protein-coupled receptors, 
whereas nicotinic acetylcholine receptors are ligand-gated ion channels (LGIC) as 
shown in Figure 5 (Hurst et al., 2013). Muscarinic receptors are involved in several 
physiological functions namely heart rate, force of contraction of smooth muscle and 
act as the main end-receptor stimulated by ACh. Their signals are relatively slow and 
evolve over seconds to minutes. On the other hand, nicotinic receptors, respond to 
endogenous ACh in muscle, autonomic ganglia, and the brain, and mediate fast 
synaptic transmission in a millisecond time frame. 
 
Figure 5: The activated forms of the acetylcholine receptor classes. 
Nicotinic ligand-gated ion channels and muscarinic G-protein coupled receptors. For 
each receptor, the non-overlapping binding sites: orthosteric and allosteric  (De Smet 
et al., 2014). 
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The central role of nicotinic receptors in converting chemical stimuli into electrical 
signals has involved them broadly in a broad range of physiological functions 
including muscle contraction, brain development, cognitive function, learning and 
memory, arousal, reward, motor control, analgesia, synaptic plasticity as well as 
pathological disorders including Alzheimer's disease, Parkinson's disease, epilepsy 
and schizophrenia (Jensen et al., 2005; Lindstrom, 2003; Mineur and Picciotto, 2008; 
Posadas et al., 2013). These receptors are the target of pharmacologically administered 
nicotine. 
1.2.1 Nicotinic Acetylcholine Receptors 
Early in the twentieth century, nicotine became a fundamental molecule in the basic 
science of pharmacology. In 1905, Langley reported that body muscles contract via a 
“receptive substance” in muscles. The identification of the muscle nicotinic 
acetylcholine receptors paved the way for the discovery of neurotransmitter receptors 
(Langley, 1905). But it was not until 1970s when neuronal nAChRs, were identified 
(Changeux et al., 1970; Miledi and Potter, 1971). A decade later, the extended family 
of nicotinic receptor has been identified (Patrick et al., 1983). 
Nicotinic acetylcholine receptors (nAChRs) were the first of all neurotransmitters 
to be identified biochemically and functionally (Lindstrom, 2003). nAChRs are 
members of a structurally related family of ligand gated ion channels that also include 
receptors for neurotransmitters such as 5-hydroxytryptamine (5-HT), g-aminobutyric 
acid (GABA), and glycine (Albuquerque et al., 2009; Hendrickson et al., 2013). 
Initially, this class of receptors was named the Cys-loop family as all receptors contain 
a conserved two disulfide-bonds cysteines separated by 13 amino acids in their 
extracellular amino terminus (Figure 6A). Recent discovery of these receptors in 
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prokaryotic cells but lacking the character of Cys-loop led to the change the in name 
from Cys-loop family to pentameric Ligand-gated ion channels (pLGIC) (Tasneem et 
al., 2005).  
 
 
 
Figure 6: Neuronal nicotinic acetylcholine structure. 
(A) Each nAChR subunit contains four transmembrane domains (M1-M4), an 
extracellular NH2- and COOH-terminal, and a prominent M3-M4 intracellular loop of 
variable length. (B) Five subunits co-assemble to form a functional subunit. (C) 
Homomeric receptors consist of α subunits. (D) Majority of nAChRs are heteromeric 
and consist of a combination of α and β subunits. Multiple α subunits may co-assemble 
with multiple β subunits in the pentameric nAChR complex (illustrated here by 
α6β3β2). ACh binding sites are represented as red triangles [Modified from: 
(Hendrickson et al., 2013)]. 
  
All nAChR subunits have an: 1) extracellular domain (ECD) approximately  ̴ 200 
amino acid long and hydrophilic in nature, 2) four transmembrane domains (TMD) 
which are hydrophobic in nature (M1 – M4), 3) the intracellular domain (ICD) which 
varies in length between different subunits, and lastly 4) an extracellular carboxy 
terminal (Figure 6A) (Albuquerque et al., 2009). In general, the ECD is the site of 
agonist (ACh) binding, TMD contains the allosteric binding site and is responsible for 
Cys-loop 
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the ion pore, permeability and selectivity (especially M2 which is conserved 
throughout LGIC), and ICD controls channel conductance (Albuquerque et al., 2009; 
Changeux, 2010; Jones et al., 2010; King et al., 2015; Paulo et al., 2009). 
Nicotinic acetylcholine receptors have a pentameric structure consisting of five 
transmembrane subunits around a central water-filled pore selective for cation (Figure 
6B). To date, 16 distinct subunits of nAchRs have been identified in the human 
proteome. Subunits are divided into two subgroups, the α and β subunits of which 5 
nAChR subunits that are expressed in muscle (α1, β1, γ, δ, and ε) and 11 nAChR 
subunits are expressed in nervous tissue (α2-7*, α9, α10, β2-4). This study mainly 
focuses on neuronal types of nAChRs. Each nAChR can be either a homomeric, 
formed by five identical subunits or heteromeric receptor that result from the 
combination of different subunits (Figures 6C & D). The nomenclature for the genes 
that encode the nAChR subunits is CHRNxy where CHRN stands for cholinergic 
receptor, nicotinic, and xy represents the subunit. For example, CHRNB4 is the gene 
for the β4 subunit. The α7 neuronal nicotinic receptor gene, CHRNA7 is located on 
the long arm of Chromosome 15, is widely expressed in both the brain (Sinkus et al., 
2015). CHRNA7 was first identified in chicken, α7 subunit immediately attracted 
much interest of physiologists and geneticists, since it forms functional homomeric 
receptors and has unique features in terms of its 1) genomic structure, 2) localization 
and function with high calcium permeability (PCa/PNa≈10), 3) rapid activation and 
desensitization by agonist (millisecond scale) (Bertrand et al., 1992; Couturier et al., 
1990), and 4) selective inhibition by α-bungarotoxin (α-Btx) and methyllycaconitine 
(MLA) (Couturier et al., 1990; Séguéla et al., 1993; Turek et al., 1995). Because of its 
simple organizational structure, the α7 subunit can be used to study structure–function 
relationships. For example, mutation of a single amino acid in the channel domain will 
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cause the whole receptor complex to be modified, which provides a better 
understanding of receptor function (Hurst et al., 2013). Despite its homomeric 
arrangement, α7-nAChR can assemble in a heteromeric form with other subunits; α7β2 
heteromeric receptors (Liu et al., 2012, 2009; Moretti et al., 2014; Thomsen et al., 
2015; Zoli et al., 2015). 
Depending on the presence, abundance, and timing of ACh binding, nAChRs exist 
in different states and undergo spontaneous conformational transitions: closed at rest, 
open pore, and desensitized (Figure 7) (Hurst et al., 2013). Prolonged exposure to low 
doses of ACh, nicotine, or a nicotinic agonist substantially will lead to desensitization, 
stabilizing the receptor in a closed state, unresponsive to further agonist stimulation.  
 
 
 
Figure 7: Proposed mechanism of activation and desensitization. 
Channel transition between three main conformational states by the binding of agonist: 
(A) closed, (B) open, and (C) desensitized, where the channel is having high binding 
affinity to agonist, but impermeable to ions [Modified from (Nys et al., 2013)].  
A 
C B 
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Orthosteric is the term used to describe the binding site for the natural ligand, and 
classical agonists are therefore referred to as orthosteric agonists. However, a group of 
compounds that lack agonist activity on nAChRs and act via a distinct transmembrane 
binding site are described as allosteric modulators, (allo- from the Greek meaning 
"other")  (Figures 5 & 8) (Flor and Acher, 2012). Allosteric modulators can modulate 
the activity of the channel. They are of three types: 1) positive allosteric modulators 
(PAMs), that potentiate the activity of the channel but only in the presence of an 
agonist with minimal level of desensitization; 2) negative allosteric modulators 
(NAMs), inhibiting channel activity upon binding, or acting as open-channel blocker; 
3) silent allosteric modulators (SAMs), having no effect on orthosteric activity but 
blocking allosteric modulation (Figure 8) (Corradi and Bouzat, 2016).  
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Figure 8: Types of Allosteric modulators. 
(A) The allosteric ligands modulate the activity of the channel by binding to a 
topographically distinct binding site from the orthosteric site and modulate the affinity 
(red) and/or efficacy (green) of the orthosteric ligand (Nishikawa et al., 1983).  
(B) The effect of different allosteric modulators on the functional response of the 
agonist represented by the concentration-response curve of the agonist (solid black). 
PAMs enhances orthosteric agonist affinity and/or efficacy (solid red, blue, and green), 
while NAM inhibit the activity of the channel by lowing orthosteric agonist affinity 
and/or efficacy (dashed red and green) (Kinon et al., 2015). 
 
 
Based on their macroscopic effect, PAMs can be classified into ‘type I’ or ‘type II’ 
PAMs, depending on their effects on receptor desensitization. Type I  increases the 
current amplitude but do not modify the channel kinetics significantly, while type II 
profoundly changes the kinetics of the currents by prolonging single channel opening 
time (Figure 9) (Clementi et al., 2000; Lewis et al., 2017). When compared with 
Allosteric 
ligand 
Orthosteric 
ligand 
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regular α7-nAChR agonists, PAMs have emerged as an important pharmacological 
target because they: 1) have greater structural diversity compared to orthosteric site 
which is highly conserved in nAChRs (Yang et al., 2012); 2) allow more flexible 
structural form and final effects; 3 have an extra neuroprotective activities, as 
activation of α7-nAChR can be inactivated by desensitization, some α7-PAMs has the 
ability to desensitize the receptor back to conducting state (Kalappa et al., 2013; Sun 
et al., 2013; Uteshev, 2014). Moreover, it has been suggested that neuronal injury 
activates cholinergic system, and the presence of PAM will reduce the level of agonist 
stimulation required for its neuroprotective effect (Uteshev, 2014). 
 
 
 
 
 
 
Figure 9: Molecular activation routes of the α7-nAChRs. 
PAM type I and II compounds (grey lines) produce differential enhancement of the 
inward currents generated by nicotinic agonists (black line). (A) PAM type I 
profoundly increase the current amplitude, (B) PAM type II significantly change the 
kinetics of the current by prolonging the single channel opening time.  
A B 
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1.2.1.1 Distribution of Nicotinic Acetylcholine Receptors 
The current existing data regarding the distribution on nAChRs suggest that it is 
relatively conservative in all vertebrate species. The distribution of nAChRs is not 
restricted to well-defined brain cholinergic pathways. The structure and localization of 
the different nAChR subtypes have been investigated using a number of 
complementary techniques, including in situ hybridization and PCR for specific 
subunit RNAs, immune-precipitation for protein subunits, imaging by 
autoradiography, PET and SPECT, and functional electrophysiological or 
neurotransmitter release assays (Mineur and Picciotto, 2008). However, despite the 
incomplete nature of the studies performed to date, it is possible to draw a map of 
nAChR distribution in the human brain as shown in Figure 10, with the α7 and β2* 
being the most widely distributed throughout the mammalian brain (the asterisk denote 
the possibility of different subunits) (Millar and Gotti, 2009).  The regional distribution 
of nAChRs subtypes has been described in the temporal cortex, cerebellum, striatum 
and basal forebrain and have been localized in a variety of brain structures, in particular 
the thalamus, cortex and the striatum (Zoli et al., 2015). 
Grady et al. examined the mouse brain using in situ hybridization to characterize 
the mRNA expression pattern of nAChRs (Grady et al., 2007). Grady’s laboratory 
demonstrated that the ventral tegmental area (VTA) and substantia nigra (SN) 
expressed variable concentrations of α 3-7, β2, and β3. Also, they reported the presence 
of heteromeric nAChRs subunits; α4α6β2β3, α6β2β3, α6β2, α4β2, and α4α5β2, on 
dopaminergic terminals of mouse striatum (Grady et al., 2007; Le Novere et al., 1996). 
Several studies have demonstrated a decline of specific nAChRs in Parkinson’s disease 
(Guan et al., 2002). 
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Figure 10: Distribution of nicotinic acetylcholine receptors human brain. 
Distribution of different subtypes of nAChRs in human brain by means of quantitative 
immunoprecipitation studies using radiolabeled (3H-Epibatine or 125I-αBungarotoxin) 
nAChRs obtained from post-mortem brains (Zoli et al., 2015). 
 
 
1.2.1.2 Alteration of Nicotinic Acetylcholine Receptors Expression 
Alteration of cholinergic neurotransmission by either genetic dysregulation or 
cholinergic denervation has been demonstrated in various studies. Several studies have 
correlated a decline of specific nAChRs to certain pathological conditions like, 
Alzheimer’s disease (Clementi et al., 2000; Nordberg, 1992; Warpman and Nordberg, 
1995), Parkinson’s disease (Guan et al., 2002; Quik et al., 2012), schizophrenia 
(Marcus et al., 2016; Timofeeva and Levin, 2011), autism (Bacchelli et al., 2015; 
Olincy et al., 2016), epilepsy (Steinlein et al., 1995; Weiland et al., 1996), and 
neuropathic pain (Marubio et al., 2003, 1999; Sullivan et al., 1994; Umana et al., 
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2013). Here, we will focus on the proposed mechanism of neuroprotective role of 
neuronal α7-nAChRs in Parkinson’s disease (Figure 11). 
 
 
 
Figure 11: Proposed mechanism of α7-nAChRs in Parkinson’s disease. 
Activation of α7-nAChRs has a neuroprotective effect on dopaminergic neurons and 
astrocytes via its anti-inflammatory and anti-apoptotic activities (Jurado-Coronel et 
al., 2016).  
Astrocytes 
Nicotine 
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1.3 Parkinson’s Disease 
The basal ganglia are a core component in the pathogenesis of Parkinson’s disease. 
The basal ganglia are a group of subcortical nuclei located near the base of the brain 
including, the caudate, putamen, (both together form the corpus striatum or 
neostriatum), the ventral stiatum, globus pallidus with its external and internal 
segments (GPe, GPi, respectively), the subthalamic nucleus (STN), and the substantia 
nigra pars reticulata (SNpr) and pars compacta (SNpr) (Figure 12). 
Dysfunction of the basal ganglia results in a wide spectrum of movement 
disorders that varies from hypokinetic disorders (e.g.; Parkinson's disease) to 
hyperkinetic disorders (e.g.; Huntington's disease). The main focus of this research 
work is the hypokinetic disorder namely, Parkinson’s disease. 
 
 
Figure 12: Structures of the basal ganglia. 
Coronal section of the brain illustrating major structures of basal ganglia. Substantia 
nigra (gray) and its innervation to striatum. The putamen (purple) and caudate nucleus 
(green) together forms the striatum. The The globus pallidus (blue) with its two parts 
externus (GPe) and internus (GPi). The subthalamic nucleus (red). The thalamus 
(orange) and the cortex (Aum and Tierney, 2018).   
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1.3.1 Background 
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
after Alzheimer's disease (AD). Parkinson’s disease was first described by an English 
physician and surgeon, James Parkinson in his Essay on the Shaking Palsy in 1817, 
which was called later Parkinson’s disease (PD) by Jean-Marie Charcot (Parkinson, 
2002). PD is an age-related disorder. The prevalence of the disease increases with 
advancing age. The prevalence is around 1% over the age of 60 and 0.3% of all ages 
in industrialized countries (de Lau and Breteler, 2006).  
1.3.2 Pathophysiology 
Parkinson is a slowly progressive multisystem disorder rather than just a disease 
involving massive neuropathological alterations in the brain. Pathologically,  the 
hallmark of the disease is the phosphorylation of alpha synuclein protein and formation 
of proteinaceous inclusions, Lewy bodies (LB) in neurons (Figure 13) and Lewy 
neurites (LN) in axons and dendrites as well as degeneration of dopaminergic 
nigrostriatal neurons (Braak et al., 1994; Del Tredici and Braak, 2016). 
Other central nervous system (CNS) neurotransmitter systems are also affected to 
varying degrees including cholinergic, GABA-ergic, glutamatergic, tryptaminergic, 
noradrenergic and adrenergic nerve cells that may show similar damage in their 
cytoskeletons (Braak and Braak, 2000). Mechanistically, some environmental insults 
and/or gene mutations contribute to the degenerative changes observed in Parkinson’s 
disease, causing mitochondrial dysfunction, oxidative stress, modifications in protein 
handling, adaptations in immune-modulators, as well as alterations in other molecular 
and cellular functions (Figure 14) (Franco-Iborra et al., 2016; Olanow and McNaught, 
2011; Schapira and Jenner, 2011). 
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Figure 13: Lewy body in affected dopaminergic neurons. 
Photomicrographs of various regions of substantia nigra in Parkinson’s patient show 
deposition of Lewy bodies and Lewy neuritis at two different magnifications. The 
upper panels (A & B) demonstrate are magnified 20 times to show the alpha-synuclein 
aggregates forming Lewy bodies (red arrows). The lower panels (C & D) demonstrate 
a 60-times magnification to show strand-like Lewy neurites (green arrows) and 
rounded Lewy bodies of various sizes (red arrows) [Modified from (Rajan, 2012)]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D C 
A B 
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Figure 14: Pathophysiology of Parkinson’s disease. 
Parkinson’s disease is a multifactorial disorder, several factors have been involved in 
dopaminergic neuron degeneration process: (1) Genetic mutation results in protein 
misfolding and oxidative stress. (2) Exposure to environmental toxins causes 
mitochondrial dysfunction and increase ROS formation. (3) Neuroinflammation and 
chronic activation of microglia causes neuronal degeneration by releasing pro-
inflammatory mediators [Modified from (Blesa et al., 2015)]. 
 
1.3.3 Diagnosis 
For identification and characterization of this anatomical, structural, and 
neurotransmitter systems dysfunction; Braak and his collaborators has grouped PD 
into six stages. Stage 1-2: where only medulla oblongata/pontine tegmentum and 
olfactory bulb/anterior olfactory nucleus are affected by inclusion bodies with no 
clinical symptoms. Stage 3-4: symptoms may start to appear as inclusion bodies invade 
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the substantia nigra and other nuclei of the midbrain and forebrain. Stage 5-6: end 
stage of the disease as the neocortex is affected with a wide range of clinical 
manifestation (Braak et al., 2004, 2003). The clinical symptoms of PD can be 
categorized into motor and non-motor symptoms as shown in Table 2. 
Table 2: Motor and non-motor symptoms of Parkinson’s disease 
 
Motor symptoms Reference 
Limb rigidity 
Cogwheel phenomenon 
Shuffling gait lack 
Arm swing while walking.  
Expressionless face (hypomimia)  
Micrographia 
Limb tremor 
Resting pill-rolling  
Loss of balance and falls 
Freezing of movements  
Postural instability 
Speech disturbances 
Swallowing problems 
Dribbling of saliva  
Dystonia 
Postural deformities  
 
 
          
              
        (Jankovic, 2008) 
 
 
 
(Virmani et al., 2015) 
(Virmani et al., 2015) 
(Williams et al., 2006) 
(Perez-Lloret et al., 2012) 
(Kalf et al., 2011) 
(Kalf et al., 2012) 
(Tolosa and Compta, 2006) 
(Doherty et al., 2011) 
Non-Motor symptoms Reference 
Orthostatic hypotension 
Constipation 
Excessive sweating 
Urinary control disturbance 
Sleep disturbances 
Visual hallucinations and illusions  
Cognitive impairment and 
Dementia 
Anhedonia  
Depression and anxiety  
Loss of smell and taste 
Limb pain 
 
(Lahrmann et al., 2006) 
(Jost, 2003) 
(Hirayama, 2006) 
(Jost, 2003) 
(Monderer and Thorpy, 2009) 
(Onofrj et al., 2007) 
(Williams-Gray et al., 2006) 
 
(Pont-Sunyer et al., 2015) 
(Reijnders et al., 2008) 
(Doty et al., 1988) 
(Williams and Lees, 2009) 
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1.3.3.1 Motor Symptoms 
Dopamine (DA) is neurotransmitter involved in coordination of movement. When 
sixty to eighty percent of dopamine producing cells in the substantia nigra are 
defunctionalized the extra pyramidal system loses the ability to effectively promote 
movement and the motor symptoms of Parkinson's disease begin to appear (Chung et 
al., 2001). UK PD Brain Bank has established specific criteria for diagnosis of 
Parkinson’s disease and presented it in three steps (Table 2). Step one which is based 
mainly on the patient’s motor symptoms include bradykinesia, defined as delay in 
initiation of voluntary movement associated with progressive reduction in patient’s 
speed and amplitude of repetitive actions (Antonini et al., 2013; Berardelli et al., 2001; 
Goetz et al., 2007). It is one of the main and core symptoms that if found, in association 
with one of the following additional symptoms i.e., resting tremor, muscular rigidity, 
or postural instability- are a criterion for the diagnosis of PD (Hughes et al., 1992). 
Step two; is to exclude any other cause for the motor symptoms such as parkinsonian 
syndrome. Step three; establishes three supportive measures. Namely, unilateral onset 
of symptoms, persistent asymmetry of clinical symptoms, induction of dyskinesia by 
the dopaminergic treatment, and good response to levodopa treatment. 
1.3.3.2 Non-Motor Symptoms 
Clinical heterogeneity of Parkinson’s disease reflects the multisystem involvement 
in the pathophysiology of the disease. Therefore, the International Movement 
Disorders Society included a range of Non-motor symptoms (NMS) to the diagnostic 
criteria of Parkinson’s disease (Postuma et al., 2015). It has been reported that NMS 
starts to appear as early as ten years before the diagnosis of PD, outlining a prodromal 
or an asymptomatic stage of the disease. There is a wide range of symptoms (Table 3), 
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most commonly: cognitive impairment, anxiety, depression, constipation, and sleep 
disturbance. PD patients suffer more from NMS than motor symptoms with advancing 
disease. 
Table 3: UK Parkinson’s disease society Brain Bank clinical diagnosing criteria 
(Hughes et al., 1992) 
 
Step 1. Diagnosis of Parkinsonian Syndrome 
Bradykinesia 
• At least one of the following 
o Muscular rigidity 
o 4-6 Hz rest tremor 
o postural instability not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction 
Step 2. Exclusion criteria for Parkinson’s disease 
• History of repeated strokes with stepwise progression of parkinsonian features 
• History of repeated head injury 
• History of definite encephalitis 
• Oculogyric crises 
• Neuroleptic treatment at onset of symptoms 
• More than one affected relative 
• Sustained remission 
• Strictly unilateral features after 3 years 
• Supranuclear gaze palsy 
• Cerebellar signs 
• Early severe autonomic involvement 
• Early severe dementia with disturbances of memory, language, and praxis 
• Babinski sign 
• Presence of cerebral tumor or communication hydrocephalus on imaging study 
• Negative response to large doses of levodopa in absence of malabsorption 
• MPTP exposure 
Step 3. Supportive prospective positive criteria for Parkinson’s disease 
• Unilateral onset 
• Rest tremor present 
• Progressive disorder 
• Persistent asymmetry affecting side of onset most 
• Excellent response (70-100%) to levodopa 
• Severe levodopa-induced chorea 
• Levodopa response for 5 years or more 
• Clinical course of ten years or more 
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1.3.4 Treatment 
The etiology of PD is multifactorial. To date, there is no drug that cures or stops 
disease progression. Being mainly a dysfunction in dopaminergic system in the brain, 
Levodopa or L-dopa (L-3,4-dihydroxyphenylalanine) was introduced in 1960s as a 
prodrug of dopamine enhancing intracerebral dopamine concentration. Since its 
approval by the FDA in 1970, L-dopa has been the gold standard treatment for 
Parkinson’s disease. Though, after several months to years of treatment with L-dopa, 
patients develop the adverse effects of dyskinesias (Brotchie and Jenner, 2011; Huot 
et al., 2013; Iravani et al., 2012). This is known as L-dopa-induced dyskinesias (LIDs) 
and it will be discussed in greater details later. With the limitation of L-dopa use, other 
strategies have been implemented to enhance dopamine release, such as; dopamine 
agonist, monoamine oxidase type B inhibitors (MAO), catechol-O-methyl transferase 
inhibitors (COMTIs), anticholinergic, beta-blocker, antipsychotic, and antiviral (Table 
3 & Figure 15) (Connolly and Lang, 2014; Gazewood et al., 2013a). Surgical 
intervention became an option with deep brain stimulation (DBS) in selected PD 
patients (Benabid et al., 2009; Morgante et al., 2007; Rizzone et al., 2014). 
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Table 4: Treatment options of Parkinson’s disease 
Drug group Mechanism of Action Indication Reference 
Levodopa 
Levodopa-carbidopa 
Bind to and activate 
dopamine post synaptic 
receptors, to overcome 
dopamine depletion 
All motor 
symptoms 
(Hisahara 
and 
Shimohama, 
2011) 
Dopamine agonist 
Bromocriptine 
Pramipexole 
Ropinirole 
Rotigotine 
Bind to and activate 
dopamine receptors, to 
overcome dopamine 
depletion 
All motor 
symptoms 
(Hisahara 
and 
Shimohama, 
2011) 
Monoamine 
Oxidase B 
inhibitors (MAO) 
Selegiline 
Rasagiline 
Inhibit dopamine breakdown 
by MAO-B enzyme, to 
increase the amount of 
available dopamine 
Early mild 
symptoms 
and motor 
fluctuations  
(Grosset et 
al., 2010) 
Catechol-O-Methyl 
Transferase 
Inhibitors 
(COMTIs) 
Entacapone 
Tolcapone 
Prevent L-dopa breakdown 
by COMT enzyme, to 
increase the amount of 
available dopamine 
Motor 
fluctuations 
(Grosset et 
al., 2010) 
Anticholinergic 
Benztropine 
Trihexyphenidyl 
Bind to and block cholinergic 
receptors  
Tremor (Gazewood 
et al., 
2013b) 
Beta-Blocker 
Propranolol 
Bind to and block β2 
receptors, help in 
symptomatic treatment of 
tremor 
Tremor (Ferreira et 
al., 2013) 
Antipsychotic 
Clozapine 
Bind to and block 5-HT2A 
receptors 
Tremor and 
dyskinesia 
(Ferreira et 
al., 2013) 
Antiviral 
Amantadine 
Bind to and block NMDA 
glutamate (excitatory) 
receptors, to reduce motor 
complications associated 
with L-DOPA  
Gait 
dysfunction 
and 
dyskinesia 
(Wolf et al., 
2010) 
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Figure 15: Schematic presentation of pathophysiology and treatment of PD. 
(A) Coronal and sagittal section of human brain. (B) The gold-standard treatment of PD with L-dopa can be enhanced by co-administration of 
COMTIs, to prevent L-dopa degradation, and administration of a dopamine decarboxylase inhibitor (DDCIs); carbidopa to prevent peripheral 
conversion of L-dopa to its active form dopamine and thus maximizing the amount of the drug that can pass BBB and reach striatum. The striatum 
is densely innervated by corticostriatal glutamatergic afferents, dopaminergic afferents, cholinergic interneurons, and GABAergic medium spiny 
neurons. (C) This heavy connection is the site of action of most of the anti-parkinsonian medications: L-dopa, dopamine agonists, MAOBIs, anti-
cholinergic, and anti-viral [Modified from (Connolly and Lang, 2014)]. 
A 
C 
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1.3.5 Prognosis 
Parkinson’s disease is a complex disorder, and with advancing age it is expected 
that disease progression will vary between patients (Poewe, 2006). NMS precedes the 
motor symptoms and is usually mild and unilateral. Later, it progresses to the 
contralateral side but still remains very responsive to treatment, in what is called the 
honeymoon period. However, with time treatment efficacy starts to decline and 
patients’ symptoms and disability worsen, affecting their quality of life with the need 
of home care and frequent hospital admissions (Low et al., 2015; Parashos et al., 2002). 
Based on several studies, life expectancy of PD patients ranges from 6.9 to 14.3 years 
(Macleod et al., 2014). Thus, the need for development of strategies to stop, slow 
down, or preferably reverse the neurodegenerative process is mandatory. So, the next 
question is how an interaction at nAChRs level may lead to an overall functional effect 
such as protection against nigrostriatal damage. Three mechanisms suggested in recent 
studies will be discussed in following sections. 
1.4 The Neuroprotective Role of Nicotine and Nicotinic Receptors Against 
Nigrostriatal Damage 
Cigarette smoking is a well-known health hazard and a risk factor of serious 
chronic disorders, including cardiovascular disorders, lung disease, and cancers. 
However, unexpectedly, cigarette use appears to confer beneficial effects in 
Parkinson’s disease. The initial evidence that nicotine which acts on nAChRs, may be 
useful as a therapy for Parkinson’s disease stemmed from the results of various 
epidemiological findings in the early 1960s (Allam et al., 2004; Elbaz and Moisan, 
2008; Gorell et al., 1999; Noyce et al., 2012; Tanner, 2010; Wirdefeldt et al., 2011). 
Nicotine is a highly lipophilic compound and the active addictive ingredient of 
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tobacco. After smoking, chewing, or sniffing, nicotine rapidly crosses the blood-brain 
barrier and binds to nicotinic receptors. Nicotine is likely to mediate neuroprotective 
effects, as many studies have shown a reduced risk of PD in current and former 
smokers (Fahn, 2010; Nicoletti et al., 2010; Tanner, 2010). This apparent 
neuroprotection against Parkinson’s disease is correlated with smoking duration, 
intensity, and recentness, and is reduced with smoking cessation. Moreover, the 
incidence of Parkinson’s disease within twin pairs was less in the twin that smoked 
compared to the nonsmoker (Tanner et al., 2002), suggesting that the neuroprotective 
effects of tobacco are independent of genetic background. Furthermore, clinical trials 
with nicotine patches showed an attenuation of PD symptoms in PD patients 
(Fagerström et al., 1994). In addition, recent studies showed that nicotine 
administration reduces dyskinesia which is a major side effect of L-dopa used as the 
primary treatment for Parkinson’s disease (Bordia et al., 2008; Huot et al., 2013; 
Iravani et al., 2012; Quik et al., 2007). All these observations raised the possibility that 
nAChR stimulation may be useful in Parkinson’s disease management (Bordia et al., 
2015; Huot et al., 2013; Iravani et al., 2012). 
1.4.1 Dopaminergic and Cholinergic Systems Correlation and Dopamine Release 
Dopamine inputs to the striatum arise from midbrain dopamine neurons located in 
the ventral tegmental area (VTA) and substantia nigra pars compacta (SNpc), which 
innervates the ventral striatum (nucleus accumbens (NAc)) and dorsal striatum 
(caudate–putamen (CPu)) (Gerfen et al., 1987; Voorn et al., 2004). The striatum is 
innervated by a high density of axonal varicosities of dopaminergic nerves forming 
dopaminergic synapses (Descarries and Mechawar, 2000; Pickel et al., 1981). 
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The cholinergic striatal interneurons are the primary source of cholinergic input to 
the striatum, containing both muscarinic and nicotinic receptors (Zhou et al., 2002, 
2001). Nicotinic acetylcholine receptors are principal modulators of neuronal 
excitability throughout the central nervous system. Presynaptic nAChRs influences the 
release of neurotransmitters, while the postsynaptic nAChRs participate in fast 
postsynaptic neurotransmission as an excitatory input in the hippocampus, and 
subcortical areas including the ventral tegmental area (Dani, 2001; Mameli-Engvall et 
al., 2006; Mansvelder et al., 2002; Pyakurel et al., 2018). 
Functional evidence for the specificity of the cholinergic innervation to the VTA 
and the SN came from studies of Blaha and Winn (Blaha et al., 1996; Blaha and Winn, 
1993). Blaha and Winn measured dopamine efflux following nicotinic agonist 
administration before and after performing a lesion in the VTA. In both cases, a 
potentiation of DA efflux from the VTA or SN was noticed as a functional evidence 
of cholinergic innervation to this area. Using electrical stimulation of the VTA, Forster 
and Blaha demonstrated that DA efflux in the striatum is mediated through nicotinic 
and glutamatergic receptors in the  SN (Forster and Blaha, 2003). Later in 2006, Quik 
and colleagues demonstrated that the levels of striatal tyrosine hydroxylase (TH), 
dopamine transporter, vesicular monoamine transporter, dopamine and nicotinic 
receptors were greater in nicotine-treated MPTP-lesioned parkinsonian animals than 
in lesioned animals not receiving nicotine (Figure 16) (Quik et al., 2006). 
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Figure 16: Effect of nicotine treatment on MPTP- lesioned primates. 
Increase in levels of tyrosine hydroxylase (A), dopamine transporter (B), vesicular 
monoamine transporter (C), and striatal dopamine (D), in nicotine-treated MPTP-
lesioned primates than in lesioned animals not receiving nicotine [Modified from 
(Quik et al., 2006)]. 
  
A 
B 
C 
D 
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In 2009, studies of Quarta supported the previous results by using α7-nicotinic 
receptor null mutant mice and compared the release of [3H]dopamine from mouse 
striatal slices. Quarta measured [3H]dopamine release after administration of (1 μM) 
Nicotine in the absence (black bar) or presence (light gray; αCTxMII, white; DHβE) 
of β2* and α6β2* nicotinic receptor blockers respectively.  α7 nicotinic receptors were 
enhanced by 1 mM of choline (selective α7-nAChR agonist). Inhibition of 
[3H]dopamine release in response to nicotine was similar in both groups of animals 
due to blocking of different subunits of nicotinic receptors. Conversely, choline failed 
to stimulate dopamine release in α7 null mutant mice, indicating that α7-nAChR plays 
a major role in dopamine release (Figure 17). Along with other results, Quarta’s study 
supported the important role of heteromeric as well as homomeric nicotinic receptor 
subtypes in dopamine release (Quarta et al., 2009). 
 
 
Figure 17: Striatal [3H]dopamine release of wild type and α7-nicotinic receptor null 
mutant mice. 
Nicotine (1 μM) was applied in the absence (black bar) or presence of αCTxMII (200 
nM, light grey bars) or DHβE (10 μM, open bars); antagonists were applied 5 min 
before nicotine and remained throughout the stimulation. α7-nAChRs were stimulated 
by application of choline (1 mM; Cho; dark grey bars) (Quarta et al., 2009). 
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Recently, Pyakurel et al. (2018) tested the effects of various nicotinic receptor 
agonists; acetylcholine, nicotine, and neonicotinoid on dopamine release using 
Drosophila melanogaster strains (Figure 18A). Measurement of dopamine release 
following acetylcholine stimulation (Figure 18B) using fast-scan cyclic 
voltammogram indicated changes in dopamine over time (Figure 18C). This current 
response was stable after subsequent stimulations. Interestingly, addition of dopamine 
synthesis inhibitor; 3-iodotyrosine; 3-IT, significantly decreased Acetylcholine 
stimulated-dopamine release (Figure 18D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Stimulation of dopamine release in in Drosophila melanogaster ventral 
nerve cord (VNC). 
(A) Electrode and stimulating pipet in VNC of Drosophila. (B) Measurement of 
acetylcholine-stimulated dopamine release by fast scan cyclic voltammetry (FSCV). 
(C) Increasing the amount of acetylcholine caused an increase evoked dopamine 
concentration. (D) Acetylcholine-stimulated dopamine release was significantly 
inhibited by dopamine synthesis inhibitor, 3-iodotyrosine; 3-IT [Modified from 
(Pyakurel et al., 2018)].  
D C 
A B  
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Moreover, Pyakurel confirmed that dopamine release is mainly mediated by 
nicotinic not by muscarinic acetylcholine receptors. After incubation with two 
different selective nicotinic receptor antagonists; (α-bungarotoxin and DHβE) (Figures 
19A & C) the current response was lowered significantly, indicating lesser dopamine 
release. In contrast, upon incubation with a muscarinic antagonist; 1 µM of atropine, 
there was no significant change (Figure 19B) (Pyakurel et al., 2018). 
 
 
Figure 19: Data of Acetylcholine stimulated dopamine release before and after bathing 
with different nicotinic and muscarinic antagonists. 
(A) Effect of 1 µM α-bungarotoxin (nicotinic antagonist) suppressed dopamine 
release. (B) Effect of 1 µM of DHβE (β2/β4 antagonist) on dopamine release. (C) Effect 
of 1 µM of atropine (muscarinic antagonist) on acetylcholine stimulated dopamine 
release. (D) Histogram presentation of the data. (Pyakurel et al., 2018). 
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1.4.2 Immune Modulation via Nicotinic Receptors 
Activation of the immune system in the CNS takes place in various neurological 
disorders such as in; stroke, neurodegenerative diseases, spinal cord injury, multiple 
sclerosis, and brain injury (Long-Smith et al., 2009; Napoli and Neumann, 2010; 
Prokop et al., 2013; Yenari et al., 2010). In the CNS, the innate immune system is 
represented by a type of macrophage, the microglia, a member of the 
reticuloendothelial system and a resident immune cell in CNS. Under normal 
physiological conditions, microglia are inactive, with a small cell body and highly 
ramified branching processes. In response to injury or pathogen invasion, microglia 
transform into active phagocytic microglia helping with the clearance of aggregated 
proteins and cell debris (Stence et al., 2001). Chronic activation of microglia leads to 
noxious effects on neurons by the release of pro-inflammatory molecules and, thus, 
contributing to the pathophysiology of neurodegenerative diseases (Figure 20A)  
(Gehrmann et al., 1995; Liu and Hong, 2003). 
 
 
Figure 20: The role of microglia in health and disease. 
(A) Unchallenged microglia perform functions in the healthy CNS including 
phagocytosis of normal apoptotic debris, secretion of trophic factors (IGF-1, TGFβ), 
and synaptic maintenance. (B) Challenged microglia respond to CNS damage 
secreting pro-inflammatory factors (TNFα, IL-1β and ROS). When these mediators 
persist unchecked, neurodegeneration can ensue (Derecki et al., 2013). 
A B 
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Current advances in molecular biology have provided evidence that 
neuroinflammation plays an important role in the pathogenesis of PD (Chung et al., 
2010; Moore et al., 2005). It has been suggested that immune reaction in the form of 
glial activation and inflammatory processes may also participate in the cascade of 
events leading to neuronal degeneration in PD. Activated microglia express various 
cell-surface receptors, leading to increased levels of cytokines such as tumor necrosis 
factor-α (TNF-α), interleukin-1β (IL-1β), and interferon-γ in the substantia nigra of 
PD patients (Figure 20B) (Kreutzberg, 1996; Nagatsu and Sawada, 2005). These 
contribute to the development of chronic inflammation of the brain, leading to 
neuronal dysfunction and death in the form of neurodegenerative disorders such as PD 
(Chung et al., 2010; Orr et al., 2002). 
 
Figure 21: Staining of Primary human macrophages with fluorescein isothiocyanate 
(FITC)-labelled α-bungarotoxin (α -Bgt, 1.5 mgml21). 
(A) Binding of α- Bungarotoxin to nicotinic receptors on the surface of macrophages 
stained with (FITC)-labelled α-bungarotoxin. (B)  500 µmol of Nicotine was added 
before the addition of α -bungarotoxin. (C & D) Higher magnification revealing 
receptor clusters. Magnifications: a, b, X50; c, X200; d, X450 (Wang et al., 2003). 
A B 
C D 
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Neuronal nAChRs have been shown to regulate inflammation, in particular via the 
α7-nAChR activation in microglia, this is known as ‘cholinergic anti-inflammatory 
pathway’.  In his letter to Nature journal, Wang first established the relationship 
between the cholinergic and immune systems (Figure 21) (Wang et al., 2003).  
A year later, Shytle and collaborators demonstrated the expression of α7-nAChRs 
on microglia (Figure 22A) and their results suggested that α7-nAChRs play important 
roles in the neuroinflammatory processes (Figure 22B) (Shytle et al., 2004). Consistent 
with these findings, it has been demonstrated that nicotine has a neuroprotective effect 
on dopaminergic neurons via an anti-inflammatory mechanism mediated by the 
modulation of microglial activation (Park et al., 2007). Both Shytle and Park 
documented that nicotine treatment decreased microglial activation, with significant 
reduction of the bacterial cell wall endotoxin LPS-induced TNF- α release (Park et al., 
2007; Shytle et al., 2004). 
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Figure 22: RT–PCR analysis of α7-nAChRs expression on microglia using N9 and 
primary cultured microglial cells. 
(A) Expression of α7-nAChRs on microglia cell live. (B) Anti-inflammatory effect of 
Nicotine or ACh on LPS-induced TNF-α release. This effect is abolished after addition 
of α-Bgt. (C, D) The anti-inflammatory effect of Nicotine or ACh is dose dependent 
[Modified from (Shytle et al., 2004)]. 
 
In following studies, α7-nAChRs has been also identified on astrocytes (Liu et al., 
2015). Activation of α7-nAChRs can inhibit H2O2-induced astrocyte apoptosis in a 
concentration dependent manner (Figure 23A). This effect is abolished after 
administration of a selective α7-nAChRs antagonist, methyllycaconitine (MLA) 
(Figure 23B). Several protective mechanisms have been suggested including; 
A 
C 
B 
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maintenance of the Bax/Bcl-2 balance, and inhibition of cleaved caspase-9 activity via 
α7-nAChR activation. Nicotine prevents H2O2-induced loss of mitochondrial 
membrane potential (ΔΨm) (Figure 23B) (Liu et al., 2015). 
 
Figure 23: Nicotine inhibits H2O2-induced astrocyte apoptosis through protection of 
mitochondrial membrane potential. 
(A) Activation of α7-nAChRs on astrocytes by nicotine inhibits H2O2-induced 
apoptosis. Addition of MLA abolish this protective effect. (B) Nicotine inhibits H2O2-
induced loss of mitochondrial membrane potential (ΔΨm). Addition of MLA abolish 
this protective effect (Liu et al., 2015).  
 
A 
B 
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1.4.3 Effect of Nicotinic Receptors on L-Dopa Induced Dyskinesia 
L-dopa-induced dyskinesia (LID) which occurs in majority of patients on prolonged 
L-dopa treatment (Ahlskog and Muenter, 2001), can be very debilitating and impairs 
patient’s quality of life. Indeed, LID represent one of the major drawbacks of L-dopa 
treatment (Calabresi et al., 2008; Carta et al., 2008; Fahn, 2008; Fox et al., 2008; 
Jenner, 2008). 
The pathophysiological mechanism behind LID is not fully understood, but it is 
primarily due to the altered handling of levodopa presynaptically as well as dopamine 
receptors hypersensitization postsynaptically (Bastide et al., 2015). 
Several pharmacological approaches to treat LID have been implicated. For 
example the use of amantadine, a nonselective NMDA receptor antagonist has been 
suggested (Blanchet et al., 1996) but its effect is limited, short-lived and associated 
with many adverse effects (Sawada et al., 2010; Thomas et al., 2004; Verhagen 
Metman et al., 1998)Reduction of L-dopa daily dose has also been considered as a line 
of LID treatment, but this might lead to the re-emergence of PD symptoms (Goetz et 
al., 2005; Tambasco et al., 2012). The surgical approach has been also suggested for 
the treatment of LID, namely, deep brain stimulation (DBS). Deep brain stimulation is 
based on targeting the nuclei of selective deep brain structures such as; the internal 
segment of the globus pallidus (GPi), subthalamic nucleus (STN), and thalamus by 
high-frequencies electrical stimuli. This is based on interruption and/or modulation of 
the neuronal signaling of the structures within the basal ganglia (Brown and Eusebio, 
2008; Obeso and Lanciego, 2011). Though it is an effective method of treatment, it 
needs careful selection and screening of patients with dyskinesia with quality of life 
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severely affected, with on–off fluctuations, and treatment-resistant tremor. It is an 
invasive procedure with considerable side effects (Okun, 2012).  
The demand for safe and non-invasive approaches in treating LID is crucial. Many 
laboratories are targeting different neurotransmitter systems in the brain, such as; the 
serotonergic, glutamatergic, GABAergic, adrenergic, cannabinoid, opioid, adenosine 
and other neurotransmitter systems to test the effect of pharmacological agents on 
different neurotransmitter systems. Any one of these has the potential to improve 
dyskinesias, in fact some laboratories have shown promising results (Blandini and 
Armentero, 2012; Brotchie et al., 2005; Cenci and Lundblad, 2007, 2006; Fox et al., 
2009; Linazasoro et al., 2008; Olanow et al., 2006; Quik et al., 2008; Samadi et al., 
2006; Sgambato-Faure and Cenci, 2012). 
One of the proposed strategies against LID is to target neuronal nicotinic 
acetylcholine receptors. Accumulating evidence suggests that nicotine and nAChR can 
reduce the abnormal involuntary movements or dyskinesias complicating L-dopa 
treatment (Hickey and Stacy, 2013; Kerr, 2010; Quik et al., 2014, 2012). Pioneering 
studies were done on MPTP-induced Parkinson in monkeys to investigate the effect of 
long-term nicotine treatment against nigrostriatal damage in non-human primates 
where they exhibited parkinsonian motor symptoms very similar to those in 
Parkinson’s disease patients and develop abnormal involuntary movements after L-
dopa treatment analogous to those in L-dopa-treated Parkinson’s disease patients. The 
results demonstrated the effectiveness of nicotine treatment in PD model (Quik et al., 
2006). This was followed by number of studies by Quik and his colleagues where they 
could demonstrate that nicotinic administration to L-dopa-treated animal models led 
to ~60% decrease in LIDs (Figure 24). Nicotine reduced LIDs -whether given orally 
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via the drinking water, by systemic injection or by minipump- showing the effect is 
independent of rout of administration (Mihalak et al., 2006; Ween et al., 2010). 
 
 
Figure 24: Nicotine administration reduces L-dopa-induced dyskinetic-like 
movements in rats and monkeys. 
(A) Unilateral 6-OHDA injectted rat, nicotine treatment reduced AIM score 
significantly compared to vehicle group (Tanuja Bordia et al., 2008). (B) MPTP-
lesioned monkeys receiving oral nicotine treatment. Nicotine significantly reduced 
dyskinesia compared to vehicle group (Bordia et al., 2008; Quik et al., 2007). 
 
This reduction is more reflective with prolonged nicotine treatment with no 
development of tolerance, indicating that long term molecular and cellular changes 
underlie the nicotine-mediated decline in LIDs (Bordia et al., 2015, 2008; Quik et al., 
2013, 2007; Zhang et al., 2013). Neuroprotective effect of nicotine is achieved by 
stimulation of various subtypes of nAChRs, mainly α7 and α4β2*/α6β2* nAChRs. 
This was evidenced by using α7(−/−) and α4(−/−) knockout models (Quik et al., 2013). 
LID Patients after a period also suffer from “on-off” fluctuations due to a progressive 
reduction in their dopamine storing capacity. The term “on-time” refers to periods of 
the day where Parkinsonian symptoms are under adequate control and the opposite is 
true. The effect of TC-8831, an α6β2*/ α4β2* nAChR agonist on LID has been 
evaluated. In addition, the duration and quality of ON-time (‘good’ ON-time: time 
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without disabling dyskinesia, ‘bad’ on-time: time with disabling dyskinesia) was 
studied and compared to amantadine. TC-8831caused a significant reduction in the 
duration of ‘bad’ ON-time (62%) as well as severity of LID (reduced chorea and 
dystonia) with minimal effect on L-DOPA anti-parkinsonian benefits, in a dose 
dependent manner. Parallel to TC-88331, amantadine reduced ‘bad’ ON-time by up to 
61% but total ON-time has dropped by up to 23% (Figure 25) (Johnston et al., 2013). 
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Figure 25: Effect of TC-8831 and amantadine in combination with L-DOPA in MPTP-
lesioned monkeys. 
(A) Effect of TC-8831 in combination with L-DOPA on duration and quality of ON-
time. TC-8831 treatment significantly reduced the duration of ‘bad’ ON-time at 0.03, 
0.1, and 0.3 mg/kg compared to vehicle alone. (B) Effect of amantadine in combination 
with L-DOPA on duration and quality of ON-time. Amantadine at 3 mg/kg, afforded 
a significant reduction in duration of ‘bad’ ON-time and an increase in the duration of 
‘good’ ON-time, compared to vehicle alone [Modified from (Johnston et al., 2013)]. 
 
A B 
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Quik and his colleagues, have tested several nAChR agonists compounds ABT-
089, ABT-894 (α6β2*/ α4β2* nAChR partial and full agonists respectively), and ABT-
107 (α7-nAChR agonist) in monkey model of Parkinson’s disease. All agents yielded 
up to 60% reduction in LID in monkeys (Zhang et al., 2014, 2015). A newly developed 
α7-nAChR agonist ABT-126, has proved to be effective in treating LID in moderate 
to severe nigrostriatal damage in MPTP-treated squirrel monkeys. The anti-dyskinetic 
effect of ABT-126 was dose dependent (Figure 26) (Zhang et al., 2014, 2015). ABT-
126 is safe and well tolerated by patients and currently has reached phase 2 clinical 
trials for Alzheimer's disease (Gault et al., 2015). 
 
Figure 26: Effect of ABT-126 on LID in MPTP treated monkeys . 
(A) Various doses of ABT-126 were used (0.03, 0.1, 0.3 and 1mg/kg). (B) ABT-126 
significantly reduced LID in a dose dependent manner compared to vehicle alone 
[Modified from (Zhang et al., 2015)]. 
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1.4.4 Molecular Neuroprotective Mechanisms of Nicotinic Acetylcholine 
Receptors 
Epidemiological and experimental evidence indicate that nicotine is protective for 
the vulnerable dopamine neurons in Parkinson disease. The molecular mechanism 
involves alterations in calcium (Ca2+) signaling, although calcium independent 
nAChR-mediated mechanisms (cytosolic Ca2+) have also been reported (Dajas-
Bailador and Wonnacott, 2004; Picciotto and Zoli, 2008; Shimohama, 2009; Ward et 
al., 2008).  
Stimulation of nAChR mediates several intracellular changes, namely protein 
kinases such as; protein kinase A (PKA), extracellular signal-regulated mitogen-
activated protein kinase (ERK/MAPK), calcium-calmodulin-dependent protein kinase 
(CaM) and phosphatidylinositol 3-kinase (PI3K)/Akt-or protein kinase B-dependent 
signaling (Toulorge et al., 2011). Modulation of protein kinases are all calcium 
dependent. On the other hand, calcium independent modulation involves modifications 
in the JAK2 (Janus kinase 2)/PI3K and/or JAK2/STAT3 (signal transducer and 
activator of transcription 3) pathways (Hosur and Loring, 2011; Kawamata and 
Shimohama, 2011). These pathways are also known as survival pathways leading to 
cell survival by modulating different downstream signaling cascades such as; caspase 
activity (3, 8 and 9), cell survival proteins such as Bcl-2 (B-cell lymphoma 2) and Bcl-
x, NFκB, CREB (cAMP response element-binding), and other molecular components 
(Figure 27). Also it has been reported that nicotine-induced changes in basic fibroblast 
growth factor-2 (FGF-2), brain-derived neurotrophic factor (BDNF) and nerve growth 
factor (NGF) in brain dopaminergic and other regions attenuate neuronal damage 
(Belluardo et al., 2000; Formaggio et al., 2010; Massey et al., 2006; Zhou et al., 2004). 
In addition to neuroprotective role of nicotine- nAChRs stimulation, other mechanisms 
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are involved in its neuroprotective effect of nicotine, including: reduction in 
mitochondrial complex 1 activity, inhibition of reactive oxygen species generation, 
oxidative or anti-oxidative potential and radical scavenging properties (Cormier et al., 
2003; Ferger et al., 1998; Newman et al., 2002; Xie et al., 2005). Overall, all these data 
suggest the involvement of multiple molecular transduction mechanisms in nicotinic 
receptor-mediated neuroprotection under various pathological conditions. 
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Figure 27 : α7-nicotinic acetylcholine-mediated molecular signaling mechanism. 
α7-nAChR neuroprotective mechanisms through Ca2+-dependent and non-
Ca2+dependent mechanisms, modulating an intracellular cascade of events via 
activation of several protein kinases, leading to modification in immune activity, 
suppression of apoptosis, alteration of synaptic plasticity and eventually cell survival 
[Modified from (Quik, Perez et al., 2012)]. 
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1.5 Animal Models of Parkinson’s Disease  
The use of animal models has contributed significantly to a better understanding 
of disease process and made a significant breakthrough in development of new 
therapeutic strategies specially in LID and surgery. An ideal animal model of PD 
should include both pathological and clinical manifestation (motor and non-motor 
symptoms), involving central and peripheral nervous system, dopaminergic and non-
dopaminergic neurons. Unfortunately, none of the available models includes the full 
picture of PD, still they can replicate many of the disease characteristics. Experimental 
models can be categorized into two main classes: toxic and genetic. 
1.5.1 The Neurotoxin Model 
Many pharmacological and toxic agents have been implicated in primates as well 
as in rodents and other mammals. Though neurotoxic models considered to be the best 
for testing nigrostriatal dopaminergic degeneration, some drawbacks need to be 
mentioned: the rapidly progressive dopaminergic degeneration (within days – weeks) 
compared to the disease progression in human taking years to develop, most of the 
animal models lack the pathological hallmark; Lewy bodies, and motor/behavioral 
abnormalities (Blesa and Przedborski, 2014). 
1.5.1.1 Classical Model: 6-Hydroxydopamine 
6-Hydroxydopamine (6-OHDA) is a catecholaminergic neurotoxin that 
selectively damages dopaminergic and noradrenergic neurons (Luthman et al., 1989). 
This model of “Chemical Denervation” was first established by Ungerstedt in 1968 
and proved to knock out 60 – 90 % of tyrosine hydroxylase (TH)-positive neurons in 
SNpc. 6-hydroxydopamine is a photosensitive compound and can be rapidly oxidized 
56 
 
 
 
 
if exposed to light, hence it should be protected from light exposure, also its dissolved 
in ascorbic acid to protect it from oxidation (Bové and Perier, 2012). As 6-OHDA 
cannot cross blood-brain barrier, it should be injected directly (mostly as unilateral 
injection; hemiparkinsonian model) into the targeted area; medial forebrain bundle 
(MFB), substantia nigra pars compacta (SNpc), striatum or intraventricular 
administration (Blandini et al., 2008; Rodríguez Díaz et al., 2001). 
Since it’s a hydroxylated analog of dopamine (Figure 28), 6-OHDA is taken up by 
the neurons via dopamine transporters (DAT) and accumulate in the cytosol where it 
gets oxidized leading to ROS formation and cytotoxicity due to oxidative stress (Figure 
29) (Blum et al., 2001; Graham, 1978; Rangel-Barajas et al., 2015; Saner and Thoenen, 
1971). Proteinaceous aggregates and Lewy-like inclusions are not produced in this 
type of PD (Blesa and Przedborski, 2014).  
 
 
 
Figure 28: Chemical structures of 6-hydroxydopamine (6-OHDA) and dopamine 
(Bové and Perier, 2012) 
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For the following reasons, it was decided to use the animal model of PD in which 
multiple injections of 6-OHDA into the striatum was employed: 1) Striatal nerve 
terminals are more sensitive to 6-OHDA toxicity than the axon and cell bodies (Bruyn, 
1983; Malmfors and Sachs, 1968). 2) Progressive and less extensive lesion are more 
relevant to the pathophysiology of PD (Cannon and Greenamyre, 2010). 3) Striatal 
injection produces also non-motor symptoms of the disease; cognitive, psychiatric, and 
GI symptoms (Branchi et al., 2008; Tadaiesky et al., 2008). 4) Including wider and 
larger area of striatum can increase the success rate (Tieu, 2011). 5) It provides a well-
characterized behavioral, biochemical, and pathological feature of the disease which 
is correlated tightly with the number of injection sites (Rosenblad et al., 1999). 6) Any 
model that induce a predictable lesion over a long period of time will provide a greater 
opportunity for neuroprotective strategies to succeed, and striatum is therefore an ideal 
target to test for neuroprotection (Kirik et al., 1998). 
Following unilateral 6-OHDA injection, drug-induced rotation test (drug: 
dopamine receptor agonist; apomorphine or dopamine releasing compound such as 
amphetamine) are performed to assess the extent of motor impairment. Systemic 
injection of any of these drugs will result in asymmetrical rotation. Number of turns 
are counted to ipsilateral side in case of intraperitoneal injection of amphetamine or 
contralateral side in case of subcutaneous injection of apomorphine (Dunnett and 
Torres, 2011; Hefti et al., 1980b; Ungerstedt and Arbuthnott, 1970). 
 
 
 
 
58 
 
 
 
 
 
 
Figure 29: Molecular Mechanisms for different animal models of PD. 
Schematic diagram demonstrates site of action of pharmacological agents or genetic 
manipulations leading to nigrostriatal degeneration and striatal dopamine depletion. 
The cell represents a substantia nigra dopaminergic neuron with its cell body in the 
substantia nigra and its terminals in the striatum. Reserpine and Methamphetamine 
deplete dopamine at the nerve terminals, resulting in striatal dopamine deficiency. 6-
OHDA can affect all catecholamine neurons; therefore, it is stereotactically targeted 
into the substantia nigra, the nigrostriatal tract or the striatum. The neurotoxic effects 
of 6-OHDA are believed to involve oxidative stress-related mechanisms. MPP+ the 
active metabolite of MPTP, is selectively taken up by the dopaminergic neurons via 
its affinity for the dopamine transporter (DAT). The mechanism of action of paraquat 
is believed to involve oxidative stress; due to its structural similarity to MPP+, its toxic 
effects could be via the mitochondria. Rotenone, a potent inhibitor of complex I, is 
believed that rotenone-induced partial inhibition of complex I and the subsequent 
oxidative stress renders dopaminergic cells selectively vulnerable to chronic low levels 
of mitochondrial dysfunction. Direct administration of 3-NT into the striatum tests the 
involvement of oxidative stress, specifically peroxynitrite, in nigrostriatal 
dopaminergic degeneration. Mutations in the α-synuclein gene, linked to a small group 
of familial PD cases, are suggested to play a role in neuronal degeneration and 
increased protein aggregation (Sherer et al., 2003). 
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The site of 6-OHDA injection significantly affects the characteristics and extent of 
neurodegeneration (Agid et al., 1973; Przedborski et al., 1995). Injection of 6-OHDA 
into substantia nigra, cause a very rapid degeneration process of dopaminergic neurons 
(up to 90% loss) to take place within hours (12 hours) producing a complete damage 
in the nigrostriatal pathway, followed by loss of striatal terminals in 2 to 3 days (Faull 
and Laverty, 1969; Jeon et al., 1995), this is similar to end-stage PD. In the medial 
forebrain bundle (MFB) model, striatal terminals are degenerated before dopaminergic 
neurons (80 - 90% loss) producing a near complete damage in the nigrostriatal pathway 
within 3 to 4 days after injection which is equivalent to end-stage in PD. In the 
consecutive 3 weeks, dopamine content is totally lost in the striatum. In comparison to 
substantia nigra and medial forebrain bundle, 6-OHDA injection into striatum, 
produces slow, (in 3 weeks’ time) progressive, and partial loss of dopaminergic 
neurons and damage in the nigrostriatal pathway in a retrograde fashion which is more 
relevant to PD (Przedborski et al., 1995; Sauer and Oertel, 1994). The percent of 
dopaminergic cell death is dose-dependent and can vary from 30 to 75% depending on 
number of injection sites. Up to four injections can be delivered into the striatum (Kirik 
et al., 1998). This model is characterized by producing non-motor symptoms; 
cognitive, psychiatric, and gastrointestinal dysfunction (Branchi et al., 2008; Cannon 
and Greenamyre, 2010). Therefore, this model was employed in this study. 
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1.5.1.2 Gold Standard: MPTP 
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model was discovered 
accidentally in California 1983 in intravenous drug abusers using an analogue of the 
synthetic opioid; meperidine which was contaminated with MPTP, patients showed 
some movement abnormalities (bradykinesia) similar to PD (Davis et al., 1979; 
Langston et al., 1983). L-dopa was successful in treating these patients and 
confirmatory postmortem studies demonstrated the loss of nigrostriatal structures in 
the brain of same patients (Davis et al., 1979; Langston et al., 1999). MPTP is a 
lipophilic compound that can cross blood-brain barrier, once inside the brain it can be 
taken up by the astrocytes and metabolized by MAO-B enzyme into its active toxic 
form 1-methyl-4-phenylpyridinium MPP+ (Figure 30). The active metabolite MPP+ 
then can be taken up by the neighboring dopaminergic neurons via dopamine 
transporters (DAT) and stored in the vesicles by vesicular monoamine Transporter 
(VMAT) displacing and releasing dopamine from the storing vesicles (Figure 29). 
Released dopamine intracellularly can form toxic compounds such as; DOPAL 
(Panneton et al., 2010) where it can be exposed to superoxide radical (5-cysteinyl-DA) 
and hydroxyl radical (6-OHDA). Still, MPP+ can be more damaging by inhibiting 
complex I causing to mitochondrial electron chain inhibition leading to energy failure 
and oxidative stress and dopaminergic cell death (Mizuno et al., 1987; Nicklas et al., 
1985). MPTP causes severe damage to nigrostriatal pathway with significant loss of 
dopaminergic neurons in the striatum and SNpc (Dauer and Przedborski, 2003). 
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Figure 30: Chemical structures of MPTP and MPP+ 
(Bové and Perier, 2012) 
 
MPTP is a toxic compound in a wide range of species including mice, monkeys, 
sheep, dogs, guinea pigs, cats, but not rats which were found to be resistant to this of 
toxicity (Bezard et al., 1998; Giovanni et al., 1994; Przedborski et al., 2001). Mouse 
model is a practical and can provide a model of genetic mutation compared to the gold 
standard-monkey model which needs highly trained lab workers (Giovanni et al., 
1994). MPTP model also lack the pathological hallmark of PD disease; Lewy bodies, 
but in the other hand some reports have investigated the expression of α-synuclein 
(Dauer et al., 2002; Halliday et al., 2009; Purisai et al., 2005; Shimoji et al., 2005; Vila 
et al., 2000). 
1.5.1.3 Rotenone 
Rotenone is a natural compound found in plants that belong to family of 
Leguminosa (Tieu, 2011). It has been used mainly in farming as a pesticide. Rotenon 
model was developed for the first time by Greenamyre and his colleagues where the 
administered rotenone chronically using low-dose treatment in rats (Betarbet et al., 
2000; Cannon et al., 2009; Sherer et al., 2003). Due its high lipophilicity, it crosses 
blood-brain barrier and enter almost all cells independent of any transporter. Similar 
to MPTP cytotoxic mechanism, rotenone also inhibits complex I with the 
consequential oxidative stress and neuronal cell death (Parker et al., 1989; Schapira et 
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al., 1989). Interestingly, chronic systemic administration of rotenone to rats replicates 
all pathological features of PD, namely; proteinaceous aggregate, Lewy-like bodies, 
α-synuclein, behavioral abnormalities, and oxidative stress (Greenamyre et al., 2010; 
Sherer et al., 2003). Rotenone can be administered by different routes of 
administration, mainly intraperitoneal daily injection (Cannon et al., 2009), 
subcutaneous, or intravenous (Fleming et al., 2004). Most recently, it has been tested 
in mice via chronic intragastric rout or administration and direct stereotaxic injection 
or infusion into the brain (Alam and Schmidt, 2004; Pan-Montojo et al., 2010). A 
major drawback of this model is the high variability between different animals with 
high mortality which may reach up to 50% (Blesa and Przedborski, 2014; Emborg, 
2004). Moreover, trials to induce PD using rotenone in other species like mice or 
monkeys were unsuccessful, and not even in humans (Blesa et al., 2012). 
1.5.1.4 Paraquat 
Paraquat (N,N’-dimethyl-4-4’-bipiridinium) is a divalent cation compound that has 
a structure similarity with MPTP (Figure 29) (Snyder and D’Amato, 1985). Originally, 
it was used as a herbicide that has been forbidden in European Union after 2007 (Bové 
and Perier, 2012). Due to its hydrophilicity, paraquat uses neutral amino acid transport 
mechanism to penetrate blood-brain barrier. Once inside the brain paraquat causes 
cytotoxicity by inducing redox cycling with a cellular diaphorase in form of NADPH 
oxidase and nitric oxide synthase leading ROS production such as superoxide radical, 
hydrogen peroxide and the hydroxyl radical causing damage of cellular lipids, 
proteins, DNA and RNA (Day et al., 1999). Injection of paraquat in mice causes dose- 
and age-dependent nigral damage (Brooks et al., 1999; McCormack et al., 2002; 
Thiruchelvam et al., 2003). Paraquat causes not only brain toxicity but multi-organ 
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toxicity; lung, liver, and kidney, which may result in death after acute exposure in 
human (Grant et al., 1980; Hughes, 1988). Several reports established the presence of 
α-synuclein aggregates and Lewy bodies in this model (Fernagut et al., 2007; Mak et 
al., 2010; Manning-Bog et al., 2002). 
Other neurotoxic models 
Several other models gave have been used to induce nigrostriatal degeneration and 
dopaminergic cell death. However, those models are not in common use. 
1.5.1.5 Reserpine 
Reserpine was one of the earliest pharmacological agents that have been used to induce 
Parkinson’s disease in rodents, after the observation that it induces movement 
abnormalities; akinesia, in injected animals (Carlsson et al., 1957). Remarkably, these 
symptoms could be reversed by L-dopa treatment (Carlsson, 1959). Carlsson 
demonstrated that reserpine depletes monoamines in general in the brains of injected 
animals. Reserpine model has been reproduced also in other mammals such as; cats, 
rabbits, guinea pigs, and monkeys (Bezard et al., 1998). Reserpine is not only 
reversible but also non-specific; it mediates it’s action by hindering catecholamine 
storage in synaptic vesicles through ATP- and magnesium mechanism (Bezard et al., 
1998), such mechanism has no direct relation to dopamine and not toxic to nigrostriatal 
pathway. The aforementioned findings have weakened the use of this model. 
1.5.1.6 α-Methyl-Para-Tyrosine 
This reversible pharmacological agent is an enzyme inhibitor, it inhibits the 
enzyme tyrosine hydroxylase in dopamine synthesis process, blocking dopamine 
synthesis (Corrodi and Hanson, 1966; Spector et al., 1965). α-methyl-p-tyrosine has 
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the same weakness points of reserpine being reversible, non-specific, and not 
triggering neurodegeneration in nigrostriatal pathway (Tieu, 2011).  
1.5.1.7 Amphetamines 
A pharmacological group of compounds that belongs to psychostimulant drugs, 
has been found to be highly neurotoxic and producing behavioral and structural 
alteration similar to PD (Cadet et al., 2007; Thrash et al., 2009). Amphetamine 
derivatives such as: methamphetamine (METH) and 3,4-
methylenedioxymethamphetamine (MDMA), p-chloroamphetamine (PCA), and 
fenfluramine are toxic to serotoninergic and dopaminergic terminals in the striatum, 
nucleus accumbens, and frontal cortex  (Hess et al., 1990; Krasnova and Cadet, 2009), 
but SN and VTA neuronal cell bodies are affected only at higher doses (Sonsalla et al., 
1996; Trulson et al., 1985).  
1.5.2 Genetic Models 
Genetic animal models of PD have been designed on previously recognized targets 
to better study the disease process and therapy (Bezard and Przedborski, 2011; 
Meredith et al., 2008), noting that none of such genetic mutations are expressed in 
humans. Moreover, most of the genetic models don’t exhibit the behavioral 
phenotypes and neurodegeneration of PD (Dawson et al., 2010). For instance, many 
studies have reported the presence of mitochondrial dysfunction (Exner et al., 2012; 
Matsui et al., 2014; Morais et al., 2014), ubiquitin-proteasome dysfunction (Dantuma 
and Bott, 2014), ROS formation (Gandhi et al., 2009; Joselin et al., 2012; Ottolini et 
al., 2013). nevertheless, none of the studies could demonstrate significant changes in 
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dopaminergic neurons (Andres-Mateos et al., 2007; Goldberg et al., 2003; Hinkle et 
al., 2012; Sanchez et al., 2014). Here are the commonly used transgenic models of PD: 
1.5.2.1 α-synuclein 
α-syn gene is the core component of Lewy bodies (LB), and a type of missense 
mutations of α-syn. It is also called Park1. Up to date, two mutations in the gene 
(A53T, A30P) identified and causes a dominantly-inherited form of familial PD 
(Goedert et al., 2013; Krüger et al., 1998). This model generates a transgenic mice with 
typical behavioral and motor phenotype, but with no effect on DA neurons (Abeliovich 
et al., 2000; Thomas et al., 2011). Conversely, studies that have been done in 
Drosophila with a mutant α-syn gene, showed a reduced TH expression with a 
significant dopaminergic nigral cell loss, and inclusion bodies (Feany and Bender, 
2000). With all these controversies, hence the role of α-syn gene is still to be 
determined. 
1.5.2.2 LRKK2 
LRRK2 (leucine rich repeat kinase 2) gene is localized to membranes. 
Mutation in LRKK2 causes an autosomal dominant inherited form of PD (Healy et al., 
2008). Several mutations have been identified (Rudenko and Cookson, 2014), but all 
with no considerable disruption of SN dopaminergic neurons (Wang et al., 2008). 
1.5.2.3 PINK1 
PINK1 (phosphatase and tensin homolog- induced novel kinase 1) gene is 
localized to the mitochondria, causing autosomal recessive PD, and it’s also called 
PARK6 (Scarffe et al., 2014). In this form of mutation there is an age-dependent 
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moderate loss of dopaminergic neurons which is associated with overexpression of α-
syn (Oliveras-Salvá et al., 2014). This model shares a common phenotypes similarity 
with those of Parkin KO and DJ-1 KO mice. 
1.5.2.4 Parkin 
Parkin is an autosomal recessive mutation, accounting for 50% of familial 
cases of the disease and 20% of the young onset PD cases (Lücking et al., 2000; 
Periquet et al., 2003). Parkin KO mice show reduced DA level with minimal or no 
behavioral abnormalities (Itier et al., 2003; Kitada et al., 2009). One of this gene 
mutations; Parkin-Q311X-DAT-BAC mice displays age-dependent motor impairment 
along with loss of dopaminergic terminals in striatum and degeneration of SN cell 
bodies (Lu et al., 2009). 
1.5.2.5 DJ-1 
DJ-1 mutation is an autosomal recessive and early-onset for the disease 
(Puschmann, 2013). This form of genetic mutation results in motor and behavioral 
abnormalities, reduced DA level, but no effect on dopaminergic neuronal cells in SN 
(Goldberg et al., 2005; Kim et al., 2005). 
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1.6 Fundamental Methods of Assessing Structure and Function of Nigrostriatal 
Pathway 
Assessment of neuropathological process may vary from one study to another. 
However, when using neurotoxic model, and planning to investigate 
neurodegeneration or neuroprotection, like in our case- it is essential to study 
nigrostriatal pathway integrity and function.  
1.6.1 Dopaminergic Neurons in the Substantia Nigra Pars Compacta 
Substantia nigra pars compacta (SNpc) is a very rich area in dopaminergic neurons, 
its estimated that a mouse brain contains around 8000 ∼ 14,000 dopaminergic neurons, 
and this is variable from one strain to another (Zaborszky and Vadasz, 2001). The 
density of dopaminergic neurons is not distributed homogenously in SN being denser 
in rostral region. In Figure 31, coronal section of SN from caudal to rostral regions 
show variable distribution of the cells. Therefore, to sample the populations from all 
regions of SN we should choose an unbiased quantification method ensuring sampling 
of all regions at systemic section intervals. Currently, the gold standard method is to 
use unbiased stereological cell counting with an optical fractionator system (West et 
al., 1996, 1993, 1991). 
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Figure 31: Dopaminergic neuronal distribution in striatum and substantia nigra. 
(I) Dopaminergic cell bodies reside in SNpc and their terminals project to striatum for 
dopamine release. Coronal sections at SN from caudal (A) to rostral (H) showing 
heterogenous distribution of dopaminergic neurons. Coronal sections at striatum from 
caudal (J) to rostral (P) showing heterogenous distribution of dopaminergic terminals 
(Tieu, 2011). 
  
69 
 
 
 
 
1.6.2 Dopaminergic Terminals in the Striatum 
The density of dopaminergic terminals in the striatum correlates with the cell 
bodies they originate from in the SN, hence, the distribution of striatal terminals would 
vary moving from caudal to rostral (Bockaert et al., 1976; Widmann and Sperk, 1986). 
Immunohistochemical reaction of TH activity is a good measure of quantification. 
Another way of assessing dopamine terminals level is immunoblotting technique using 
TH and DA markers.  
1.6.3 Striatal Dopamine  
All the above-mentioned forms of assessments are assessing the structural integrity 
of nigrostriatal pathway, its important also to assess the function of this pathway. This 
can be done by measuring striatal dopamine release and its reflection on motor activity 
and behavior. Measuring of striatal dopamine release can be performed by using high-
performance liquid chromatography (HPLC) with an electrochemical detector. 
1.6.4 Lewy Body Aggregates 
Lewy bodies are considered the pathological hallmark in PD. There are several 
methods for detection of this mis-/or unfolded protein aggregates. An easy straight 
forward method is to use an antibody against α-synuclein (Beach et al., 2008). 
1.6.5 Behavioral/Motor Assessment 
As we mentioned earlier, dopamine depletion is reflected on animals’ behavior. 
There are several behavioral tests to assess the locomotor activities of animal models, 
such as; rotarod, drug-induced rotation, limb use asymmetry, forelimb placing test, 
swim test, adhesive removal test, and pole test (Meredith and Kang, 2006).  
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Chapter 2: Aims and Objectives 
The main goal of in this study was to investigate the effect of curcumin application 
on the functional properties of human neuronal 7 nicotinic acetylcholine receptors 
(nAChRs). This work was divided into two main parts:   
2.1 In-vitro Electrophysiological Study 
o In the first part of the study, human 7-nAChR were expressed homomerically in a 
Xenopus oocyte expression system to investigate: 
1. The effect of curcumin on the functional properties of 7-nAChRs. 
2. Determination of the voltage-dependence of curcumin action on the α7-
nAChRs, and the role of endogenously expressed Ca2+ activated Chloride 
channel and the role of pertussis toxin sensitive G proteins in mediating the 
effect of curcumin on the α7-nAChR.  
3. The effect of curcumin on other nAChRs subunits & ligand gated ion channels. 
4. The effect of other curcumin analogues and metabolites on 7-nAChRs. 
5. The binding affinity of curcumin and its derivatives with 7-nAChRs. 
2.2 In-vivo Study 
o To establish the neuroprotective effect of curcumin in animal model of Parkinson’s 
disease by investigating: 
1. Improvement of abnormal motor behavior of the animals. 
2. Effect of curcumin on the survival of dopaminergic striatal nerve terminals. 
3. Effect of curcumin on the survival of dopaminergic neurons in SNpc. 
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o To test whether the neuroprotective effect of curcumin in animal model of PD is 
mediated through an α7-nAChRs. 
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Chapter 3: Materials and Methods 
3.1 Electrophysiological In-vitro Study 
Materials 
3.1.1 Female Xenopus Oocytes 
Mature female African clawed frogs (Xenopus laevis) were purchased from 
Xenopus Express, Haute-Loire, France (Figure 32). They were housed in in a water-
tank (dimensions; 32 cm width, 130 cm length, and 66 cm height) filled with 
dechlorinated water. The room temperature was maintained at 19-21°C with a 12/12-
hour light/dark cycle. Frogs were fed twice a week with food pellets, supplied by 
Xenopus Express, France. Tank-water was changed twice a week. Animal care and 
handling experiments conducted in this study were in accordance with institutional 
guidelines and approved by the Animal Ethic Committee of the CMHS/UAEU. 
 
Figure 32: An adult female Xenopus laevis (Professor Murat Oz’s laboratory) 
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3.1.2 Chemicals 
Table 5: Chemicals required for the experiments 
Compounds Formula weight Manufacturer/ CAS # 
Curcumin 368.38 Santa Cruz/458-37-7 
α-Bungarotoxins ~ 8500 Sigma / T-0195- 
Acetylcholine Chloride 181.7 Sigma, USA/ A6625 
5-Hydroxytryptamine  387.4 Sigma, USA / H-7752 
Glycine 75.07 Sigma, USA / G7126 
Sodium Chloride (NaCl) 58.44 Sigma, USA/ S-3014 
HEPES 238.3 Sigma, USA/ H3375 
Potassium Chloride (KCl) 74.55 Mallinckrodt, USA/ 6858 
Magnesium Sulphate (MgSO4) 246.5 Sigma, USA/ M9391 
Sodium Bicarbonate (NaHCO3) 84.01 Sigma, USA/ S6014 
Magnesium Chloride (MgCl2) 95.22 Sigma, USA/ M8266 
Calcium Chloride (CaCl2) 110.9 Sigma-Aldrich, USA/C-4901 
Barium Chloride (BaCl2) 244.28 BDH, England/R-20-25 S:45 
Sodium Hydroxide (NaOH) 40 
Amresco, USA/ 
Lot.#214613010 
Hydrogen Chloride (HCl) 37% 
Sigma-Aldrich, USA/ 
25.814.B 
Gentamycin Sulphate salt 
(mixture of 3 major components 
designated as C1, C1a, and C2) 
C1 = 477.6  
C1a = 449.5 
C2 = 463.6  
Sigma-Aldrich, USA/ G1264  
Theophylline 180.2 Sigma/ T-1633 
Sodium Pyruvate 110.04 Sigma-Aldrich, Japan/P5280 
Penicillin G 356.4 Sigma, USA/ P3032 
Streptomycin sulfate 1457.4 Sigma-Aldrich, USA/ S9137 
BAPTA 764.68 Sigma-Aldrich / A-1076 
Benzocaine 165.2 Sigma, USA/ E-1501 
Collagenase-A CLS-1 (from 
Clostridium histolyticum) 
Concentration 
200 u/mg 
Worthington, biochemical 
corporation, NJ, USA / 
LS004196 
PKC-412 570.64 Tocris, Minneapolis, MN 
Go-6983 442.51 Tocris, Minneapolis, MN 
KT-5720 537.61 Tocris, Minneapolis, MN 
KN-62 721.84 Tocris, Minneapolis, MN 
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3.1.3 Other Materials 
Table 6: Other materials and devices used in the study 
Device or Material Specifications Company of Purchase 
Electrode Holder -- 
World Precision Instruments, 
Sarasota, FL, USA 
Magnetic stand and 
Manipulators 
Catalog #7739 Narishige, Tokyo, Japan 
Silver Wires -- 
World Precision Instruments, 
Sarasota, FL, USA 
Borosilicate Glass 
tubing 
for microelectrodes 
Glass thin-walled 
with filament 1.5 mm 
Catalog #TW150F-4 
World Precision Instruments, 
Sarasota, FL, USA 
Vertical Puller 
 
Model 700D, heater 
adjusted to 48 and 
solenoid adjusted to 70 
οC to get optimal 
resistance of 1-2 MΩ 
David Kopf Instruments, 
Tujunga, CA, USA 
Microfill filling 
syringe 
-- 
World Precision Instruments, 
Sarasota, FL, USA 
Micro-4 
Microsyringe 
pump controller 
Model UMC4-C 
World Precision Instruments, 
Sarasota, FL, USA 
Automatic Nano-liter 
injector 
Nanoject 
 
Drummond Scientific 
Company, Broomall, USA 
RNAase free water in 
1.8ml Eppendorf 
tubes 
Lot #M25/80502 
Epicenter Biotechnologies 
Madison, Wisconsin, USA 
pH Meter  Model 450 
Corning pH meter, Albany, 
NY, USA 
Stirrer 
Rotomix type 50800, 
Model #M50825 
Barnstead/ thermolyne, 
Dubuque, IA, USA 
Picofuge Catalog #400550 
Stratagene, Santa Clara, CA, 
USA 
Petri Dishes Catalog #127,60mm Sterillin, Newport, UK 
Surgical Accessories  
Scissors, forceps, 
scalpels 
World Precision Instruments, 
Sarasota, FL, USA 
Surgical Sutures 
Catgut Chrom, reverse 
cutting 3/8 circle, USP 
4/0, SMI 
DemeTech Corporation, 
Miami, Florida, USA 
Dissecting 
microscope 
Model GSZ 
Bunton Instruments Co Inc, 
Rockville, MD, USA 
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3.1.4 Experimental Setup 
The experimental setup for electrophysiological recordings using the two electrode 
voltage-clamp is shown in Figure 33 and 34. Two-electrode voltage clamp (TEVC) 
technique was applied using a GeneClamp-500B amplifier (Axon Instruments, 
Molecular Devices, Inc., Sunnyvale, CA, USA), as described previously (Ashoor et 
al., 2013) recording setup included magnetic holding devices (Kanetec USA 
Corporation, Bensenville, IL, USA), two manual micromanipulators (M33; 
Märzhäuser, Wetzlar, Germany) and head-stages for voltage (HS-2A Headstage, Gain 
1 MG, Axon Instruments, Molecular Devices, Inc., Sunnyvale, CA, USA) and current 
(HS-2A Headstage, Gain 10MG) were attached to the manipulators. The two glass 
electrodes were inserted in electrode holders and then connected to the head-stages. 
Micromanipulators were used to control the electrodes and impale the oocyte. 
The perfusion apparatus consisted of perfusion tubes and bottles containing 
extracellular solutions connected to the recording bath by silicon tubing (Cole Parmer 
Instrument Company, I.D. 1/16 inch, O.D. 1/8 inch and WALL1/32, Vernon Hills, 
Illinois, USA). Flow rate of perfusion was set to 3 - 5 ml/minute. A multichannel 
perfusion system was used for drug applications included tubing (C-Flex tubing, Cole-
Parmer Instrument Company, I.D. 1/32 inch, O.D. 3/32 inch and WALL1/32 inch, 
Vernon Hills, Illinois, USA), 50 mL glass syringes, and coupling devices. The drug 
application system was based on gravity flow by means of a micropipette that was set 
at a distance of about 2-3 mm from the oocyte position in the perfusion 
chamber/recording chamber (Warner Instruments LLC, Hamden, CT, UK) designed 
for placing oocyte to be impaled with the microelectrodes (Figure 34). The perfusion 
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solution in the recording chamber was removed by using a glass suction tube 
connected to an adjustable vacuum source and collected in the waste tank. 
 
 
 
Figure 33: Two-electrode voltage-clamp (TEVC) recording set-up from Xenopus 
oocytes. 
The oocyte was placed in the recording chamber and continuously bathed with 
physiological solution. The oocyte membrane was penetrated with two 
microelectrodes one for voltage sensing and the other for current injection. Drugs and 
compounds were applied using gravity-based multichannel application system, at the 
time of drug application the perfusion was stopped. TEVC is achieved using 
Genclamp500 amplifier interfaced to a PC computer equipped with 
electrophysiological software for data acquisition (Professor Murat Oz’s laboratory). 
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Figure 34: The oocyte impaled with two microelectrodes. 
Illustration of the plastic chamber. The oocyte was placed in the recording chamber 
and perfused continuously during the experiment (Professor Murat Oz’s Laboratory). 
 
A fiber optic light source was used for illumination of the recording chamber (Fiber 
Lite, High Intensity Illuminator Series 180, Dolan-Jenner Industries Inc. Boxborough, 
MA, USA). A Low-power stereo-dissection microscope was used for visual 
observation of the recording chamber (Olympus, Tokyo, Japan, SZ-STB1, 100 AL0.5 
X, WD186). Computer set up for data acquisition consisted of a Compaq computer, 
(Compaq Corporation, Wynyard, UK) and analog-digital converter, BNC 2081 
(National Instruments, Austin Texas, USA). 
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Methods 
3.1.5 Preparation of Required Solutions 
3.1.5.1 Modified Barth’s Solution 
Modified Barth’s Solution (MBS) was used during oocytes isolation process. The 
composition of MBS is shown in table below: 
a) Calcium free MBS solution: 
Table 7: Calcium free MBS solution composition 
Compound Concentration 
(mM) 
1x 
(Weight in grams) 
10x 
(Weight in grams) 
NaCl 88 5.14 51.4 
HEPES 10 2.38 23.8 
NaHCO3 2.1 0.2 2 
KCl 1 0.075 0.75 
MgSO4 0.8 0.2 2 
The above components were dissolved in distilled water to get total volume of 1 L and 
the pH was adjusted to 7.5 using NaOH. 
b) Calcium containing MBS solution: 
Similar to previous composition, with the addition of 0.22 g and 2.2 g of CaCl2 
(2mM) to make stock solutions of 1x and 10x respectively. All compounds were 
dissolved in distilled water to get total volume of 1 L and the pH was adjusted to 7.5 
3.1.5.2 Oocyte Storage Solution 
The storage solution was prepared as following: 1) 100 ml of 10x Calcium 
containing MBS solution; 2) 900 ml Distilled water; 3) Antibiotic materials shown in 
(Table 8) were dissolved in the previous solution; 5) pH was adjusted to 7.5; 6) The 
mixture was filtered and stored in a sterile container.  
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Table 8: Antibiotic materials 
Compound Concentration  Weight in grams 
Penicillin G 10,00 U/L 0.02 
Gentamycin Sulphate 
salt 
50mg/L 0.1 
Streptomycin 10mg/L 0.01 
Sodium pyruvate 2mM 0.22 
Theophylline 0.5mM 0.09 
3.1.5.3 Extracellular Solution 
ND96 extracellular solution was used in the two-electrode voltage-clamp 
technique to record ion currents mediated by the nAChRs, and normal Ringer’s 
solution was used to record ion currents mediated by the glycine and 5-HT3 receptors.  
The recipes for both ND96 and normal Ringer’s solution used were as follow: 
a) ND96 solution: 
Table 9: ND96 solution composition 
Compound 
Content  
(mM)  
1x  
(Weight in grams) 
10x  
(Weight in grams) 
NaCl 96  5.61 56.1 
KCl 2 0.15 1.5 
MgCl2 1 0.10 1.0 
HEPES 5 1.19 11.9 
CaCl2 or 
BaCl2 
1.8 
1.8 
0.20 
0.439 
2.0 
4.39 
The above components (1x) are dissolved in Distilled Water to produce a total volume 
of 1 L and the pH was adjusted to 7.5 using NaOH. 
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b) Normal Ringer’s solution: 
Table 10: Normal Ringer’s solution composition 
Compound 
Content  
(mM)  
1x  
(Weight in grams) 
10x  
(Weight in grams) 
NaCl 115 6.72 67.2 
KCl 1 0.074 0.74 
CaCl2 1.8 0.199 1.99 
HEPES 10 2.38 23.8 
The above components (1x) were dissolved in distilled water to get total volume of 1 
L and the pH was adjusted to 7.4 using NaOH. 
3.1.6 Drug Application 
Stock solutions of the test compounds were prepared in ND96 solution when 
recording ion currents mediated by the nAChRs (or in normal Ringer’s solution when 
recording ion currents mediated by glycine and serotonin receptors) using the 
following formula: 
Weight (mg) = (MW) x (Volume (L)) x (concentration (mM)) 
Further dilutions were prepared using the Charles equation: 
C1 x V1 = C2 x V2 
Where, 
C1 = concentration of stock solution 
V1 = volume of stock solution to be used 
C2 = desired concentration to be prepared 
V2 = desired volume to be prepared 
Stock solutions and required dilutions were prepared freshly before 
starting the experiments. 
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3.1.7 Isolation and Maintenance of Oocyte from Xenopus Laevis 
Xenopus laevis female frogs were anesthetized in 1L of 0.03% w/v benzocaine 
solution, prepared by dissolving 300 mg of ethyl p-aminobenzoate in 15 mL of 70 % 
ethanol and then adding that to 1L of cold tap water. The end point of anesthesia was 
determined by failure to respond to noxious stimuli induced by pinching of the lower 
limbs. Under described conditions, usually 5-10 minutes to achieve full anesthesia, the 
anesthetized frog was placed on crushed ice covered with a wet paper towel to avoid 
skin from drying out during surgery while maintaining low core body temperature 
during surgery. A small incision of about 1.5 cm length was made through the 
epidermal layer and in the inner muscular layer of the lower abdominal area slightly 
to the left or right of the midline, and a similar cut.  Using sterilized forceps, one to 
two ovarian lobes (small clumps of oocytes) were removed and placed in a petri dish 
containing Ca2+- free MBS (Figure 35). 
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Figure 35: Steps of oocyte isolation and preparation. 
A flow diagram of oocytes isolation steps. Female Xenopus frog was anesthetized, and 
ovarian lobes were taken out and kept in Ca2+- free solution. Fine forceps were used 
to separate oocyte clusters into small pieces, followed by enzymatic treatment using 
collagenase enzyme. Finally, the collagenase solution washed away with Ca2+- free 
solution and then with Ca2+-containing solution for several times. Mature healthy-
looking oocytes were collected for injection  [Modified from (Nakagawa and Touhara, 
2013)]. 
 
After removing the ovarian lobes, the muscular layer as well as the outer skin were 
sutured with absorbable Catgut sutures. After surgery, the frog was kept in a container 
filled with tap water with the head elevated (to prevent drowning) and the rest of the 
body submerged, and closely monitored for recovery, based on free swimming 
behavior. Recovery from the anesthesia usually take up to 1 hour. After 3-4 hours after 
recovery, the frog was returned to the main frogs’ container. Each frog was utilized 
for three to four surgeries with a gap of two to three months between each procedure. 
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3.1.8 Oocyte Preparation 
The preparation of oocytes was performed according to procedures described earlier 
(Oz et al., 2003). Briefly, using fine forceps, the inner ovarian epithelium, theca, and 
follicular layers were removed as much as possible to produce smaller clusters of 
oocytes (Figure 36). 
 The resulting oocyte clusters were then treated with collagenase A solution 
(collagenase enzyme solution was prepared by dissolving 80 mg of Collagenase, type 
A, in 25 ml of Ca2+ Free MBS solution). The oocyte clusters were incubated in a small 
conical flask containing 12.5 ml collagenase solution with constant stirring (60-80 
rotations/minute) at room temperature for 1.5 hour.  After that, collagenase solution 
was replaced with fresh collagenase solution 12.5 ml and kept in stirring for another 
1.5 hour. Finally, oocytes were washed gently; 5 times using Ca2+ Free MBS, then 5 
times with Ca2+ containing MBS solution. Subsequently, oocytes were transferred to 
a petri dish filled with Ca2+ containing MBS for oocyte selection.  
Only healthy-looking mature oocytes (stage V-VI) were selected under a dissecting 
microscope (Bunton Instruments Co Inc., Model GSZ, Rockville, MD, U.S.A.). Stage 
V and VI oocytes characterized by larger size with 1.0 mm - 1.2 mm diameter, rounded 
shape, and clear dark brown animal pole and yellow vegetal pole divisions (Figures 36 
& 37) were selected. The oocytes were subsequently maintained in MBS at 18 °C and 
used within 5 - 7 days. 
Throughout the electrophysiological experiments, we employed a Xenopus oocyte 
expression system for the following reasons: 1) methods for harvesting and 
maintaining oocytes are well established and straightforward. As a result, high 
numbers of cells with desirable expression levels were routinely available. 2) the 
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oocytes are freshly derived from living frogs, thus they can be treated as primary cell 
culture. 3) the two-electrode voltage clamp technique is a relatively less laborious and 
a high-yield electrophysiological assay system. 4) the two-electrode voltage clamp 
technique is stable for many hours, making it an ideal method for experiments 
requiring long-recording times. 
 
Figure 36: Frog’s ovarian lobe. 
(A) An ovarian lobe, containing oocytes at different developmental stages. (B) 
Separating oocytes by removal of epithelial and follicular layers manually with fine 
forceps. Isolated stage V and VI oocyte of Xenopus laevis after collagenase treatment. 
 
A 
B 
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Figure 37: Stages of oocyte development. 
Oocytes vary in size according to maturation stage. Oocyte size range from 100 – 1300 
µM (Wozniak et al., 2018). 
 
3.1.9 Synthesis of cRNA 
The cDNA clone of human α7-nAChR was kindly provided by Dr. J. Lindstorm 
(University of Pennsylvania, PA, U.S.A.). Capped cRNA transcripts were synthesized 
in vitro using a mMESSAGE mMESSAGE kit (Ambion, Austin, TX, U.S.A.) and 
analyzed on 1.2% formaldehyde agarose gel to check the size and quality of the 
transcripts (Figure 38). 
Human α7-nAChR mRNA was prepared by in vitro transcription and confirmed 
by gel analysis.  Restriction enzyme (Xbal) was used to digest the cDNA of human α7 
nAChR, and it was cleaned by the Qiagen kit.  Linearized plasmid cDNA was 
transcribed in vitro by SP6 RNA polymerase to produce α7-nACh receptor RNA using 
a mMESSAGE mMACHINE kit. This RNA was cleaned and purified by 
phenol:chloroform extraction and ethanol precipitation. The quantity of RNA was 
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estimated by OD260 measurement and quality was assessed by agarose gel.  Capping 
enzyme and 2’-O-methyltransferase were used to add a cap and poly(A) tail to RNA, 
and the resulting mRNA was suspended in DEPC-treated water.  Once more, mRNA 
was cleaned by phenol:chloroform extraction and ethanol precipitation, then run 
against RNA in agarose gel to confirm the addition of 5’ cap and 3’ poly(A)tail (Figure 
38). 
 
 
Figure 38: Agarose gel analysis of mRNA 
Lane 1: NEB ssRNA ladder with 9,7,5,3,2,1, and 0.5 kilo bases markers. 
Lane 2:  2 μg RNA of 5-HT3A receptor. 
Lane 3 and 4: 1.5 and 0.75 μg mRNA of 5-HT3A receptor, respectively.  
Lane 5: 3μg RNA of α7-nAChR.  
Lanes 6 and 7: 1.8 and 0.9 μg mRNA of α7-nAChR, respectively.  
3.1.10 In-vitro cRNA Synthesis 
The mMessage mMachine kit used to synthesize the capped cRNA transcripts was 
purchased from Ambion (SP6 kit, Austin, TX, USA). The synthesized capped cRNA 
transcripts were analyzed on 1.2% formaldehyde agarose gel to check the quality and 
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size of the transcripts. The cDNA clones of human α7-nAChR was provided by Dr. J. 
Lindstorm (University of Pennsylvania, PAM, USA). 
3.1.11 Microinjection of cRNA into Oocytes 
The mRNA concentration of synthesized human α7-nAChRs and other subunits 
used in this study are shown in (Table 11). They were stored as 1μl aliquots in freezer 
at -80o C. Once the oocytes were prepared and sorted, only one RNA aliquot was 
transferred in an ice bucket to the laboratory. To maintain a RNase free environment 
while working with cRNA, the tube was centrifuged using a microcentrifuge at 1200 
rpm for 1- 3 min, and then by using a sterile pipette and RNase/DNase free pipette tips 
(Denville Scientific Inc., Metuchen, NJ, USA), and resulting cRNA pellet was diluted 
to a final concentration of 10 ng/50 nl in RNase-/DNase- free water. Only 3 to 4 μL of 
diluted cRNA was used for each batch of oocytes, and the remaining cRNA was 
returned to the freezer. A vertical puller (Model 700 D, David Kopf Instruments 
Tujunga, CA, USA) was used for making glass microelectrodes with fine needle 
shaped tip from autoclaved glass capillaries (World Precision Instruments, Sarasota, 
FL, USA). The tip of each glass microelectrode was broken by applying gentle 
pressure using a fine pair of forceps (Fine Science Tools Inc., Vancouver, Canada) 
under a dissecting microscope (Bunton Instruments Co., Rockville, MD, USA). 
The glass needle was backfilled with mineral oil (Sigma, St. Louis, MO, USA) using 
a 1 ml glass syringe. Then the glass needle was fitted into a microdispenser connected 
to the micromanipulator (Figures 39 & 40).  
  
88 
 
 
 
 
Table 11: The initial concentration of all subunits 
Receptor Subunit  Main stock conc. (µg/µl) 
nACh receptors 
α7 3.7 
α3 2.43 
α4 2.15 
β2 1.66 
β4 1.71 
Glycine receptor 
α1 2.18 
α2 1.678 
α3 1.595 
5-HT3 receptor A 2.1 
 
Subsequently, 3 to 4 μL of diluted cRNA or distilled water was dropped on the 
center of a mineral oil drop placed on parafilm (American National Can Co., 
Greenwich, CT, USA). By focusing on the drop under the dissecting microscope, the 
tip of the glass needle was placed at the center of the droplet, and the aqueous phase 
was carefully withdrawn into the glass needle using the withdrawal option on the 
microdispenser controller. After loading the sample, the sorted oocytes were arranged 
in a U-shaped pattern in a small petri dish, containing MBS, with mesh-bottom to hold 
the oocytes in place during the microinjection procedure. Each oocyte was impaled by 
the glass needle and gently injected with 50 nL of cRNA solution or distilled water 
using the microinjector (driven by a Micro-4, micro syringe pump controller).  
 
 
89 
 
 
 
 
 
Figure 39: Microelectrode set-up for cRNA injection. 
Schematic presentation of microinjector set-up. The glass microelectrode backfilled 
with cRNA solution for oocyte injection (Bianchi, 2006; Nakagawa and Touhara, 
2013). 
 
Figure 40: cRNA injection set-up (Professor Murat Oz’s Laboratory) 
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Following the injection, the oocytes were stored in 25 ml petri dishes filled with 
oocyte storage solution and incubated at 18ºC. In initial experiments, the oocytes were 
divided into two groups; oocytes that were injected with cRNA encoding the human 
α7-nAChR, and oocytes that were injected with distilled water (control). Xenopus 
oocytes were used in the electrophysiology study 2-3 days after microinjection to allow 
maximal expression of receptors. Healthy oocytes were transferred to fresh dishes with 
new storage solution daily. A bottle of storage solution was stored in the incubator 
with the oocytes. The oocytes were used for about 7-10 days. 
3.1.12 Two Electrode Voltage Clamp 
The voltage clamp technique is a method that allows ion flow across the cell 
membrane to be measured as an electric current while the transmembrane potential is 
held constant (clamped) with a feedback amplifier. Functional properties of ion 
channels expressed in Xenopus oocytes can be studied effectively using the two-
microelectrode voltage clamp (TEVC). In TEVC, two intracellular microelectrodes 
were employed, a voltage sensor electrode and a current injection electrode to maintain 
the transmembrane potential at the desired/command voltage. The voltage electrode 
was connected to the membrane potential amplifier to measure the membrane potential 
(Vm). The membrane potential as measured by the voltage-sensing electrode and a high 
input impedance amplifier was compared with a command voltage, and the difference 
is brought to zero by a feedback amplifier. The injected current by the amplifier 
provides a measure of the total membrane current (Im).  
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Figure 41: Schematic of glass microelectrode assembly. 
Glass microelectrode mounted on electrode holder containing a coated silver wire 
(AgCl2) to allow signal transmission. Microelectrode was filled with electrolyte 
solution; potassium chloride (KCl). Glass microelectrode was used to measure the 
intracellular voltage difference. 
 
The experimental setup for TEVC is depicted in Figure 33. At the beginning of the 
experiments, perfusion containers and application systems were filled with the 
appropriate solutions and allowed to run through the connected tubes. For each 
experiment, a single oocyte was placed in the recording chamber and continuously 
perfused with ND96 solution at a rate of 3 - 5 ml/minute.  The oocyte was impaled 
with two glass microelectrodes prepared using a vertical microelectrode puller (heater 
and solenoid values were adjusted to a setting of 50 and 70, respectively; David Kopf 
Instruments Tujunga, CA, USA) and filled with 3 M KCl solution (Figure 41). Using 
the micromanipulator, the tip of the two electrodes were dipped into the bath solution, 
and the voltage of both electrodes was adjusted to 0 mV. Then, the animal pole (the 
dark pole) of the oocyte was impaled with the two microelectrodes (Figure 42). Pipette 
resistances ranged from 0.5-1.8 MΩ. The tip of the electrode was visualized using the 
microscope. After both electrodes were inserted, the amplifier was set in voltage-
clamp mode, and the clamp-voltage was set on -70 mV. Drugs were applied by a 
Pin connector 
KCl filled 
microelectrode 
KCl fluid 
Silver wire 
Ag/AgCl pellet 
Glass 
microelectrode 
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gravity-based multichannel application system via a micropipette positioned about 2-
3 mm from the impaled oocyte. Perfusion of the ND96 was stopped immediately 
before the drug application and started immediately after drug application. 
 
 
Figure 42: Schematic illustration of two-electrode voltage clamp setup using Xenopus 
oocytes. 
The membrane of the oocyte at the animal pole was penetrated with two 
microelectrodes; one for voltage sensing and the other for current injection, while the 
transmembrane potential was held constant with the feedback amplifier [Modified 
from (Nakagawa and Touhara, 2013)]. 
 
Throughout the experiment oocytes were voltage clamped at a holding potential of 
-70 mV (command potential) using a Geneclamp 500 amplifier (Axon Instruments, 
Molecular Devices, Inc, Sunnyvale, CA, USA). Current responses were recorded and 
stored digitally for further analysis using Strathclyde Electrophysiology Software, 
WinWCP V4.0.8/ WinEDR V3.7.1 (University of Strathclyde, Glasgow, UK). 
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3.1.13 Parameters Tested by Electrophysiological Recording 
The oocytes were voltage-clamped at a holding potential of -70 mV using a 
GeneClamp-500 amplifier (Axon Instruments, Molecular Devices, Inc., Sunnyvale, 
CA, USA), and current response induced by application of 100 µM of acetylcholine 
chloride (ACh) was recorded digitally on an IBM\PC.  
3.1.13.1 Concentration Response Curve (EC50 determination) 
For α7-nAChR, three to five recordings of ion current induced by ACh (100µM) 
were measured with 5 min intervals of wash out with ND96 solution. The average of 
stable readings was calculated and considered as control reading. After obtaining the 
control readings, different concentrations of curcumin were routinely applied, and 
100µM ACh solution applied at the end of 5 min intervals which also included same 
concentration of curcumin. The current induced by ACh + curcumin application was 
recorded, and the average of 2-3 readings were calculated to determine the effect of 
curcumin. Thereafter, drug application was stopped, and the oocytes were washed with 
ND96 alone to obtain the recovery readings (100 µM ACh alone).  
Concentration-response data for each oocyte were normalized to the maximum 
current produced with 100 µM ACh for that oocyte, and percentage of potentiation 
was calculated by dividing the average of drugs-induced currents by the control values 
obtained before drug application. Curcumin was used at varying concentrations to 
construct dose response curves. For each concentration of curcumin, averages of 5-6 
oocytes were used. The concentration of curcumin which produced a 60 % potentiation 
of ACh-induced currents (IC50) was obtained by nonlinear curve-fitting and regression 
fits (logistic equation) using computer statistical software v 8.5 (Origin Lab Corp., 
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Northampton, MA, USA). Concentration of drug close to IC50 was employed for 
further studies. Also, 10 µM effect of other curcumin analogues and metabolites, 
demethoxy curcumin, bisdemethoxy curcumin, tetrahydro curcumin, demethyl 
curcumin, didemethyl curcumin, vanillylidenacetone, di-(tert-Butyl-dimethylsilyl) 
curcumin, O-tert-Butyl-dimethylsilyl curcumin, curcumin-d6 were examined for 
comparison. Except for vanillylidenacetone, all compounds were water insoluble. 
Those compounds were dissolved first in 100% dimethyl sulfoxide (DMSO). DMSO, 
at the final concentration of 0.001 % (v/v) used in our studies. 
 
 
 
Figure 43: Typical experimental protocol for electrophysiological recording from 
oocyte 
Typical electrophysiological recording from oocyte started with bathing of oocyte with 
ND96 solution, three to five agonist (ACh) induced currents on α7-nAChR was 
recorded with five-min intervals of washing with ND96 solution, followed by 
preincubation with second perfusion solution (see optimization section) for five min 
and recording of co-application of curcumin with ACh for three to five currents. 
Finally, ND96 perfusion for five min and two recovery (ACh) readings were obtained.  
For α7-nAChR (Figure 43), A typical experiment began with three to five control 
recordings of α7-nAChR ion currents induced by 100 µM of ACh with five-min 
intervals of washing with ND96 solution. The average of stable readings was 
Washout 
followed by  
5 min 
perfusion/pre
-incubation 
ACh ACh ACh ACh ACh 
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calculated as the control value. Following the control recordings, the oocyte was 
perfused for a total of 15 minutes with the selected concentration of tested compound; 
Curcumin or any of its derivatives. The average three responses at the end of the 15 
min drug application were calculated to determine the effect of the compound. 
Subsequently, the application of drug was stopped, and the oocytes were washed with 
ND96 alone to obtain the recovery readings (100 µM ACh alone). 
3.1.13.2 Effect of Curcumin on α7-nAChR 
Time-course of the onset of curcumin and the vehicle applications (0.01% DMSO) 
on the maximal amplitudes of ACh-induced currents were investigated. Curcumin (10 
µM) was co-applied in presence of 100 µM ACh for 5 min without any pre-application 
(0 pre-application time), and then washed out with ND96 to obtain the recovery 
readings (ACh alone). The time course of curcumin potentiation was further tested by 
comparing the effect of varying the curcumin pre-application time on ACh-induced 
currents. 
3.1.13.3 Ca2+ Contribution to Observed Drug Action 
In this series of experiments, 50 nL of BAPTA (1,2-bis(o-aminophenoxy) ethane-
N,N,N',N'-tetraacetic acid) stock solution (100 mM) was injected into each oocyte 
(Sands, Costa & Patrick, 1993) to rule out the influence of  the endogenously expressed 
Ca2+ activated Cl- channels (CaCCs) in the plasma membrane of Xenopus oocytes. 
Stock solution of BAPTA was prepared in distilled-water and the pH was adjusted to 
7.4 by CsOH. Following BAPTA-injections, oocytes were kept in ND96 for 5 to 10 
min and placed in a ND96 solution containing Ba2+ instead of Ca2+(prepared ND96 
solution contained 1.8 mM BaCl2 instead of 1.8 mM CaCl2). In order to determine the 
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contribution of intracellular Ca2+ levels, the effect of the tested compound on the ACh-
induced currents in BAPTA injected oocytes were investigated in either Ca2+ or Ba2+ 
containing ND96 solutions, and the extent of drug potentiation was compared. 
3.1.13.4 Voltage-Dependency of Drug Action 
Voltage-dependence of the compound's action was determined by holding the 
membrane potential at different values (ranging from -120 mV to 20 mV) for 30 s. At 
each point, membrane potential was returned to -70 mV, and subsequent readings were 
taken every five minutes. During these experiments, ACh was used at a concentration 
of 100 μM. Current-voltage (I-V) relationships for ACh-induced currents were 
determined in the absence and presence of 10 μM tested compound.  
3.1.13.5 Competitive and Non-competitive Inhibition 
Concentration-response curves for ACh were determined by using increasing ACh 
concentrations starting from 1 μM to 1 mM. The effects of Curcumin on different 
concentrations of ACh-induced currents were determined in the absence and presence 
of this compound. During these experiments, oocytes were voltage-clamped at a 
holding potential of −70 mV. For any set of concentrations of ACh, experiments were 
repeated in 6-8 different oocytes and percent of potentiation was calculated as 
described earlier.  
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3.1.13.6 Effect of Curcumin on the Other Members of Cys-loop Family of 
Ligand-Gated Ion Channel 
The α7-nAChR belongs to the Cys-loop family of ligand-gated ion channels. 
Therefore, the effect of curcumin was investigated on the activity of other members of 
Cys-loop family of ligand gated ion channel. Ion current induced by 100 µM ACh, 1 
µM 5-HT, and 30 µM Gly in oocytes injected cRNAs of nicotinic, serotonin type3 and 
glycine receptors, respectively. Current sizes were compared in the presence and 
absence of 10 µM curcumin. The average of 2-3 readings in the presence curcumin 
were calculated to determine the effect of curcumin. Subsequently, drug application 
was stopped, and the oocytes were washed with ND96/Ringer solution. Percentage of 
potentiation was calculated by dividing the average of currents in the presence of 
curcumin by the control values obtained before drug application. 
3.1.13.7 Radioligand Binding  
Oocytes were injected with 5 ng of human α7-nAChR cRNA, and the functional 
expression of the receptors was tested by electrophysiology on day 3. Isolation of 
oocyte membranes was carried out by modification of a method described previously 
(Oz et al., 2004). In brief, oocytes (200–300 oocytes per assay) were suspended 
(approximately 20 ml/oocyte) in a homogenization buffer containing 10mMHEPES, 
1mMEDTA, 0.1 mM phenylmethane sulfonyl fluoride (PMSF), 0.02% NaN3, and 50 
mg/ml bacitracin (pH 7.4) at 4°C on ice and homogenized using a motorized Teflon 
homogenizer (six strokes, 15 seconds each at high speed). The homogenate was 
centrifuged for 10 minutes at 800 rpm. The supernatant was collected, and the pellet 
was resuspended in homogenization buffer and recentrifuged at 800 rpm for 10 
minutes. Supernatants were then combined and centrifuged for 1 hour at 36,000 rpm. 
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The membrane pellet was resuspended in homogenization buffer and used for the 
binding studies. Binding assays were performed in 500 ml of 10mMHEPES (pH 7.4) 
containing 50 ml of oocyte preparation and 0.1–5 nM [125I] α-bungarotoxin (2200 
Ci/mmol; PerkinElmer, Inc., Waltham, MA). Nonspecific binding was determined 
using 10 mM α-bungarotoxin. Oocyte membranes were incubated with [125I]α-
bungarotoxin in the absence and presence of drugs for 1 hour at room temperature (22–
24°C). The radioligand was separated by rapid filtration onto GF/C filters presoaked 
in 0.2% polyethyleneimine. Filters were then washed with two 5-ml washes of ice-
cold HEPES buffer, and the radioactivity was determined by counting samples in a 
Beckman Gamma-300 g-counter (Beckman Coulter, Inc., Indianapolis, IN).  
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Figure 44: Radioligand binding assay. 
(A) Preparation of cell membrane: α7-nAChR cRNA injected oocytes were 
homogenized and centrifuged through several steps to get the pellet containing 
membrane fractions. (B) Measurement of [125I] α-bungarotoxin radiolabeled oocytes 
in the presence and absence of compound (curcumin), followed by filtration and 
counting. 
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3.1.14 Statistical Analysis 
In oocyte experiments, average values were calculated as the mean ± S.E.M. 
Statistical significance was analyzed using Student’s t test or analysis of variance 
(ANOVA) as indicated. Concentration-response curves were obtained by fitting the 
data to the logistic equation 
y= Emax/[1 + (x/EC50)
-n] 
Where x and y are concentration and response, respectively; Emax is the maximal 
response; EC50 is the half-maximal concentration; and n is the slope factor (apparent 
Hill coefficient). 
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3.2 Molecular Docking Experiments 
The NMR structure of the human α7-nAChR transmembrane domain was obtained 
from the protein data bank (“wwPDB: Worldwide Protein Data Bank,” n.d.) (PDB: 
2MAW (Bondarenko et al., 2014)). The transmembrane domain structure prepared via 
the Protein Preparation Wizard (Sastry et al., 2013) in the Maestro program (“Maestro 
11 | Schrödinger,” n.d.);  mainly to assign protonation states on ionizable groups and 
to set up partial charges on the protein atoms. Brief energy minimization was employed 
to relief any existing clashes between protein residues. Residues believed to play a role 
in type II PAM binding were used to define the binding site for docking; which 
included the whole intra-cavity of the α7-nAChR transmembrane domain. Then, a grid 
box was created using the Receptor Grid Generation module in Glide (“Small-
Molecule Drug Discovery Suite | Schrödinger,” n.d.).  
All ligands were created using Maestro (“Maestro 11 | Schrödinger,” n.d.) and 
prepared using LigPrep (“LigPrep | Schrödinger,” n.d.) in order to give partial charges 
to ligand atoms, assign protonation states on ionizable groups, and generate a single 
low energy conformation for each ligand using the OPLS forcefield. Using Glide 
(“Small-Molecule Drug Discovery Suite | Schrödinger,” n.d.), all prepared ligands 
were docked into the previously prepared intra-cavity of the α7-nAChR 
transmembrane where the extra-precision (XP) Algorithm  was employed for 
conformational sampling. Subsequently, docked poses were scored via Glide_XP 
which contains terms for hydrogen bonding, electrostatic interactions, van der Waals 
interactions, desolvation penalty and intra-ligand contact penalty (Friesner et al., 
2006).  
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3.3 In-vivo Study: Animal Model of Parkinson’s Disease 
3.3.1 Animals 
A total of 50 adult male Wistar rats weighing between 220 and 250 grams at the 
beginning of the study were used.  Four or five rats were housed in a large cage with 
free access to rat chow and water under a 12:12 h light–dark cycle, at a room 
temperature (22 °C). All experimental procedures were approved by the Animal Ethics 
Committee of the CMHS, UAE University and were performed in accordance with the 
guidelines of the European Communities Council directive of 24 November 1986 
(86/609/EEC).   
The rats were randomly assigned into Five groups: 1) Vehicle treated group 
(ascorbic acid injection into the right striatum, and received daily oral gavage carboxy 
methyl cellulose (CMC) n= 6, 2) 6-OHDA treated group (6-OHDA injection into right 
striatum) n= 8, 3) 6-OHDA + curcumin pre- and post-treatment [intra-gastric oral 
gavage curcumin (200 mg/kg) once a day for four weeks in total (2 weeks before and 
2 weeks after surgery), with 6-OHDA lesioning at the end of week 2 of curcumin 
treatment) n= 8, 4) 6-OHDA + curcumin + MLA (the same as group 3, with the 
addition of MLA I.P injection 10 min before curcumin administration) n= 9, and 5) 6-
OHDA + MLA (the same as group 2, with the addition of MLA I.P injection 10 min 
before apomorphine-induced rotation testing), n=8.  
3.3.2 Drugs 
6-hydroxydopamine hydrochloride, apomorphine hydrochloride, and curcumin, 
were purchased from Sigma-Aldrich (Sigma Chemicals Co.; St. Louis, MO), and MLA 
was purchased from Abcam, USA. 
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6-OHDA-HCl with the purity ≥97%, was dissolved in ice-cold 0.01% ascorbate in 
0.9% normal saline and used within 2 hours after preparation. Apomorphine-HCL with 
the purity ≥98.5%, was dissolved in 0.1 ascorbic acid in saline and prepared on 
demand. Curcumin was suspended in 0.5% sodium carboxy methyl cellulose (CMC) 
and 50 µL of (10 M) NaOH and prepared on daily bases. MLA was dissolved in normal 
saline and preserved in +4℃. 
3.3.3 Surgical Procedure   
All rats were deeply anesthetized using an equal mixture of ketamine 
hydrochloride (80 mg/kg, Pantex Holland B.V., Holland) and xylazine Hydrochloride 
(20 mg/kg, Troy Laboratory PTY Limited, NSW, Australia) administered 
intraperitoneally. To lesion the nigrostriatal pathway, the heads of the animals were 
shaved and placed into a Stoelting stereotaxic frame and a unilateral hole on the right-
side of the skull was made aiming at the striatum (Figure 46). The rats were divided 
into Five groups. The first group (n=8) received unilateral injections of 6-OHDA, at 
three distinct locations within the caudate-putamen (7 µg in each site). The neurotoxin 
6-OHDA-HCl (Sigma Chemicals Co.; St. Louis, MO) was dissolved in ice-cold 0.01% 
ascorbate in 0.9% normal saline and used within 2 hours. Three intrastriatal 6-OHDA 
injections were performed using pulled glass micropipette with an outer diameter of 
approximately 50 µm. Seven µg 6-OHDA (dissolved in 2 µl) was injected at each site, 
using the following coordinates; AP: +1.0, -0.1, -1.2 / ML: -3.0, -3.7, -4.5 / DV: -5.0, 
-5.0, -5.0) (Figure 47). The tooth bar of the stereotaxic frame was fixed at 0.0 relative 
to bregma (Paxinos and Watson, 2004). 6-OHDA was injected at a rate of 1 µl/min, 
and the injection micropipette was left in place for an additional 3 minutes to prevent 
backflow. All rats were allowed to recover for 3 weeks before behavioral testing. 
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Vehicle treated group received equivalent volumes of dissolvent (0.01% ascorbic acid) 
instead of the toxin (Figure 45).   
 
 
Figure 45: Time course of the experiment. 
Curcumin/MLA pre-treatment (200 mg/kg; intragastric gavage, 1 µg/g/body weight; 
I.P) was started 2 weeks before surgery. 6-OHDA intra-striatal injection was 
performed after week 2. This was followed by one-week recovery to ensure head 
wound healing, and to allow proper animal handling for curcumin oral administration, 
which was continued for 2 weeks post-recovery. At the end of the 3 weeks, 
apomorphine-induced rotation test was conducted. Lastly, animals were sacrificed, 
and brains were collected for processing and data analysis. 
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Figure 46: Stereotaxic surgery to lesion nigrostriatal pathway. 
The head of the animal was placed into a Stoelting stereotaxic frame and a unilateral 
hole on the rite of the skull was made. Three intrastriatal 6-OHDA injections were 
performed using 3 coordinated relative to the bregma (see Figure 47), according to the 
rat brain atlas of Paxinos and Watson, 2004. 
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Figure 47: The three sites of 6-OHDA intra-striatal injection. 
Anterior-posterior (AP) and medio-lateral (ML) coordinates are in mm from bregma; 
dorso-ventral (DV) coordinates are in mm from dura. 
ML 
DV 
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3.3.4 Apomorphine-Induced Rotational Behavior 
Three weeks after surgery, drug-induced rotational behavior was monitored in rounded 
bowl (42cm wide at top and 22 cm deep) (Truong et al., 2006). Animals were injected 
with 0.25 mg/kg apomorphine-HCL (Kirik et al., 1998) (Sigma - Aldrich) (dissolved 
in 0.1 ascorbic acid in saline) subcutaneously or 0.1 ascorbic acid alone for vehicle 
treated group, and rotational asymmetry was monitored. Directly after injection of 
vehicle or drug, the animals were allowed to acclimatize in the bowl for 5-min. Turns 
of 360° in the clockwise and counter-clockwise directions were continuously recorded 
for 30 min. Net rotational asymmetry score was expressed as full body turns/min. 
Direction contralateral to the lesion was considered as positive. Rats that exhibited 5-
7 full turns/min were included in the study as Parkinsonian animals (Kozlowski et al., 
2004; Metz and Whishaw, 2002; Shimizu et al., 2008). All rotational data were 
expressed as means of the full turns per minute ± SEM. The data were expressed as 
the net (contralateral minus ipsilateral turns) rotations/min. 
3.3.5 Histology 
Animals were euthanized with an over dose of urethane 25% (2 ml/200 g of animal 
weight) injected intraperitoneally and perfused transcardially through the ascending 
aorta with 50 ml of phosphate buffered saline (PBS), followed by 500 ml of 4% 
paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4) over 20 min. The brains 
were removed, post-fixed in the same fixative solution for 4 hours and stored in 30% 
sucrose and kept until they had sunk before being sectioned at cryostat. Coronal 
sections (40 µm thickness) of striatum and substantia nigra were collected serially and 
processed for detection of TH immunoreactivity using the avidin–biotin-complex 
(ABC) method, as previously described (Shehab et al., 2015, 2003). 
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Immunohistochemical staining for tyrosine hydroxylase 
Immunohistochemical staining was performed on free-floating sections. For this 
purpose, brain sections were first rinsed three times with PBS solution followed by 
incubation in a 50% ethanol for 30 min to increase the penetration of the antibodies 
(Llewellyn-Smith et al., 1992). After rinsing in PBS, the sections were then incubated 
overnight at room temperature in primary antibody solution containing 1% bovine 
serum albumin in PBS containing Triton-X-100. The primary antibodies used for 
immunohistochemical staining were raised in rabbit against tyrosine hydroxylase (TH) 
as a marker for dopaminergic neurons, AB152, Millipore; at 1:1000 dilution). On the 
second day, the sections were rinsed in PBS and then incubated with biotinylated goat 
anti-rabbit IgG (Jackson, 1:500) for 1 h then in extravidin-peroxidase conjugate 
(Sigma, 1:1000) for another hour. After rinsing, to visualize any TH+ 
immunoreactivity the sections were incubated for 5–8 min in a solution of 25 mg 
diaminobenzidine (DAB) in 50 ml 0.1 M phosphate buffer (PB, pH 7.4) with 7.5 μl 
hydrogen peroxide (30%) and 1 ml nickel chloride (3.5%) added to intensify the 
reaction. Finally, the sections were rinsed in PB and mounted on gelatin-coated slides. 
After drying in air the sections were dehydrated in graded alcohol, cleared in xylene 
and mounted with DPX mounting media. All antibodies were diluted in PBS 
containing 0.3% Triton. 
3.3.6 Measurement of Striatal Fiber Density  
Striatal TH+ immunoreactive fibers were captured with Nikon microscope (Nikon, 
Japan) equipped with DS-Ri2 camera. Using Image J software (National Institutes of 
Health, USA), optical densitometry of TH+ stained striatal terminals was measured. 
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The average optical density over the entire area of the striatum for four striatal 
sections in each animal was quantified: rostral (+1.56 mm from Bregma), middle 1 
(+0.72 mm from Bregma), middle 2 (+0.12 mm from Bregma), and caudal (−0.24 mm 
from Bregma) in each animal. To compensate for differences in background coloring 
between the slides, the optical density was subtracted from values obtained in the 
cortex of each sample. The data were expressed as a percentage of the fiber density on 
the lesioned side to the non-lesioned side. 
3.3.7 Stereological Analysis 
Substantia nigra cell counts 
The total number of TH+ neurons in the SNpc in both hemispheres was estimated 
with an unbiased stereology using the optical fractionator (West, 1999), 
StereoInvestigator, (MicroBrightField, Colchester, VT, USA). The final number of 
animals included in stereological analysis was as follow: Vehicle treated = 6[6], 6-
OHDA = 8[9], 6-OHDA+Cur = 8[8], 6-OHDA+Cur+MLA = 8[8], 6-OHDA+MLA = 
8[8] (numbers in square parenthesis represent the number of animals that were used 
for the behavioral testing). To estimate the number of TH+ cell numbers in the SNpc, 
the borders defining the SNpc were delineated by using a low-power objective lens 
(5X; S Plan) on referral to anatomical morphology. The counting was done using a 
63X Plan-Apo oil objective to generate counting areas of 106X106 µm. A counting 
frame (3184µm2) was placed randomly on the first counting area and systematically 
moved through all counting areas. The section thickness was estimated to be 25±5 µm, 
after dehydration and coverslipping, in different animals. Guard volumes of 2 µm were 
excluded from each surface to avoid the problem of lost caps. The sampling interval 
in the X-Y axis was adjusted so that at least 100 cells were counted for each region of 
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interest. The coefficient of error due to the estimation was calculated according to 
(Gundersen & Jensen, 1987) and values < 0.10 was accepted. For each animal the 
optical density was measured at three sections at three different rostrocaudal levels 
according to the atlas of Paxinos & Watson (2004) over the whole substantia nigra: (i) 
AP 4.8; (ii) AP 5.6; (iii) AP 6.2, relative to the bregma. The data represents the percent 
of surviving nigral TH+ neurons per level as well as the total survival analysis of the 
three rostrocaudal levels of the lesioned (right) side in comparison with the intact (left) 
side. 
3.3.8 Statistical Analysis 
ANOVA with post hoc Bonferroni test was used to analyze differences in 
behavioral tests and cell numbers between groups. Paired t test was used to compare 
Apomorphine-induced rotation with and without MLA post-injection. Results were 
expressed as means ± SEM. 
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Chapter 4: Results 
4.1 Results 
4.1.1 Effects of Curcumin on α7-nicotinic Acetylcholine Receptors 
Application of 100 μM ACh for 3 - 4 seconds activated fast inward currents that 
desensitized rapidly in oocytes injected with cRNA encoding the α7-subunit of human 
nAChR (Figure 48A). In addition, ACh-induced currents were inhibited completely 
with 100 nM α-bungarotoxin (Figures 48A & B), indicating that these currents are 
mediated by the activation of α7-nAChRs. Bath application of curcumin (100 µM) for 
5 minutes did not produce detectable currents in oocytes expressing α7-nAChRs (n = 
8 oocytes). 
The effect of curcumin was tested on ion currents induced with ACh (100 µM). An 
effect of 10-minute curcumin (1 μM) application on α7-nAChR–mediated currents is 
shown in Figure 49A. Time courses of effects of curcumin or vehicle (0.1% DMSO) 
applications on the maximal amplitudes of ACh-induced currents are presented in 
Figure 49B. Curcumin caused a significant potentiation of the current, which was 
partially reversed during a 10–15-minute washout. In the absence of curcumin, vehicle 
(0.1% DMSO) alone did not alter the amplitude of the ACh-induced current, further 
suggesting that curcumin acts on nAChRs (Figure 49A, controls vs. curcumin 
treatment group at 10 minutes of exposure, ANOVA, n = 5–7; P < 0.05). 
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Figure 48: The effects of acetylcholine and α-bungarotoxin in oocytes expressing α7-
nAChR. 
(A) Records of currents activated by acetylcholine (ACh, 100 μM) in control 
conditions (left), after 10 min pretreatment with α-bungarotoxin (100 nM) and co-
application of 1 μM curcumin and ACh (middle), and 15 min washout (right). (B) 
Application of ACh activates transient inward currents only in oocytes injected with 
mRNA encoding α7-nAChR (on the left). In 58 oocytes injected with mRNA encoding 
α7-nAChR, bath application of 100 μM ACh induced rapidly activated transient 
inward current. However, bath application of 100 μM ACh did not induce a detectable 
inward current in 54 distilled water (DW) injected oocytes. The summary of the 
experiments showing the effects of α-bungarotoxin (100 nM) on α7-nAChRs (on the 
right). Bath application of α-bungarotoxin for 10 min completely inhibited inward 
currents in oocytes injected with mRNA encoding for α7-nAChRs. 
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Figure 49: Effects of curcumin on α7-nicotinic acetylcholine receptors. 
(A) Records of currents activated by Ach (100 mM) in control conditions (left), after 
10-minute pretreatment with curcumin (1 µM) and co-application of 1 µM curcumin 
and ACh (middle), and 15-minute washout (right). (B) Time-course of the effect of 
vehicle (0.1% DMSO; open circles) and curcumin (1 mM; filled circles) on the 
maximal amplitudes of the ACh-induced currents. Each data point represents the 
normalized mean ± S.E.M. of six to eight experiments. The horizontal bar indicates 
the duration of curcumin or vehicle application. 
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4.1.2 Concentration Response Curve 
The potentiating effect of curcumin was significantly dependent on the application 
mode. For example, without preincubation, coapplication of curcumin (1 μM) and 
ACh (100 μM) did not alter the amplitudes of maximal currents (Figure 50A). 
However, when oocytes were preincubated with curcumin, the drug was found to 
potentiate maximal ACh-induced currents in a time-dependent manner, reaching a 
maximal level within 5 minutes with a half-time (τ1/2) of 1.6 minutes (Figure 50A). 
Since the magnitude of the curcumin effect was time-dependent, 10-minute curcumin 
application time was used routinely to ensure equilibrium conditions. Curcumin was 
found to upregulate the function of α7-nAChR in a concentration-dependent manner 
with EC50 and slope values of 0.21 ± 0.14 µM and 1.6, respectively (Figure 50B). 
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Figure 50: Effect of curcumin on α7-nicotinic acetylcholine receptors is time- and 
concentration-dependent. 
(A) Effect of curcumin as a function of curcumin preapplication time. Each data point 
represents the mean ± S.E.M. of six to seven oocytes. (B) Curcumin potentiates α7-
nAChR function in a concentration-dependent manner. Each data point represents the 
mean ± S.E.M. of six to nine oocytes. The curve is the best fit of the data to the logistic 
equation described in the Materials and Methods section. 
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4.1.3 Effects of Curcumin on α7-nAChRs are not Mediated by G-proteins 
As shown in Figures 49B & 50B, regulation of α7-nAChR function by curcumin 
occurs gradually, reaching steady-state levels within a few minutes of curcumin 
application. Therefore, it is possible that activation of second messenger pathways by 
G-protein-coupled receptors (Liu et al., 2013; Pérez-Lara et al., 2011; Yang et al., 
2015) is involved in curcumin regulation of α7-nAChRs. Thus, we investigated the 
effects of pretreatments with NEM (10 mM, 50 nl, 30-minute preincubation time), a 
sulfhydryl-alkylating agent that blocks G-protein-effector interactions by alkylating α-
subunits of PTX-sensitive GTP binding protein (Oz and Renaud, 2002), and GDPβS 
(10 mM, 50 nl, 30-minute preincubation time), an agent that inhibits binding of GTP 
to the α-subunit of G-proteins (Oz et al., 1998). Treatments with NEM and GDPβS did 
not alter the extent of curcumin potentiation of α7-nAChR (Figure 51A). 
Similarly, pretreatment with PTX (5 µg/ml, 50 nl, 30-minute preincubation time), 
toxin that inhibits the α-subunit of Gi/o proteins, did not reverse the potentiating effect 
of curcumin (Figure 51B).  
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Figure 51: Effects of curcumin on α7-nAChR are not mediated by G-proteins. 
(A) Bar presentation of the effects of 1 µM curcumin application (10 minutes) on the 
maximal amplitudes of ACh (100 mM)-induced currents in oocytes injected with 50 
nl of distilled water, controls (n = 16), or NEM (10 mM, 50 nl, n = 8) and GDPbS (10 
mM, 50 nl, n = 7) 30 minutes before recordings. (B) Bar presentation of the effects of 
1 μM curcumin on 30 μM ACh activated currents in 50 nL distilled water-injected 
control oocytes and pertussis toxin injected oocytes. There is no statistically significant 
difference between the groups (ANOVA, P>0.05). 
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4.1.4 Effects of Curcumin on α7-nAChRs are not Mediated by Protein Kinases 
We also investigated the involvement of protein kinases A and C, and Ca2+-
calmodulin–dependent kinase (CaM-kinase) in curcumin potentiation of α7-nAChRs. 
For this purpose, the effects of curcumin were tested in oocytes pretreated with PKC-
412 (nonspecific kinase inhibitor, 10 µM for 30 minutes pretreatment), Go-6983 
(specific protein kinase C inhibitor, 10 µM for 30 minutes), KT-5720 (specific protein 
kinase A inhibitor, 10 µM for 30 minutes), and KN-62 (specific inhibitor of CaM-
kinase II, 50 µM for 30 min). Curcumin continued to upregulate nicotinic receptor–
mediated currents in oocytes pretreated with kinase inhibitors (Figures 53A & B). 
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Figure 52: Effects of curcumin on α7-nAChR are not mediated by prtein kinases. 
(A) Bar presentation of the effects of 1 μM curcumin on α7-nAChR–mediated currents 
in oocytes pretreated with vehicle (0.01% DMSO, n = 5) or PKC-412 (PKC; 10 mM, 
30-minute pretreatment, n = 7), or Go-6983 (GO; 10 mM, 30-minute pretreatment, n 
= 6). (B) Bar presentation of the effects of 1 mM curcumin on a7-nAChR–mediated 
currents in oocytes pretreated with vehicle (0.01% DMSO, n = 7) or KT-5720 (KT; 10 
mM, 30-minute pretreatment, n = 7) and KN-62 (KN; 50 mM, 30-minute pretreatment, 
n = 6). 
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4.1.5 Effects of Curcumin on α7-nAChRs are not Dependent on Intracellular Ca2+   
Activation of α7-nAChRs allows sufficient Ca2+ entry to activate endogenous 
Ca2+-dependent Cl− channels in Xenopus oocytes (Sands et al., 1993; Uteshev, 2012). 
Therefore, it was important to determine whether the effect of curcumin was exerted 
on nAChR–mediated currents or on Cl− currents induced by Ca2+ entry. For this 
reason, we injected the Ca2+ chelator BAPTA into oocytes and replaced extracellular 
Ca2+ with Ba2+ which can pass through α7-nAChRs but causes less activation of Ca2+-
dependent Cl− channels (Sands et al., 1993). Under these conditions, we tested the 
effect of curcumin in a solution containing 2 mM Ba2+ in BAPTA-injected oocytes. 
Curcumin (1 µM) produced the same level of potentiation (195 ± 18 in controls vs. 
210 ± 22 in BAPTA-injected oocytes; ANOVA, P > 0.05; n = 6 to 7) on ACh-induced 
currents in BAPTA-injected oocytes when currents were recorded in Ca2+-free solution 
containing 2 mM Ba2+ (Figure 53A). It is important to mention that in the oocyte 
expression system, curcumin-induced changes in nicotinic receptor–mediated currents 
can be attributable to Ca2+-activated Cl− channels and concomitant alterations in the 
holding currents. However, in control experiments, curcumin (100 µM for 10 minutes) 
did not change the magnitudes of holding currents in oocytes voltage clamped at −70 
mV (n = 7), indicating that intracellular Ca2+ levels were not altered by curcumin. 
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Figure 53: Effects of curcumin on α7-nAChR are not dependent on intracellular Ca2+ 
levels. 
Bar presentation of the effects of 1 μM curcumin application (10 min) on the maximal 
amplitudes of ACh (30 μM) induced currents in oocytes injected with 50 nl distilled-
water, controls (n=9) or BAPTA (200 mM, 50 nl, n=8). There is no statistically 
significant difference between the groups (ANOVA, P>0.05). 
 
 
4.1.6 Effects of Curcumin are not Dependent on Changes in Membrane Potential 
In the next series of experiments, we examined if the extent of curcumin 
potentiation of the α7-nAChR–mediated current is altered by changes in the membrane 
potential. As indicated in Figure 54A, the potentiation of ACh (30 µM)-induced 
currents by curcumin (1 µM) does not appear to be voltage-dependent. The extent of 
curcumin potentiation was similar at all tested membrane potentials from -100 to +40 
mV. Evaluation of the current-voltage relationship (Figure 54B) indicates that the 
extent of potentiation by curcumin does not change significantly at different test 
potentials (P ˃ 0.05, n = 5 -7, ANOVA). 
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Figure 54: Effects of curcumin are not dependent on changes in membrane potential. 
(A) Current-voltage relationships of acetylcholine-activated currents in the absence 
and presence of curcumin. Normalized currents activated by 30 µM ACh before 
(control, filled circles) and after 10-minute treatment with 1 µM curcumin (open 
circles). Each data point presents the normalized means and S.E.M. of seven 
experiments. (B) Quantitative presentation of the effect of curcumin as percentage of 
controls at different voltages.   
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4.1.7 Effects of Curcumin at Different Concentrations of Acetylcholine 
In the next series of experiments, we attempted to test the effects of curcumin at 
different ACh concentrations. Traces of low ACh (10 µM)-induced currents after 10-
minute treatment with 1 µM curcumin are presented in Figure 55A. At low ACh 
(10 µM) concentrations, curcumin caused approximately 11- to 12-fold increase of 
ACh-induced currents with an EC50 of 58 nM (Figure 55B). Our experiments indicated 
that the extent of curcumin potentiation decreased significantly with increasing 
concentrations of ACh (Figure 56A). Concentration-response curves for ACh in the 
absence and presence of 1 µM curcumin are presented in Figure 56B. In the presence 
of 1 µM curcumin, the maximal ACh response increased by 60%–70% of controls (n = 
6–8). In the absence and presence of curcumin, the EC50 values for ACh were 107 ± 
18 and 63 ± 16 μM, and slope values were 2.2 ± 0.4 and 1.9 ± 0.3, respectively (n = 
6–7). 
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Figure 55: Effects of curcumin at different concentrations of acetylcholine. 
(A) Records of currents activated by ACh (10 mM) in control conditions (left), after 
10-minute pretreatment with curcumin (1 µM) and co-application of 1 µM curcumin 
and ACh (middle), and 10-minute washout (right). (B) Concentration-dependent effect 
of curcumin on α7-nAChRs activated by low acetylcholine concentration. Each data 
point represents the mean ± S.E.M. of six to eight oocytes. The curve is the best fit of 
the data to the logistic equation described in the Materials and Methods section.  
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Figure 56: Acetylcholine concentration response curve. 
(A) Bar presentation of the effect of curcumin at different acetylcholine 
concentrations. Bars represent the means ± S.E.M. of five to eight experiments. (B) 
Effect of curcumin on the ACh concentration-response relationship. Oocytes were 
voltage clamped at -70 mV, and currents were activated by applying ACh (1 mM to 3 
mM). Oocytes were exposed to 10 µM curcumin for 10 minutes, and ACh was 
reapplied. Paired concentration-response curves were constructed, and responses 
normalized to maximal response under control conditions. Data points obtained before 
(control) and after 10-minute treatment with curcumin (10 µM) are indicated by filled 
and open circles, respectively. Each data point presents the normalized means ± S.E.M. 
of 7–11 experiments. 
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4.1.8 Effects of Curcumin on the Desensitization of Nicotinic Receptors  
The results of functional studies indicate that curcumin significantly decreases 
desensitization of currents mediated by the activation of α7-nAChRs. Normalized and 
superimposed current traces in the absence or presence of 1 μM curcumin are 
presented in Figure 57A. A summary of the results showing the effect of curcumin 
(1 μM) on the half decay times of the α7-nAChR–mediated currents is shown in Figure 
57B. In the absence and presence of curcumin, means of half decay times were 208 ± 
42 and 643 ± 85 seconds, respectively (paired t test; n = 8; P ˂ 0.01). These findings 
suggest that curcumin causes a significant decrease of α7-nAChR desensitization. We 
further investigated whether curcumin could convert α7-nAChRs that were already 
desensitized by a concentration of an agonist back to conducting state. We tested the 
effect of a bath application of curcumin (10 µM) on the α7-nAChRs that was 
desensitized by 100 µM nicotine application for 25–30 seconds (n = 6). As illustrated 
in Figure 57C, subsequent addition of curcumin resulted in activation of a sustained 
inward current that was reversed during washout. 
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Figure 57: Effect of curcumin on the desensitization of nicotinic receptors. 
(A) Normalized current traces in control (100 mM ACh) and in the presence of 1 µM 
curcumin. (B) Bar presentation of the effect of curcumin (1 mM) on mean 
desensitization half-times of nicotinic receptors activated by 100 µM ACh. Bars 
represent the means ± S.E.M. of eight experiments. (C) Effect of curcumin (10 mM) 
on a7-nicotinic receptors desensitized by bath application of 100 mM nicotine (n = 6). 
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4.1.9 Effects of Curcumin on the Specific Binding of [125I]α-bungarotoxin   
[125I]α-bungarotoxin competes with ACh, an endogenous activator of α7-nAChRs, 
by binding to the ACh binding site on the receptor (Albuquerque et al., 2009). For this 
reason, the effect of curcumin was investigated on the specific binding of [125I]α-
bungarotoxin. Equilibrium curves for the binding of [125I]α-bungarotoxin in the 
presence and absence (controls) of curcumin are presented in Figure 58A. Maximum 
binding activities (Bmax) of [
125I]α-bungarotoxin were 3.61 ± 0.37 and 3.47 ± 0.41 
pM/mg (means ± S.E.M.) for controls and curcumin-treated preparations, respectively. 
The apparent affinities (KD) of the receptor for [
125I]α-bungarotoxin were 0.87 ± 0.26 
and 0.67 ± 0.23 pM for controls and curcumin, respectively. There was no statistically 
significant difference between controls and curcumin-treated groups with respect 
to KD and Bmax values (P > 0.05, ANOVA, n = 6–7), suggesting that curcumin does 
not compete with α-bungarotoxin at the same binding site. Curcumin up to a 
concentration of 100 μM did not cause a significant change on the specific binding of 
[125I]α-bungarotoxin (Figure 58B).  
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Figure 58: Effects of curcumin on the specific binding of [125I]α-bungarotoxin. 
(A) The effects of curcumin on the specific binding of [125I]α-bungarotoxin to oocyte 
membrane preparations. In the presence and absence of curcumin, specific binding as 
a function of the concentration of [125I]α-bungarotoxin is presented. Data points for 
controls and curcumin (10 mM) are indicated by filled and open circles, respectively. 
Data points are the means of four independent experiments carried out in triplicate. 
(B) The effects of increasing concentrations of curcumin on the specific binding of 
[125I]α-bungarotoxin. Each data point represents the normalized means and S.E.M. of 
five to seven experiments. 
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4.1.10 Effects of Curcumin on the Current Mediated by Different Nicotinic 
Receptor Subunits and Other Members of Ligand-Gated Ion Channels 
The effect of curcumin on the functional properties of other neuronal nAChR 
subtypes was also examined. Application of curcumin (10 µM for 15 minutes) did not 
cause alterations of ACh (100 µM)-induced currents mediated by different subtype 
combinations of nicotinic receptors expressed in oocytes (Figure 59A). Similarly, 
curcumin (10 µM for 15 minutes) did not cause significant changes on the amplitudes 
of currents mediated by 5-HT3A (1 µM 5-HT) subunit and glycine receptors (30 µM 
glycine; mediated by α1β1, α2β1, and α3β1 subunit combinations) (Figure 59B). 
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Figure 59: Effects of curcumin on the current mediated by different nicotinic 
receptor subunits and other members of LGICs. 
 (A) Comparison of the effect of 10 mM curcumin on ACh (100 mM)-induced currents 
mediated by α7-, α3β2-, α3β4-, α4β4-, and α4β2- subunit combinations of nicotinic 
receptors expressed in oocytes. Bars represent the mean potentiation ± S.E.M. from 
six to eight experiments. (B) Comparison of the effects of 10 mM curcumin on 5-HT3 
receptors and a1b1, a1b2, and a3b1 glycine receptor subunits expressed in oocytes. 
Bars represent the mean effect ± S.E.M. from five to seven experiments. 
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4.1.11 Effects of Other Curcumin’s Analogues and Metabolites on the Current 
Mediated by α7 Nicotinic Acetylcholine Receptors 
The following experiment was done to screen the effects of various selected 
curcumin’s analogues and metabolites at 10 µM concentration, on the function of α7-
nAChR. The effects of the two curcumin’s analogues; demethoxycurcumin (DMC), 
bisdemethoxycurcumin (BDMC), and seven curcumin’s metabolites; 
tetrahydrocurcumin, demethylcurcumin, didemethylcurcumin, vanillylidenacetone, 
di-(tert-Butyl-dimethylsilyl) curcumin, O-tert-Butyl-dimethylsilyl curcumin, and 
curcumin-d6.  
Both curcumin analogues; DMC and BDMC potentiated ACh (100 µM)-induced 
currents but lesser than curcumin potentiation (133.3 ± 10.5, 132.3 ± 8.7, and 181.0 ± 
11.3 respectively, n=6, ANOVA) (Figure 60A). 
Moreover, curcumin showed maximum stimulation of 100 µM ACh-induced 
current through α7-nAChR-expressing oocytes compared to all other screened 
metabolites (181.0 ± 11.3, n=6) (Figure 60B) and therefore it was selected for further 
in-vivo study. Summary of the effects of 15 minutes bath applications of curcumin 
analogues and metabolites on the ACh-induced ion currents are shown in Figure 60A 
and B. 
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Figure 60: Effects of curcumin analogues and metabolites on Acetylcholine-mediated 
current. 
(A) Effects of curcumin analogues: demethoxycurcumin (DMC) and 
bisdemethoxycurcumin (BDMC) (10 µM) on ACh-induced current in comparison to 
curcumin. (B) Effects of several curcumin metabolites (10 µM) on ACh-induced 
current in comparison to curcumin. Bars represent the mean % potentiation ± S.E.M. 
n=6 to 8. 
 
A 
B 1: Tetrahydrocurcumin 
2: Demethylcurcumin 
3: Didemethylcurcumin 
4: Vanillylidenacetone 
5: Di(tert-butyl-dimethylsilyl) curcumin 
6: O(tert-butyl-dimethylsilyl) curcumin 
7: Curcumin-d6 
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4.1.12 Docking of Curcumin and Curcumin Derivatives into the Human α7-
nAChR Transmembrane Domain  
Docking simulations generated interesting binding modes (Figure 61) for 
curcumins with remarkable docking scores, as shown in and Table 12. Curcumin 
obtained excellent binding energy, scoring as low Glide-XP score as -10.53 kcal/mol. 
All ligands were able to score better binding energies than the known type II PAMs 
PNU-120596 (-6.29 kcal/mol) and most of them scored better than TQS (-8.33 
kcal/mol). As shown in Figure 61, curcumin had the optimum shape complementarity 
to fill the intra-cavity of the α7-nAChR transmembrane domain, despite its large size. 
Curcumin was able to form multiple hydrogen bonding interactions with the side 
chains of Ser249 and Thr289 as well as the backbone amide of Lys239. Additionally, 
its aromatic ring was involved in a cation-π interaction with the protonated amine of 
Lys239 and in a π-π interaction with the aromatic ring of Phe230 (Figure 61).  
Curcumin binding was also potentiated by forming extensive hydrophobic interactions 
with the side chains of the surrounding residues (e.g. Ile222, Ser223 and Ala226). 
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Table 12: Binding energies of curcumin and curcumin derivatives, generated from 
their docking into the human α7-nAChR transmembrane domain, along with the 
docking scores of two known type II PAMs. 
Ligand name Glide-XP (kcal/mol) 
Curcumin -10.53 
Demethyl curcumin -11.28 
Didemethyl curcumin -11.68 
Tetrahydro curcumin 10.33 
Demethoxy curcumin -9.55 
Vanillylidenacetone -6.40 
Bisdemethoxy curcumin -8.80 
Di-(tert-Butyl-dimethylsilyl) curcumin -6.34 
O-tert-Butyl-dimethylsilyl curcumin -9.2 
TQS -8.33 
PNU-120596 -6.29 
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Figure 61: The binding mode of curcumin (cyan sticks) obtained from docking into 
the human α7-nAChR transmembrane domain (gray sticks). 
Residues that, when mutated, had a significant effect on potentiation by type II PAMs 
are shown as orange sticks with white labels (Young et al., 2008). Green dotted lines 
indicate for hydrogen bonding. Blue dotted lines indicate for cation-π and π-π stacking 
interactions. Picture was generated via MOE (“MOE: Molecular Operating 
Environment,” n.d.).  
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4.2 In-vivo Results 
The neuroprotective effects of curcumin, given orally (200 mg/kg) two weeks pre- 
and post-surgically were determined by behavioral and morphological analysis. The 
assessment of motor function was performed three weeks after surgery. This was 
followed by brain sectioning and immunohistochemistry processing. 
4.2.1 Apomorphine-Induced Rotation Test 
Deficits in the motor function were clearly observed in the 6-OHDA-treated rats. The 
injection of apomorphine in these rats provoked a strong contralateral turning response 
with the average of 257.8 ± 23.4 turns/ 30 min in the 6-OHDA group in comparison 
with the vehicle treated group where turns in both sides almost negligible (8.9 ± 5.0 
turns/ 30 min, ANOVA, P˂0.000). Statistical analysis showed that curcumin 
administration has improved motor performance in the 6-OHDA+Cur group as the 
turning response was significantly lower compared to 6-OHDA treated group (126.9 
± 23.8 turns/ 30 min, ANOVA, P˂ 0.002). However, administration of α7-nAChRs 
blocker; MLA abrogated the neuroprotective effect of curcumin in 6-
OHDA+Cur+MLA treated group in comparison with 6-OHDA+Cur group (226.9 ± 
23.8 turns/ 30 min, ANOVA, P˂ 0.039). The aim of having 6-OHDA+MLA animal 
group is to investigate if there is any effect for MLA per se. Therefore, MLA I.P 
injection preceded apomorphine S.C injection by 10 min in 6-OHDA+MLA treated 
group. The MLA treated group did not show any significant statistical difference from 
6-OHDA or from 6-OHDA+Cur+MLA group (231.7 ± 30.2 turns/ 30 min, ANOVA, 
P value in between groups = 1.00) (Figure 62). MLA itself didn’t have any effect on 
turning response as indicated by motor assessment performed before and after MLA 
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injection (250.1 ± 39.4 compared to 231.7 ± 30.2 turns/ 30 min, ANOVA, P=1.00) 
(Figure 63). 
 
 
 
Figure 62: Motor performance of the rats was assessed using apomorphine-induced 
rotation test (0.25 mg/kg) expressed as full body turn per minute over 30 min. 
The vehicle group showed normal turning response with no side preference. Turning 
response increased significantly in 6-OHDA-injected rats (ANOVA, P˂0.000). 
Curcumin pre- and post-treatment significantly reduced turning response in 
comparison to 6-OHDA group (ANOVA, P˂0.001) through an α7-mediated 
mechanism. Administration of MLA, an α7-receptor blocker, abolished curcumin 
effect and the number of turns were comparable to 6-OHDA group (ANOVA, P˂1). 
MLA by its own has no effect, this is indicated by the last group, were number of turns 
was comparable to 6-OHDA+Cur+MLA or 6-OHDA treated groups (ANOVA, P=1). 
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Figure 63: Apomorphine-induced rotation test in 6-OHDA injected rats before and 
after MLA I.P injection. 
Comparison of apomorphine-induced rotation test (0.25 mg/kg) with and without 
MLA I.P treatment. MLA as an α7-nAChR blocker I.P injection didn’t induce a 
significant change in turning response of 6-OHDA injected rats compared to their 
motor assessment without MLA injection, indicating that MLA itself has no effect on 
turning response.   
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4.2.2 Morphological Analysis 
4.2.2.1 Effects on Tyrosine Hydroxylase-Positive Striatal Innervation 
The extent of denervation caused by the intrastriatal 6-OHDA injection was 
analyzed by TH-immunohistochemistry in serial coronal sections throughout the 
rostro-caudal extent of the striatum. Quantitative assessment of striatal. TH fiber 
density was obtained by optical density measurements at four defined rostro-caudal 
levels, as shown in Figure 64.  
Vehicle treated rats had no significant difference between both lesioned and non-
lesioned side throughout the four rostocaudal levels of the striatum (98.29±5.9 / 
ANOVA). In contrast, multiple 6-OHDA-injection resulted in an extensive 
denervation in the striatum diffusing all over the four rostocaudal levels compared to 
vehicle treated group (7.14±3.2 / ANOVA, P˂0.000). In third group of rats, pre- and 
post-surgical curcumin treatment was administered orally on daily bases for four 
weeks as described earlier in Methods section. Curcumin treatment has a restorative 
effect on TH+ innervated fibers compared to 6-OHDA treated group (32.46±4.2 / 
ANOVA, P˂0.011). To investigate whether the effect of curcumin was mediated via 
α7-nAChRs or no, we treated the rats with a selective α7-nAChRs blocker; MLA (I.P) 
prior to curcumin daily treatment. Blocking α7-nAChR reversed the neuroprotective 
effect of curcumin throughout the four levels of striatum in 6-OHDA+Cur+MLA 
treated rats compared to 6-OHDA+Cur group (4.81±1.85 / ANOVA, P˂0.005), with 
no statistical difference from 6-OHDA group (P˃1.000). When the same amount of 
toxin was injected to 6-OHDA+MLA, with MLA injection before motor assessment, 
MLA alone showed no effect on striatal innervation (7.79±0.9 / ANOVA), compared 
to 6-OHDA or 6-OHDA+Cur+MLA (P˃1.00) (Figure 65). 
141 
 
 
 
 
 
 
Figure 64: Photographs of TH immunoreactive fibers. 
Four approximately equally spaced rostocaudal levels of the right (lesioned) striatum 
as shown for the five animal groups included in the study. The intra-striatal 6‐OHDA 
lesion caused degeneration of the TH‐positive fibers mainly in the central and lateral 
parts of head and tail of the caudate putamen leaving the medial and ventral sectors 
partially intact (compare A and B). Curcumin treatment protected TH‐positive fiber 
innervation to a large extent. 6-OHDA+Cur+MLA treatment reversed the protective 
effect curcumin. MLA treated rats alone showed no difference from 6‐OHDA or 6-
OHDA+Cur+MLA groups. 
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Figure 65: Striatal TH-immunoreactive fiber density expressed as a percentage of the 
fiber density on the lesioned side to the non-lesioned side. 
The density was measured at four rostrocaudal levels of the striatum: rostral (+1.56 
mm from Bregma), middle 1 (+0.72 mm from Bregma), middle 2 (+0.12 mm from 
Bregma), and caudal (−0.24 mm from Bregma). The multiple intra-striatal 6-OHDA 
injection caused an extensive damage to TH+ fibers throughout the four levels of 
striatum compared to vehicle treated group (ANOVA, P˂0.000). The neuroprotective 
effect of curcumin was markedly obvious in curcumin treated group through an α7-
receptor mediated mechanism, at all rostrocaudal levels of stratum; in comparison with 
6-OHDA treated group (ANOVA, rostral P˂0.011). MLA, an α7-receptor blocker, 
reversed the protective effect of curcumin in 6-OHDA+Cur+MLA group (ANOVA, 
P˂0.000 at all levels). MLA antagonist had no effect by itself as indicated by the last 
animal group; 6-OHDA+MLA showed no statistical difference from 6-
OHDA+Cur+MLA group or 6-OHDA treated rats (ANOVA, P˃1.000 at all level). 
Values represent mean % of control side ± SEM. 
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4.2.2.2 Effects on Tyrosine Hydroxylase-Positive Neurons in Substantia Nigra 
The total number of SN TH+ neurons were assessed bilaterally (using the left un-
lesioned side as a control) in each animal by the unbiased stereological analysis using 
the optical fractionator principle. The counted region included substantia nigra pars 
compacta. The number of TH positive neurons in three different levels of SN (caudal, 
middle, and rostral) were counted for each animal; to overcome several anatomical and 
technical confounding factors such as; non-homogeneous distribution of dopaminergic 
neurons, variability between animals, variability in the immunohistochemical staining 
from one batch of specimens to another. The intra-striatal 6-OHDA injection caused a 
substantial loss of SN cells with sparing of VTA TH+ neurons. There was no 
significant difference bilaterally in vehicle treated group at the three levels; caudal, 
middle, rostral, and total survival SN cell analysis [rostral: 100.3±6.2, middle: 
94.0±6.6, caudal: 105.6±5.0, total: 99.7±2.5 / ANOVA]. However, on day 21 after 6-
OHDA lesioning, the number of the TH-positive neurons were markedly decreased on 
the lesioned side compared with vehicle treated group at all rostrocaudal levels 
[ANOVA, rostral: 11.3±2.9 (P˂0.000), middle: 10.2±2.0 (P˂0.000), caudal: 8.9±2.6 
(P˂0.000), total: 9.9±1.9 (P˂0.000)]. Curcumin pre- and post-treatment had a 
neuroprotective property and could significantly restore 6-OHDA damaging effect on 
dopaminergic neurons in comparison with 6-OHDA treated animals at caudal, middle, 
rostral and total survival SN cell count in 6-OHDA+Cur treated group [rostral: caudal; 
[ANOVA, rostral: 30.2±5.1 (P˂0.003), middle: 39.2±6.8 (P˂0.000), caudal: 42.5±4.6 
(P˂0.000), total: 32.0±4.7 (P˂0.000)]. In contrast, blocking of α7-nAChR with MLA 
I.P injection prior to curcumin oral administration significantly reversed the 
neuroprotective effect of curcumin at all the three levels in 6-OHDA+Cur+MLA 
treated group [ANOVA, rostral: 6.7±0.9 (P˂0.000), middle: 12.3±2.6 (P˂0.000), 
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caudal: 12.9±1.3 (P˂0.000), total: 10.3±1.4 (P˂0.000)], supporting that curcumin 
neuroprotective effect is mediated via α7-nAChR. The SN cell count in 6-
OHDA+MLA animal group were comparable to 6-OHDA+Cur+MLA or 6-OHDA 
groups with no statistical difference between the three groups at all levels [ANOVA, 
rostral: 6.7±1.9, middle: 7.0±1.2, caudal: 8.0±3.3, total: 7.1±2.0 (P˃1.0 at all levels)], 
as it was not expected from this group to have any change at cellular level and the main 
target of this group was to test the behavioral variation due to MLA administration.  
Noting that, in all sections, the SN on the un-lesioned left side, both the 
morphology and the number of TH-positive neurons remained unchanged (Figures 66 
& 67). 
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Figure 66: Photomicrographs of coronal sections of SN for TH immunohistochemistry. 
Sections show three rostrocaudal levels from the SN on the lesion side. 6-OHDA 
treated rats showed sever loss of TH-positive cells in the SN at all levels compared to 
vehicle group (ANOVA, P˂0.000 at all levels). Curcumin treated rats showed 
significant improvement in cell survival in comparison with 6-OHDA injected rats 
(ANOVA, rostral P˂0.003, middle P˂0.000, and caudal P˂0.000). MLA, an α7-
receptor blocker, reversed the protective effect of curcumin in 6-OHDA+Cur+MLA 
group (ANOVA, P˂0.000 at all levels). MLA antagonist had no effect by itself as 
indicated by the last animal group; 6-OHDA+MLA showed no statistical difference 
from 6-OHDA+Cur+MLA group or 6-OHDA treated rats (ANOVA, P˃1.0 at all 
level). 
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Figure 67: Stereological assessment of total numbers of TH-positive cell bodies in the 
SN at all three levels; rostral, middle, and caudal. 
The multiple intra-striatal 6-OHDA injection caused a dramatic loss of TH+ neurons 
in the pars compacta compared to vehicle treated animals (ANOVA, rostral P˂0.000, 
middle P˂0.000, caudal P˂0.000, and total P˂0.000). The neuroprotective effect of 
curcumin was markedly obvious in curcumin treated group through an α7-receptor 
mediated mechanism, at all rostrocaudal levels; rostral (A), middle (B), and caudal (C) 
in comparison with 6-OHDA treated group (ANOVA, rostral P˂0.003, middle 
P˂0.000, caudal P˂0.000, and total P˂0.000). MLA, an α7-receptor blocker, reversed 
the protective effect of curcumin in 6-OHDA+Cur+MLA group (ANOVA, P˂0.000 at 
all levels). MLA antagonist had no effect by itself as indicated by the last animal group; 
6-OHDA+MLA showed no statistical difference from 6-OHDA+Cur+MLA group or 
6-OHDA treated rats (ANOVA, P˃1.0 at all level (D)). 
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Chapter 5: Discussion 
5.1 Discussion 
In the present study, electrophysiological, in silico (computational), behavioral, 
and morphological analyses were used to provide evidence that curcumin (i) 
upregulates the function of human α7-nAChRs expressed in Xenopus oocytes and (ii) 
reverses neurodegeneration in rat models of 6-OHDA of PD through an α7-nAChR 
mechanism.  
5.1.1 Effects of Curcumin on α7-Nicotinic Acetylcholine Receptor 
Many researchers have extensively studied curcumin in recent years. However, 
molecular and cellular targets mediating the pharmacological actions of curcumin 
remain largely unknown. In this study, the effects of curcumin on the functional 
properties of α7-nicotinic acetylcholine receptor have been investigated, using the two-
electrode voltage clamp technique. The effect of curcumin was tested on ion currents 
induced with acetylcholine. Curcumin caused a significant potentiation of the current, 
which was partially reversed during washout.  
The potentiation effect of curcumin was significantly dependent on the mode of 
application. For example, without preincubation, the co-application of curcumin and 
ACh did not alter the amplitude of maximal currents. Whereas, preincubation of 
curcumin caused an increase in the extent of α7-nAChRs potentiation. It is likely that 
this preincubation time is crucial for oocyte preparation to adapt the effect of curcumin 
on the expressed α7-nAChRs by the oocytes. This is because the preincubation timing 
allows longer timeframe for the compound with the same experimental dose used, 
eventually resulting in a more potent effect.  
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The time course of the effect of curcumin on the maximal amplitudes of ACh-
induced currents was relatively slow which might indicate the possible interaction of 
curcumin with the lipid membrane. The enhancement of α7-nAChR function by 
curcumin is reversible and occurs in a time- and concentration-dependent manner. 
Moreover, other curcumin derivatives have been screened and as expected, they 
showed potentiation effects on α7-nAChRs, although to a lesser extent in comparison 
to curcumin. Being products of curcumin themselves, curcumin metabolites had a 
comparable potentiation effects on the receptor function.  
The potentiation effect of curcumin was also obvious on other subtypes of nAChRs 
and the other members of ligand gated ion channels; serotonin and glycine receptors. 
Curcumin was found less effective on other nicotinic receptor subunit combinations 
and other members of ligand-gated ion channels. 
5.1.2 Effects of Curcumin on α7-Nicotinic Receptor are not Mediated by G-
proteins and Protein Kinases, and are not Dependent on Intracellular 
Ca2+ Levels, and Membrane Potential 
A relatively slow time course of curcumin effect and the results of earlier studies 
on curcumin modulation of various second messenger pathways and kinases 
(Mahmmoud, 2007; Takikawa et al., 2013) suggest that activation of G-protein-
coupled receptors (Liu et al., 2013; Pérez-Lara et al., 2011; Yang et al., 2015) and/or 
kinase-mediated phosphorylation is involved in curcumin-induced upregulation of α7-
nAChRs (Talwar and Lynch, 2014; Zhang et al., 1995). However, neither treatments 
with established kinase inhibitors nor pharmacological disruption of G-protein activity 
reversed curcumin potentiation of α7-nAChRs, suggesting that curcumin acts directly 
on ion channel-receptor complex. Furthermore, the enhancement of α7-nAChR 
function by curcumin is not altered by changes in intracellular Ca2+ levels, or 
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membrane potential. This was evidenced by the same level of curcumin potentiation 
at all tested membrane potentials. 
In Xenopus oocytes, activation of α7-nAChRs, due to their high Ca2+ permeability, 
allows sufficient Ca2+ entry to activate endogenous Ca2+-dependent Cl− channels 
(Hartzell et al., 2005; Sands et al., 1993). Ca2+-activated Cl− channels are highly 
sensitive to intracellular Ca2+ levels [KD of Ca
2+-activated Cl−channels for Ca2+ is less 
than 1 µM; see review by (Hartzell et al., 2005)], and alterations in intracellular 
Ca2+ levels would be reflected by changes in the holding current under voltage-clamp 
conditions. Curcumin has been reported to alter Ca2+ homeostasis in various cell types 
(Dyer et al., 2002; Ibrahim et al., 2011; Moustapha et al., 2015; Wang et al., 2012). 
Therefore, the direct actions of curcumin on Ca2+-dependent Cl− channels may 
contribute to the observed effects of curcumin on ACh-activated currents in this 
expression system. However, in Xenopus oocytes injected with BAPTA and recorded 
in a solution containing 2 mM Ba2+, co-application of curcumin did not cause 
alterations in baseline or holding currents and continued to potentiate α7-nAChR–
mediated ion currents after the chelation of intracellular Ca2+ by BAPTA, suggesting 
that Ca2+-dependent Cl− channels were not involved in curcumin potentiation of 
nicotinic responses. In addition, the reversal potential in solutions containing Ba2+ was 
not altered in the presence of curcumin, suggesting that the potentiation by curcumin 
is not due to alterations in the Ca2+ permeability of the α7-nAChR-channel complex. 
Negative results in BAPTA calcium chelating experiment; may advocate a second 
review of experimental set-up including solutions. More importantly, it would have 
been appropriate to test BAPTA effectiveness on any other well-established 
intracellular Ca2+-dependent pathway as a positive control study before starting 
oocytes’ experiments. 
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5.1.3 Effects of Curcumin at Different Concentrations of Acetylcholine 
Previous studies have demonstrated that curcumin acts on several integral 
membrane proteins, including enzymes, transporters, and ion channels (Li et al., 2017; 
X. Zhang et al., 2014), T-type Ca2+channels in bovine adrenal cells (Enyeart et al., 
2009); IC50 = 10–20 µM), L-type Ca2+ channels in hippocampal neurons (Liu et al., 
2013); IC50 ≈ 10 µM), TREK-1 K+ channels (Enyeart et al., 2008); IC50 = 0.9 µM), 
Kv1.4 K+ channels (Liu et al., 2006) in bovine adrenal cells, Kv1.4. K+ channels (Lian 
et al., 2013); IC50 = 4.2 µM) in human T-lymphocytes, ERG K
+ channels (Hu et al., 
2012), IC50= 5.5 µM; (Choi et al., 2013), IC50 = 10.6 µM; (Banderali et al., 2011), 
IC50 = 2 µM), and K
+ channels in rabbit coronary arterial smooth muscle cells (Hong 
et al., 2013); IC50 = 1.1 µM). In addition to voltage-dependent conductance, curcumin 
has also been shown to act on transient-receptor potential receptors (Yeon et al., 2010; 
Zhi et al., 2013). In this study, curcumin was applied in the concentration range of 1 
nM to 100 µM, and it was found that it can enhance the effects of ACh on the function 
of α7-nAChRs in a concentration-dependent manner, with EC50 values ranging from 
58 nM to several micromolar. The concentration of curcumin in plasma and its ability 
to pass the blood-brain barrier following oral and intravenous administration have been 
studied previously (Anand et al., 2007). When curcumin was given orally at a dose of 
2 g/kg to rats, a maximum serum concentration of 1.35 µg/ml ± 0.23 μg/mL was 
attained at time 0.83 h (Shoba et al., 1998). Since curcumin is a highly lipophilic 
compound with a logP (octanol–water partition coefficient) value of 3.3 
(https://pubchem.ncbi.nlm.nih.gov/compound/curcumin#section=Top), its membrane 
concentration is expected to be considerably higher than blood levels. Therefore, the 
functional modulation of α7-nAChRs demonstrated in this study can be 
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pharmacologically relevant. Because of curcumin’s lipophilicity, it would be 
interesting to test the effects of curcumin with a different application such as 
intracellular injection allowing direct interaction with its transmembrane binding site.  
As mentioned earlier, the roles of G-proteins, kinases, and intracellular Ca2+ levels 
in curcumin actions were excluded in our functional and pharmacological studies. 
Further experiments indicated that the extent of curcumin potentiation decreased 
significantly with increasing concentrations of ACh suggesting that curcumin acts 
through a non-competitive mechanism of action.  
5.1.4 Effects of Curcumin on the Specific Binding of [125I]α-bungarotoxin 
By definition, an antagonist is a compound that upon binding to the receptor, have 
no effect on their own but rather block the action of an endogenous or exogenous 
agonist (Williams and Raddatz, 2006). There are two types of antagonist; competitive 
antagonist where the antagonist and the agonist bind to the same active binding site, 
so both are competing to bind to the same receptor. While non-competitive antagonist 
binds to a different site other than the active site and block the action of the agonist 
(Swinney, 2004). 
Our results demonstrated the negative correlation between an increase in ACh 
concentrations and the extent of curcumin potentiation, and this assumption was 
supported by competition radioligand binding experiments. Notably, binding of α-
bungarotoxin, a competitive antagonist of ACh, was not altered in the presence of 
curcumin, suggesting that curcumin does not interact with the ACh binding site in the 
receptor. 
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5.1.5 Effects of Curcumin on Desensitization of Nicotinic Receptors 
It is likely that curcumin, a highly lipophilic agent, first dissolves into the lipid 
membrane and then diffuses into a non-annular lipid space to potentiate the function 
of the ion channel-receptor complex. Consistent with this idea, the effect of curcumin 
on α7-nAChR reached a maximal level within 5–10 minutes of application, suggesting 
that the binding site(s) for these allosteric modifiers is located inside the lipid 
membrane and requires a relatively slow (in minutes) time course to modulate the 
function of the receptor. It is likely that these hydrophobic agents affect the energy 
requirements for gating-related conformational changes in ligand-gated ion channels 
(Spivak et al., 2007). 
α7-nAChRs recovery from desensitization is mainly dependent on agonist potency, 
concentration, and duration of exposure. Therefore, for desensitization experiment we 
have used a stronger and highly selective nicotinic agonist; nicotine with a dose of 100 
µM and much longer exposure time (25 - 30 sec). Contrarily, ACh was used in all our 
experiments. This is because ACh mimics the endogenously secreted agonist in its fast 
receptor activation of both muscarinic and nicotinic, rapid degradation, and short 
response duration. 
The hallmark charactarestics of α7-nAChRs  include its high permeability to Ca2+, 
allowing huge amount of Ca2+ influx into the cell which may have a cytotoxic effect 
(Guerra-Álvarez et al., 2015). However, the fast kinetics of α7-nAChRs exemplified 
in fast desensitization and brief opening duration may be the reason behind avoidance 
of cell toxicity. 
It is plausible that curcumin acts as an allosteric modulator for various receptors 
and ion channels at the lipid membrane, accounting for some of its pharmacological 
154 
 
 
 
 
actions in animal studies (Zhang et al., 2014). Allosteric modulators alter the 
functional properties of ligand-gated ion channels by interacting with sites that are 
topographically distinct from the ligand binding sites [see review by (Onaran and 
Costa, 2009)]. Two different types of positive allosteric modulator (PAM) have been 
postulated (Chatzidaki and Millar, 2015; Uteshev, 2014). Whereas type I enhances 
agonist-induced currents without affecting macroscopic current kinetics, type II PAMs 
delay desensitization and reactivate desensitized receptors. Further analysis of the 
curcumin effect indicated that curcumin significantly (more than 3-fold) decreased 
desensitization of the receptor and reactivate the already-desensitized nAChR to its 
conducting state suggesting that curcumin acts as a type II PAM. 
Rapid desensitization of homomeric α7-nAChRs can be tested under different 
conditions, by assembling α7 subunit with different stoichiometries; namely β2, 
forming functional heteromeric receptor subtype. It is expected that β2 subunit would 
result in a slower receptor kinetics. α7β2 receptors have been detected in various brain 
areas (Liu et al., 2012, 2009; Moretti et al., 2014; Thomsen et al., 2015; Zoli et al., 
2015). Interestingly, α7β2 has been shown to play a role in the neuropathy of 
Alzheimer’s disease and is highly susceptible to inhibition by 
the volatile anesthetic isoflurane (Liu et al., 2009; Mowrey et al., 2013).  
5.1.6 Docking of Curcumin and Curcumin Derivatives into the Human α7-
nAChR Transmembrane Domain 
All of these indications together, have guided us towards molecular docking 
studies to identify the exact binding site of curcumin -as a type II positive allosteric 
modulator- in relation to α7-nAChRs. The binding site of type II positive allosteric 
modulators (PAMs) were proposed to be within the transmembrane domain of α7-
nAChRs (Gill et al., 2011; Young et al., 2008). Several pieces of evidence have 
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indicated that amino acids within TM1-TM3 are responsible for the potentiation effect 
induced by PAMs. Out of these residues, mutations of two particular residues Ala225 
(in TM1) or Met253 (in TM2) had the greatest influence on α7-nAChR potentiation 
by the known type II PAM, PNU-120596 (Young et al., 2008). Corradi and Bouzat 
(2016) claimed that PNU-120695 is the most efficacious type II PAM and, therefore 
it has been used along with TQS as reference compounds in docking experiments. 
Like other type II PAMs, the intra-cavity of transmembrane α7-nAChR domain 
could be proposed as the binding site of curcumin and its derivatives. Fortunately, 
Bondarenko et al. have recently discovered the structure of the human α7-nAChR 
transmembrane domain, intra-cavity of which was used for curcumin docking 
(Bondarenko et al., 2014). 
Interestingly, all of the interacting residues of curcumin are located in TM1, TM2 
and TM3 which are known for their importance for type II PAM binding. Also, many 
of those residues, that when mutated play an important role in type II PAM activity, 
appear to be in close proximity to curcumin; most importantly Ala226 which had direct 
contacts with the ligand carbons. It is highly favorable that mutation at those specific 
residues lining the cavity would affect curcumin interaction with the receptor. 
Furthermore it has been postulated that this intracavity is a common PAM modulatory 
site within the pLGIC superfamily, allowing wide variety of compounds to mediate an 
allosteric effect (Corradi et al., 2011; Jayakumary et al., 2010; Nury et al., 2011; 
Sauguet et al., 2014).   
To sum up, curcumin and curcumin derivatives have what it takes to fit nicely into 
the α7-nAChR transmembrane domain intra-cavity, the proposed binding site of type 
II PAMs.  
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5.1.7 Neuroprotective Properties of Curcumin in Parkinson’s Disease 
Neurodegenerative diseases such as Alzheimer and Parkinson’s disease result from 
loss of neurons as a sequel of their dysfunction. As discussed earlier, degenerative 
changes in PD occur due to three main mechanisms; mitochondrial dysfunction, 
oxidative stress, and modifications in protein handling, affecting all cellular functions 
(Franco-Iborra et al., 2016; Olanow and McNaught, 2011; Schapira and Jenner, 2011). 
A crucial unmet demand in the management of Parkinson’s disease is the discovery 
of new approaches that could slow down, stop, or even reverse the process of 
neurodegeneration. Several pieces of experimental evidence have revealed that the 
cholinergic system is a potential pharmacological target for the treatment of PD (Guan 
et al., 2002; Quik et al., 2012). Nicotine, a selective agonist of α7-nAChRs, enhances 
the dopaminergic system in the striatum in animal models of PD (O’Neill et al., 2002; 
Picciotto and Zoli, 2008; Quik and Wonnacott, 2011). The widespread distribution of 
various subtypes of nicotinic receptors in the brain contribute significantly to nicotinic 
receptor-mediated neuroprotection mechanisms. Several in-vitro studies using primary 
cultures from different brain regions such as striatal, nigral, cortical, or neuronal cell 
lines have demonstrated that pre-treatment with nAChR agonists have a 
neuroprotective activity against toxic insults via α7 or α4β2* nAChRs mediated 
mechanisms (Bordia et al., 2015; Gatto et al., 2004; O’Neill et al., 2002; Picciotto and 
Zoli, 2008; Quik and Kulak, 2002; Roncarati et al., 2009; Ward et al., 2008; Yang et 
al., 2017). Thus, drugs/compounds that can modulate/regulate α7-nAChRs may 
possibly have a neuroprotective effect against 6-OHDA induced toxicity, which leads 
to dopaminergic neuronal loss. 
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Our in-vitro results demonstrated vividly that curcumin enhances the effects of 
ACh on the function of α7-nAChRs in a concentration-dependent manner, and that 
curcumin significantly decreases desensitization of the receptor leading the proposal 
that it acts as a type II PAM. These results suggest that curcumin may play a key role 
in brain regions affected by 6-OHDA in animal model of PD. We therefore tested this 
effect after systemic in-vivo administration in rats. α7-nAChRs are widely distributed 
throughout the brain in neuronal and non-neuronal immune cells, such as microglia 
and astrocytes (Liu et al., 2015; Park et al., 2007; Shytle et al., 2004; Wang et al., 
2003). α7-nAChR expressed on immune cells are involved in the initiation, 
maintenance, and resolution of inflammation, and modulate neuro-inflammatory 
processes. In addition, α7-nAChRs are expressed on microglia regulating 
inflammatory factors in the CNS (Bagdas et al., 2018). 
A recent systematic literature review involving 13 studies of different PD animal 
models, between the periods 2005 to 2014. All these studies except one, elaborated on 
the anti-oxidant, anti-inflammatory, and anti-apoptotic properties of curcumin (Figure 
68) and proved its neuroprotective activity and ability to improve neurological 
functions in different animal models of PD (Wang et al., 2017). 
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Figure 68: Neuroprotective mechanisms of curcumin in PD. 
Curcumin marked efficacy in different animal models of Parkinson’s disease through 
its anti-inflammatory, anti-oxidant, anti-apoptotic properties, and its ability to suppress 
iron deposition in dopaminergic neurons (Wang et al., 2017). 
 
In the present study we found that curcumin is a type II PAM of α7-nAChR. PAMs 
are compounds that facilitate endogenous neurotransmission and/or enhance the 
efficacy and potency of exogenous agonists, without directly stimulating the agonist 
binding sites. Since α7-nACh receptor PAMs have been reported to be active in animal 
models of Parkinson’s disease (Bagdas et al., 2015; Freitas et al., 2013b, 2013a; Munro 
et al., 2012), in the next step, the effects of curcumin on motor function were assessed 
in the 6-OHDA induced model of PD. 
A variety of agents and toxins have been used to induce neurotoxicity which 
involves the destruction of dopaminergic system in animal models of PD. These 
include 6-OHDA, MPTP, rotenone, and many others. 6-OHDA is the most commonly 
used rat model of PD (Cicchetti et al., 2009; Uversky, 2004). In this study, we found 
that multiple intra-striatal injection of 6-OHDA successfully developed PD in the rat 
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as evidenced by the loss of TH-immunoreactive cells, a marker of dopaminergic 
neurons and motor dysfunction of the SNpc. The mortality rate of around 6.8 % in this 
study which was calculated from the loss of one rat from 6-OHDA group and two rats 
from 6-OHDA+Cur group was relatively low. 
The drug-induced rotation test is the gold standard assessment of unilateral 6-
hydroxydopamine (6-OHDA) lesions. The direction of rotation differs according to 
the drug used. Amphetamine, a dopamine releasing compound, induces striatal 
dopamine release, and also inhibits its reuptake-, thus strongly activating DA release 
in the intact side. Therefore, amphetamine induces animals to rotate in a direction 
ipsilateral to the lesion side which has weak or no DA to be stimulated (Figure 69) 
(Schwarting and Huston, 1996; Ungerstedt, 1971). In contrast, Apomorphine is a direct 
DA agonist and has a postsynaptic mechanism of action. Because of apomorphine's 
predominant postsynaptic mechanism of action, it stimulates post-synaptic D1 and D2 
receptors preferentially in the lesioned side which become supersensitive to 
apomorphine stimulation, hence, a dose of 0.25 mg/kg of apomorphine induces a 
contralateral rotation in 6-OHDA treated animals (Figure 69)  (Hefti et al., 1980a; 
Hudson et al., 1993). Previous studies have shown that intra-striatal injection of 6-
OHDA causes retrograde degeneration of SN dopaminergic neurons, resulting in 
depletion of striatal dopamine (Singh et al., 2003). Consistent with previous studies, 
we found that 21 days after 6-OHDA treatment, rats displayed significant impairment 
in the motor functions. 
Apomorphine-induced rotation test was used to assess motor abnormalities 
between different groups as it induces contralateral rotations only in rats with sever 
DA depletion (≥ 75 – 95%) (Schwarting and Huston, 1996). This test is a reliable, 
objective, and closely related to the degree of nigrostriatal dysfunction as well as DA 
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depletion (Schwarting et al., 1991). Vehicle treated rats rotated equally in both 
directions and results were expressed as contralateral turns (subtracting number of 
right turns from left turns). In comparison, 6-OHDA treated rats showed a significant 
increase in number of turns contralaterally. Curcumin pre- and post-treatment 
produced significant improvement in rotation response to 6-OHDA- injected rats and 
decreased turning behavior significantly.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 69: Drug-induced rotation test in rats that had 6-OHDA injection in the right 
striatum. 
(A & B) Systemic amphetamine injection results in ipsilateral rotation. (C & D) 
Systemic apomorphine administration results in hypersensitivity of dopamine 
receptors causing contralateral rotations  (Dunnett and Torres, 2011). 
A 
B
C 
D 
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Based upon our findings that curcumin treatment significantly decreased turning 
response in 6-OHDA treated rats, we investigated the neuroprotective effects of 
curcumin against neuronal loss. 
According to the study of Dadhaniya et al. (2011), the LD50 of the preparation in 
rats as well as in mice was found to be greater than 2000 mg/kg body weight after 90 
days treatment protocol. They concluded that no Observed-Adverse-Effect Level 
(NOAEL) for the standardized novel curcumin preparation is determined as 750 
mg/kg/day, (the highest dose tested) (Dadhaniya et al., 2011). To study the effect of 
curcumin at the cellular level, a non-toxic dose of curcumin (200 mg/kg) was used. 
Thus, our dose for the in-vivo study is considered safe. Indeed, it is equivalent to 2 
g/day in human and very close to the recommended dose suggested by Perkins et al. 
(2002). 
The present study was designed to assess the ability of oral curcumin 
administration to preserve the integrity of nigrostriatal dopaminergic system (cell 
bodies, striatal terminals, and motor behavior). The total number of TH+ neurons in 
the SNpc of both hemispheres was evaluated using an unbiased stereology technique. 
In 6-OHDA+Cur treated group, curcumin significantly reduced the 6-OHDA-induced 
degenerative effect on SNpc dopaminergic neuronal cells, indicating that curcumin has 
a neuroprotective effect on DA neuronal damage by 6-OHDA. In the next step of the 
study, the involvement of α7-nAChRs in curcumin neuroprotection was investigated. 
The results demonstrated that neuroprotective effect of curcumin is mediated via α7-
nAChRs as demonstrated in 6-OHDA+Cur+MLA group. In these animals the number 
of TH positive neurons in SN were comparable to 6-OHDA group with no significance 
difference between both groups. The restorative effect of curcumin was distinctly 
reflected on denervated TH+ DA striatal fibers, as curcumin significantly protected the 
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striatal fibers from the 6-OHDA toxin through an α7-nAChRs mediated mechanism as 
indicated by the abolished effect of curcumin after the use of MLA in 6-
OHDA+Cur+MLA group. Taken together, our data suggest that, curcumin improved 
turning response, striatal fiber density, and SNpc TH-positive neuronal cells, are 
considered as a good index for curcumin to have an anti-Parkinsonian effect.   
α7-nAChR is considered to be a potential pharmacological target for several 
neurological disorders, such as Parkinson’s disease, Alzheimer's disease, and 
Schizophrenia. Currently, a number of α7-nAChR agonists and modulators are under 
clinical trials (Yang et al., 2017). In case of Parkinson’s disease and nicotinic 
receptors, several clinical trials have been conducted as shown in Table 13. 
Keeping in view that many clinical trials in which α7-nAChR agonists were used 
(e.g.: Tropisetron, EVP-6124) have been either suspended or terminated. This could 
be attributed to the lack of high selectivity indicated by cross-activity with other LGIC, 
(for example: 5-HT3 receptors) (Huang et al., 2014; Macor et al., 2001). 
In comparison, α7-nAChR PAMs, presented very positive and promising results, 
especially PNU-120695; a type II PAM which has proved to have a pro-cognitive 
effect in rodents and non-human primates but failed in clinical trials for being too-
potent drug causing a very high calcium influx and potential cytotoxic effect (Callahan 
et al., 2013; Ng et al., 2007).  
As a basic rule in research: “safety remains the most important starting point and 
efficacy becomes a matter of validation”, the need of safe and effective approach in 
regards of α7-nAChR is mandatory. Curcumin, as demonstrated in our research to be 
a type II PAM, is a natural compound with a high safety profile with no reported 
toxicity (Lao et al., 2006) has undergone several clinical trials for treatment of 
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neurodegenerative disorders (Table 14) (e.g.: Alzheimer’s disease, cognitive 
impairment). 
Overall, current findings of clinical trials on nicotinic receptors and Parkinson’s 
disease or curcumin and neuro-degenerative disorders such as Parkinson’s disease are 
very promising, but further pre-clinical studies and clinical trials are needed to improve 
curcumin’s bioavailability and define its hidden targets of curcumin. 
Our findings are in agreement with many other previous studies carried out, where 
motor, cellular, and biochemical alterations in PD rats have been improved by 
curcumin and its derivatives (Agrawal et al., 2012; Khuwaja et al., 2011; Singh and 
Kumar, 2017; Song et al., 2016; Tripanichkul and Jaroensuppaperch, 2012, 2013; 
Yang et al., 2014; Zbarsky et al., 2005), and our findings suggest a new mechanism 
for curcumin-induced neuroprotection. 
Figure 70 illustrates the possible mechanisms by which curcumin may act through 
α7-nAChR to protect against the neurotoxic effects in an animal model of Parkinson’s 
disease. The results of in-vitro, in silico, and in-vivo experiments of this study suggest 
that increasing Ca2+ influx through curcumin α7-nAChR potentiation may have a 
neuroprotective mechanism in neuronal and non-neuronal cells via various 
intracellular mechanisms. 
The lipid signaling cascade initiated by PKC, via phosphorylation of 
phosphatidylinositol 3-kinase (PI3K/Akt), is credited with modulating the activities of 
neuroprotective and apoptotic factors, such as Bcl-2 and caspases, respectively. In 
addition to to their neuronal expression, α7-nAChRs are expressed on microglia and 
astrocytes, playing a major role in immune response via “cholinergic anti-
inflammatory pathway”, activation of α7-nAChR and increase in IC Ca2+ 
concentration modulate Janus kinase 2 (JAK2) and/or signal transducer and activator 
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of transcription 3 (STAT3), ending up with upregulation of protein kinase B (PKB) 
leading to inhibition of nuclear factor-kB (NFκB). IC Ca2+ trigger protein kinase A 
(PKA) and/or calcium-calmodulin-dependent protein kinase (CaMK) which in turn 
trigger extracellular signal-regulated mitogen-activated protein kinase (ERK/MAPK) 
pathway. ERK/MAPK signaling is a crucial event in cell survival pathway via 
upregulation of the cellular transcription factor; cAMP response element-binding 
(CREB), increasing gene expression of tyrosine hydroxylase, and enhancing dopamine 
release. As an end result, maintaining cell viability through α7-nAChR activation 
induce dopamine release from synaptic vesicles via Ca2+-dependent facilitation 
mechanism.  
Collectively, all or some of these factors may contribute to decrease apoptosis, 
modify immune response, and alter synaptic plasticity enhancing neuronal protection 
and survival (Hosur and Loring, 2011; Picciotto and Zoli, 2008; Quik and Kulak, 2002; 
Ward et al., 2008). 
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Figure 70: Hypothetical model of Ca2+- dependent cell survival mechanism. 
Curcumin modulate α7-nAChR allosterically allowing more Ca2+ entry into the cell as 
depicted from the electrophysiological recording. Increase in intracellular Ca2+ 
concentration will lead to a cascade of events in dopaminergic neurons (from left to 
right): Facilitation of dopamine release from synaptic vesicles. Activation of ERK by 
PKA and/or CaMK, upregulate CREB protein, increase tyrosine hydroxylase activity, 
and activate dopamine release.  JAK2/STAT3 signaling pathway leads to inhibition of 
NF-kB translocation via PKB activation. Increase in IC Ca2+ attenuates inflammatory 
response in immune cells activating protein kinase C, PKC appears to activate 
downstream signaling PI3K/AKT pathways that promotes Nrf-2 translocation 
resulting in modulation of cell survival proteins; Bcl-2 and caspase.   
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Table 13: nAChRs and PAMs in clinical trials for treatment of PD (“Home - ClinicalTrials.gov,” n.d.) 
Title  Status Conditions Interventions Characteristics Sponsor/Collabroters 
Evaluation of 5-
[123I]-A-85380 and 
SPECT imaging in 
Individuals With 
Parkinson’s Disease 
Completed  Parkinson’s 
Disease 
Drug: [1231]-
IA-85380 
Phase: 
• Phase 2  
Study Design: 
• Intervention Model: Single 
Group Assignment 
• Masking: None (Open 
Lable) 
• Primary Purpose: 
Diagnostic 
Institute of 
Neurodegenerative Disorders 
United States Department of 
Defense 
Cholinergic Nicotinic 
Receptors and 
Cognition in PD 
Completed Parkinson’s 
Disease 
 Phase: 
Study Design: 
• Observetional Model: 
Cohort  
• Time Perspective: Cross-
Sectional 
University of Michigan  
Michael J. Fox Foundation 
for Parkinson’s Research 
Varenicline 
Treatment for 
Excessive Daytime 
Sleepiness in 
Parkinson’s Disease 
Active, not 
recruiting 
Parkinson’s 
Disease 
Drug: 
Varenicline  
Drugc: Placebo  
 
Phase: 
• Phase 4 
Study Design: 
• Allocation: Randomized 
• Intervention Model: 
Crossover Assignment 
• Masking: Double 
(Participant, Investigator) 
•  Primary Purpose: 
Treatment 
VU University Medical 
Center  
Center for Human Drug 
Research, Netherlands 
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Table 13: nAChRs and PAMs in clinical trials for treatment of PD (“Home - ClinicalTrials.gov,” n.d.) (Continued) 
Title Status Conditions Interventios Characteristics Sponsor/Collabroters 
PET Study of the 
Nicotinic Receptors 
in Human 
Terminated Healthy 
Parkinson’s 
Disease  
Alzheimer’s 
Disease 
Epilepsy 
Drug: Curcumin Phase: 
Study Design: 
• Time Prespective: 
Prospective 
Commissariat A L’ebergie 
Atomique 
Single Photon 
Emission Computed 
Tomography to 
Study Receptors in 
Parkinson’s Disease 
Completed Parkinson’s 
Disease 
Drug: I-123-5-
IA85380 
 National Institute of 
Neurological Disorders and 
Stroke (NINDS) 
National Institutes of Health 
Clinical Center (CC) 
A Genetic and 
Perfusion Study of 
Response to 
Cognitive Enhancers 
in Lewy Body Disease 
Completed  Lewy Body 
Disease 
Drug: 
Cholinesterase 
Inhibitors 
(Rivastigmine, 
Aricept, 
Galantamine)  
Study Design: 
• Observetional Model: 
Cohort 
• Time Perspective: 
Prospective 
Sunnybrook Health Sciences 
Center 
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Table 14: Curcumin in clinical trials for treatment of various neurodegenerative disorders (“Home - ClinicalTrials.gov,” n.d.) 
Title  Status Conditions Interventions Characteristics Sponsor/Collabroters 
A Pilot Study of 
Curcumin and 
Ginkgo for Treating 
Alzheimer’s Disease  
Completed  Alzheimer’s 
Disease 
Drug: Placebo 
and ginkgo 
extract 
Drug: 
Curcumin and 
ginkgo extract 
 
Phase: 
• Phase 1 
• Phase 2  
Study Design: 
• Allocation: Randomized 
• Intervention Model: Parallel 
Assignment 
• Masking: Double 
• Primary Purpose: Treatment 
Chinese University of 
Hong Kong 
BUPA Foundation 
Kwong Wah hospital 
Curcumin and Yoga 
Therapy for Those at 
Risk for Alzheimer’s 
Disease  
Recruiting Mild 
Cognitive 
Impairment 
Drug: 
Curcumin 
Behavioral: 
aerobic yoga 
Behavioral: 
non-aerobic 
yoga 
Dietary 
Supplement: 
Placebo 
Phase: 
• Phase 2 
Study Design: 
• Allocation: Randomized 
• Intervention Model: Factorial 
Assignment 
• Masking: Quadruple (Participant, 
Care provider, Investigator, Outcome 
Assessors)  
• Primary Purpose: Prevention 
VA Office of Reasech 
and Development 
heather.d’adamo@va.gov 
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Table 14: Curcumin in clinical trials for treatment of various neurodegenerative disorders (“Home - ClinicalTrials.gov,” n.d.) (Continued) 
Title  Status Conditions Interventions Characteristics Sponsor/Collabroters 
Efficacy and Safety 
of Curcumin 
Formulation in 
Alzheimer’s 
Disease 
Unknown 
status 
Alzheimer’s 
Disease 
Dietary 
Supplement: 
Curcumin 
Formulation 
Dietary 
Supplement: 
Placebo  
 
Phase: 
• Phase 1 
Study Design: 
• Allocation: Randomized 
• Intervention Model: Single Group 
Assignment 
• Masking: Double   
• Primary Purpose: Treatment 
Jaslok Hospital and 
Research Center 
Pharmanza Herbal Pvt 
Ltd. 
Verdure Sciences 
University of California, 
Los Angeles 
A Randomized, 
Double-blind, 
Placebo controlled 
Trial of Curcumin 
in Leber’s 
Hereditary Optic 
Neuropathy 
(LHON) 
Completed Optic 
Atrophy, 
Hereditary, 
Leber’s 
Drug: 
Curcumin 
Phase: 
• Phase 3 
Study Design: 
• Allocation: Randomized 
• Intervention Model: Prallel Assignment 
• Masking: Double  
• Primary Purpose: Treatment 
Mahidol University 
Curcumin in 
Pateints With Mild 
to Moderate 
Alzheimer’s 
Disease 
Completed Alzheimer’s 
Disease 
Dietary 
Supplement: 
Curcumin C3 
Complex 
Phase: 
• Phase 2 
Study Design: 
• Allocation: Randomized 
• Intervention Model: Parallel 
Assignment 
• Masking: Double 
• Primary Purpose: Treatment 
John Douglas French  
Foundation 
Institute for the Study of 
Aging (ISOA) 
National Institute on 
Aging (NIA) 
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Chapter 6: Conclusions 
To our knowledge, this is the first study to establish that: 
• Curcumin selectively enhances the effect of ACh on the function of α7-
nAChRs in a concentration dependent manner. 
• The effects of curcumin on α7-nicotinic receptor are not mediated by G-
proteins and protein kinases, and are not dependent on intracellular Ca2+ levels, 
and membrane potential. 
• Curcumin does not interact with ACh binding to receptors. 
• Curcumin significantly decreased desensitization of the receptor and 
reactivates the already-desensitized nAChR back to conducting state. 
• Curcumin and curcumin derivatives fit nicely into the α7-nAChR 
transmembrane domain intra-cavity, the proposed binding site of type II 
PAMs. 
• Curcumin pre- and post-treatment significantly improved motor function in the 
6-OHDA induced model of PD. 
• Curcumin pre- and post-treatment attenuated the toxic effects of 6-OHDA on 
the reduction level of striatal dopamine. 
• Curcumin treatment protected dopaminergic neuronal cells in SNpc from 6-
OHDA toxicity, suggesting that curcumin produced significant restoration of 
dopamine in the nigrostriatal pathway. 
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Limitations and Future Directions 
1- One of the limitations in this study was the lack of positive control in BAPTA 
and protein kinase experiments. Testing BAPTA effectiveness on any well-
established intracellular Ca2+-dependent pathway, as a positive control study 
before starting oocytes’ experiments, would have provided further evidence 
that Ca2+-activated Cl- channels plays no role in curcumin α7-nAChR 
activation, and the same applies for protein kinase experiments. 
2- Curcumin solubility: DMSO was used as curcumin dissolvent in in-vitro study 
with a final concentration of 0.001%. However, in in-vivo study higher doses 
of curcumin and DMSO injected intraperitoneally were required. This method 
resulted in a high mortality rate. Therefore, it was decided to use different 
dissolvent (CMC) and different route of administration (intragastric). 
3- Our results from molecular docking experiment demonstrated that curcumin 
performed better than PNU-120695 which is considered as a reference 
compound for PAM type II. Therefore, it would be very informative to test it 
in-vivo and perform a comparative study in PD animal model.  
4- Parkinson’s disease is neurodegenerative disorder, where inflammation and   
oxidative stress plays a major role in the pathophysiology of the disease. Thus, 
biochemical analysis and western blotting of anti-inflammatory, and anti-
oxidant biomarkers would have provided valuable information and should be 
the next step. 
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Appendix 
 
Optimization 
In-vitro 
• Acetylcholine 
- Stock solution of the Acetylcholine (100 µM) was prepared in ND96 solution 
using the following formula: 
Weight (mg) = (MW) x (Volume (L)) x (concentration (mM)) 
= 181.7 x 0.2 L x 0.100  
= 3.6 mg of ACh in 200 ml ND96   
- Further dilutions were prepared using the Charles equation: 
C1 x V1 = C2 x V2 
- For preparation of 10 µM ACh; 
100 x V1 = 10 x 100 ml (ND96) 
          V1 = 10 ml of 100 µM stock solution plus 90 ml ND96  
               = 100 ml ACh solution of 10 µM concentration, divided into two parts:   
50 ml for first application line, and the remaining 50 ml was for the preparation of 
the second application line solution.  
Stock solutions and required dilutions were prepared freshly before 
starting the experiments. 
ACh was applied every five minutes. Shorter intervals would lead to stimulation 
the receptor during the desensitized state (the channel is insensitive to agonist 
stimulus). 
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• Curcumin 
Curcumin is a highly hydrophobic compound and is soluble only in organic solvents 
e.g., dimethyl sulfoxide (DMSO). 
 Stock solution of the curcumin (10 µM) was prepared in DMSO (0.001%) using 
the following formula: 
Weight (mg) = (MW) x (Volume (L)) x (concentration (mM)) 
         = 368.38 x 0.001 L x 10 
         = 3.68 mg of curcumin in 1 ml of DMSO   
- Further dilutions were prepared using the Charles equation: 
C1 x V1 = C2 x V2 
- For preparation of 10 µM curcumin; 
10 x V1 = 0.01 x 50 ml (ACh sol.) 
               V1 = 0.05 ml  
                   = 50 µl of curcumin stock solution (10 µM) plus 50 ml ACh solution 
prepared in the First step; second application line. 
- First perfusion was ND96 physiological solution  
- Second perfusion using curcumin stock solution (10 µM) 
C1 x V1 = C2 x V2 
10 x V1 = 0.01 x 600 ml ND96 
       V1 = 0.6 ml of curcumin stock solution (10 µM) plus 600 ml ND96. 
Since the magnitude of the curcumin effect was time-dependent, 10-minute 
curcumin application time was used routinely to ensure equilibrium conditions. 
Same concept was applied for different concentrations of curcumin used in the study, 
and also for other curcumin derivatives with the respect of the molecular weight of 
each compound. 
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• Glycine 
- Preparation of 30 µM from stock solution: 
C1 x V1 = C2 x V2 
100 x V1 = 0.03 x 100 
         V1 = 30 µl of Gly (100 mM) in 100 ml Ringer physiological solution.  
50 ml for first application line, and the remaining 50 ml was for the preparation of 
the second application line solution.  
To prepare 10 µM from 100 mM stock curcumin: 
C1 x V1 = C2 x V2 
100 x V1 = 0.01 x 50 
         V1 = 5 µl of curcumin stock solution (100 mM) in 50 ml of Gly (30 µM) Ringer 
solution, as a second application line.  
- First perfusion was Ringer physiological solution  
- Second perfusion using curcumin stock solution (10 µM) 
C1 x V1 = C2 x V2 
10 x V1 = 0.01 x 600 ml ND96 
       V1 = 0.6 ml of curcumin stock solution (10 µM) plus 600 ml Ringer solution. 
• 5HT3  
- Preparation of 1 µM from stock solution: 
C1 x V1 = C2 x V2 
100 x V1 = 0.001 x 100 
         V1 = 1 µl of 5HT (100 mM) in 100 ml Ringer physiological solution.  
50 ml for first application line, and the remaining 50 ml was for the preparation of 
the second application line solution.  
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- To prepare 10 µM from 100 mM stock curcumin: 
C1 x V1 = C2 x V2 
100 x V1 = 0.01 x 50 
         V1 = 5 µl of curcumin stock solution (100 mM) in 50 ml of Gly (30 µM) Ringer 
solution, as a second application line.  
- First perfusion was Ringer physiological solution  
- Second perfusion using curcumin stock solution (10 µM) 
C1 x V1 = C2 x V2 
10 x V1 = 0.01 x 600 ml ND96 
       V1 = 0.6 ml of curcumin stock solution (10 µM) plus 600 ml Ringer solution. 
• BAPTA 
- Preparation of stock solution: 
Weight (mg) = (MW) x (Volume (L)) x (concentration (mM)) 
= 476.23 x 0.001 x 100 
= 47.623 mg BAPTA in 1 ml D/W  
pH was adjusted to 7.4 by CsOH, and stored at +4℃ 
• Barium 
- Preparation of Barium-containing solution: 
ND96 solution but with substitution of BaCl2 (1.8 mM) instead of CaCL2 (1.8 mM). 
• Protein Kinases Inhibitors 
Stock solution of (100 µM) for each protein kinase inhibitor, to prepare the working 
concentration of 10 µM using the formula: 
C1 x V1 = C2 x V2 
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100 x V1 = 0.1 x 10 
         V1 = 0.01 ml  
         V1 = 10µM of stock solution plus 1 ml ND96 physiological solution for pre-
incubation. 
Oocytes were pre-incubated for 30 minutes before electrophysiological recording.  
• Nicotine 
- Preparation of 100 mM stock solution: 
Weight (mg) = (MW) x (Volume (L)) x (concentration (mM))  
                     = 462.4 x 0.001x 100 
                     = 46.24 mg in 1 ml D/W 
- To prepare 100 µM from 100 mM stock solution of nicotine 
C1 x V1 = C2 x V2 
100 x V1= 0.1x100 
          V1= 0.1 ml of tock in 100 ml of D/W  
In-vivo 
• 6-hydroxydopamine (6-OHDA) 
- Preparation of 0.9% NaCl: 
0.9 NaCl in 100 ml H2O 
- Preparation of 0.01% ascorbic acid solution: 
10 mg of L-ascorbic acid in 0.9% NaCL 
- Preparation of 6-OHDA injection solution: 
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Thirty-five milligram of 6-OHDA was dissolved in 1o ml of ice-cold 0.01% 
ascorbate in 0.9% normal saline and aliquoted into 250 µl Eppendorf tubes and 
kept in -40℃ until use. 
• Curcumin 
- Preparation of 0.5% CMC (vehicle): 
0.5 gm CMC added to 100 ml distilled water, stirred, and heated up to 60℃ until it 
dissolves completely. 
- 200 mg of curcumin plus 50 µl of NaOH (10M) in 2 ml of 0.5% CMC.  
• Methyllycaconitine (MLA)  
Methyllycaconitine (MLA) is the most potent and selective competitive antagonist 
of α7-nAChR (Turek et al., 1995). MLA was prepared in normal saline, no need for 
pH adjustment, kept in +4℃ in fridge and its stable compound. MLA half-life is 
around 19 min, and for in-vivo use its administered 10 min for maximal effect.  
- Dose: 1 mg/kg/rat for 4 weeks, other research papers have used it 1-3 mg/kg, 
but to avoid toxicity the daily dose should be 1/10th of the LD50 (LD50=5 
mg/kg, 1/10th = 0.5 mg/kg), so we have used (1 mg/kg rat) = (1 µl/gram rat). 
• Apomorphine  
The dose of apomorphine that has been used in the study (0.25 mg/KG SC) (Kirik 
et al., 1998) was significantly lower than the toxic dose (160 mg/kg) (“Sax’s 
Dangerous Properties of Industrial Materials, 5 Volume Set, 12th Edition,” n.d.). 
Apomorphine was dissolved in 0.1 ascorbic acid in saline and prepared on demand. 
Animals were injected subcutaneously with apomorphine-HCL. 
 
